Patent Application
20130217871
The present invention relates to hydroxyalkyl starch conjugates comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one primary hydroxyl group, wherein the hydroxyalkyl starch is linked via said primary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula
HAS′(-L-M)n
wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold, preferably a mean molecular weight MW greater than or equal to 60 kDa, more preferably in the range of from 80 to 1200 kDa, and more preferably of from 90 to 800 kDa, and a molar substitution (MS) in the range of from 0.6 to 1.5. Moreover, besides the conjugate, the invention relates to the method for preparing said conjugate and conjugates obtained or obtainable by said method. Further, the invention relates to the HAS cytotoxic agent conjugates for the treatment of cancer as well as to pharmaceutical compositions comprising these conjugates for the treatment of cancer.
Hydroxyalkyl starch (HAS), in particular hydroxyethyl starch (HES), is a substituted derivative of the naturally occurring carbohydrate polymer amylopectin, which is present in corn starch at a concentration of up to 95% by weight, and is degraded by other amylases in the body. RES in particular exhibits advantageous biological properties and is used as a blood volume replacement agent and in hemodilution therapy in clinics (Sommermeyer et al., 1987, Krankenhauspharmazie, 8(8): 271-278; Weidler et al., 1991, Arzneimittelforschung/Drug Research, 41: 494-498).
Cytotoxic agents are natural or synthetic substances which decrease the cell growth. A major drawback of many cytotoxic agents is their extreme low water solubility which renders the in vivo administration of the agent extremely complicated. Thus, this poor water solubility usually has to be overcome by complex formulation techniques including various excipients, wherein these excipients usually also show toxic side effects. As an example, the emulsifier Cremophor EL and ethanol, which are used to formulate taxol-based agents in order to deliver the required dosis of these taxol-based agents in vivo, shows toxic effects such as vasodilation, dispnea, and hypotension. In particular, Cremophor EL has also been shown to cause severe anaphylactic hypersensitivity reactions, hyperlipidaemia, abnormal lipoprotein patterns, aggregation of erythrocytes and peripheral neuropathy (“Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation”, European Journal of Cancer”, Volume 31, Issue 13, Pages 1590-1598). In fact, the maximum dose of, for example paclitaxel, a taxol-based cytotoxic agent that can be administered to mice by injection, is dictated by the acute lethal toxicity of said Cremophor EL vehicle.
This is one reason why the potential use of soluble prodrugs, in particular macromolecular prodrugs, as a means of administering biologically effective cytotoxic agents to mammals has been proposed. Such prodrugs include chemical derivatives of the cytotoxic agents which, upon administration, will eventually liberate the active parent compound in vivo.
Besides the enhancement of the water solubility of the drug, prodrugs have been proposed to provide an advantageous targeting and/or an enhancement of the stability of the therapeutic agent. Further, such prodrugs were suggested to prolong the circulation lifetime, to provide an extended duration of activity, or to achieve a reduction of side effects and drug toxicity. Thus, besides the preparation of prodrugs of water insoluble cytotoxic agents, providing prodrugs of water soluble cytotoxic agents is also of high interest in order to modify the onset and/or duration of action of the cytotoxic agent in vivo.
A typical example in the preparation of prodrugs of cytotoxic agents involves the conversion of alcohols or thioalcohols to either organic phosphates or esters (Remington's Pharmaceutical Science, 16th ed., A. Ozols (ed.), 1980).
Numerous reviews have described the potential application of macromolecules as high molecular weight carriers for cytotoxic agents yielding in polymeric prodrugs of said agents. It was proposed that by coupling the cytotoxic agents to polymers, it is possible to increase the molecular weight and size of the prodrug so that the weight and size of the prodrugs are too high to be quickly removed by glomerular filtration in the kidney and that, as consequence, the plasma residence time can be drastically increased.
Most modifications to date have been carried out with polyethylene glycol or similar polymers with polyethylene glycol (PEG) being generally preferred as polymer because of its easy availability and the possibility to give defined products upon reaction of limited available functional groups for coupling to a cytotoxic agent being present in PEG.
For example, WO 93/24476 discloses conjugates between taxane-based drugs, such as paclitaxel, to polyethylene glycol as macromolecule. In these conjugates, paclitaxel is linked to the polyethylene glycol using an ester linkage.
Similarly, U.S. Pat. No. 5,977,163 describes the conjugation of taxane-based drugs, such as paclitaxel or docetaxel, to similar water soluble polymers such as polyglutamic acid or polyaspartic acid.
Likewise, polyethylene glycol conjugates with cytotoxic agents, such as camptothecins, are disclosed in WO 98/07713. According to WO 98/07713, the polymer is linked via a linker to a hydroxyl function of the cytotoxic agent providing an ester linkage which allows for a rapid hydrolysis of the polymer drug linkage in vivo to generate the parent drug. This is achieved by using a linker comprising an electron-withdrawing group in close proximity to the ester bond. No polysaccharide-based conjugates were disclosed in WO 98/07713.
In a similar way, the influence of sterically demanding groups on the release rate of cytotoxic agents being incorporated into polyethylene glycol conjugates has been described in WO 01/146291A1.
U.S. Pat. No. 6,395,266 B1 discloses branched PEG polymers linked to various cytotoxic agents. The branched polymers are considered to be advantageous compared to linear PEG conjugates since a higher loading of parent drug per unit of polymer can be achieved. The actual activity of these conjugates in vivo for the treatment of cancer was, however, not shown.
Similar to U.S. Pat. No. 6,395,266 B1, EP 1 496 076 A1 discloses Y-shaped branched hydrophilic polymer derivatives conjugated to cytotoxic agents such as camptothecin. Again, the actual activity of these conjugates in vivo was not shown.
In a similar way, the following patent and non-patent literature discloses PEG conjugates: Greenwald et al., J. Med. Chem., 1996, 39: 424-431 and U.S. Pat. No. 5,840,900.
PEG, however, is known to have unpleasant or hazardous side effects such as induction of antibodies against PEG (N. J. Ganson, S. J. Kelly et al., Arthritis Research & Therapie 2006, 8:R12) and nephrotoxicity (G. A. Laine, S. M. Hamid Hossain et al., The Annals of Pharmacotherapy, 1995 November, Volume 29) on use of such PEG or PEG-related conjugates. In addition, the biological activity of the active ingredients is most often greatly reduced in some cases after the PEG coupling. Moreover, the metabolism of the degradation products of PEG conjugates is still substantially unknown and possibly represents a health risk. Further, the functional groups available for coupling to cytotoxic agents are limited, so a high loading of the polymer with the respective drug is not possible.
Thus, there is still a need for physiologically well tolerated alternatives to such PEG conjugates with which the residence time of low molecular weight substances in the plasma can be increased and/or the efficacy of these drugs can be increased and/or non-specific toxicity can be decreased. Further, there is the need for macromolecular prodrugs which provide an advantageous targeting of the tumor and/or which, upon administration, will eventually liberate the active parent compound in vivo with improved pharmacodynamic properties.
It would be particularly desirable to provide prodrugs which take advantage of the so-called Enhanced Permeability and Retention (EPR) effect. This EPR effect describes the property by which certain sizes of molecules, such as macromolecules or liposomes, tend to accumulate in tumor tissue much more than they do in normal tissue (reference is made to respective passages of U.S. Pat. No. 6,624,142 B2; or to Vasey P. A., Kaye S. B., Morrison R., et al. (January 1999) “Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee”. Clinical Cancer Research 5 (1): 83-94). The general explanation for that effect is that tumor vessels are usually abnormal in form and architecture. This is due to the fact that, in order for tumor cells to grow quickly, they must stimulate the production of blood vessels.
Without wanting to be bound to any hypothesis, it is contemplated that the EPR effect allows for an enhanced or even substantially selective delivery of macromolecules to the tumor cells and as consequence, enrichment of the macromolecules in the tumor cells, when compared to the delivery of these molecules to normal tissue.
WO 03/074088 describes hydroxyalkyl starch conjugates with, for example, cytotoxic agents such as daunorubicin, wherein the cytotoxic agent is usually directly coupled via an amine group to the hydroxyalkyl starch yielding in 1:1 conjugates. No use of these conjugates in vivo was shown. Further, in WO 03/074088 no cleavable linkage between the cytotoxic agent and hydroxyalkyl starch was described, which, upon administration, would be suitable to readily liberate the active drug in vivo.
Thus, there is still the need to provide new prodrugs of cytotoxic agents being bound to advantageous polymers for the treatment of cancer in vivo.
Thus, it is an object of the present invention to provide novel conjugates comprising a polymer linked to a cytotoxic agent. Further, it is an object of the present invention to provide a method for preparing such conjugates. Additionally, it is an object of the present invention to provide pharmaceutical compositions comprising these novel conjugates as well as the use of the conjugates and the pharmaceutical composition, respectively, in the treatment of cancer.
Surprisingly, it was found that linking of a cytotoxic agents via a primary hydroxyl group to a hydroxyalkyl starch derivatives may lead to conjugates showing at least one of the desired beneficial properties, such as improved drug solubility, and/or optimized drug residence time in vivo, and/or reduced toxicity, and/or high efficiency, and/or effective targeting of tumor tissue in vivo. Without wanting to be bound to any theory, it is believed that the specific biodegradable hydroxyalkyl starch polymers of the invention may exhibit an optimized size, characterized by specific values of MW, which is large enough to prevent the elimination of the intact conjugate—comprising the polymer and the cytotoxic agent—through the kidney prior to any release of the cytotoxic agent. Thus, rapid elimination of the cytotoxic agent through the kidney by filtration through pores may be avoided. Further, the specific biodegradable hydroxyalkyl starch polymers of the invention comprised in the conjugate may exhibit an optimized molar substitution MS, and/or the conjugate as such may exhibit a preferred overall chemical constitution, so as to allow for a degradability of the hydroxyalkyl starch polymer comprised in the conjugate and release of the cytotoxic agent in favorable time range. Further, it is believed that in contrast to most of the polymers described in the prior art, such as polyethylene glycol and derivatives thereof, the polymer fragments obtained from degradation of the conjugate of the present invention can be removed from the bloodstream by the kidneys or degraded via the lysosomal pathway without leaving any unknown degradation products of the polymer in the body.
Without wanting to be bound to any theory as to how the conjugates of the invention might operate, it is further believed that at least some of the conjugates of the invention might be able to deliver the respective cytotoxic agent into extracellular tissue space, such as into tissue exhibiting an EPR effect. However, it has to be understood that it is not intended to limit the scope of the invention only to such conjugates which take advantage of the EPR effect; also conjugates which show, possibly additionally, different advantageous characteristics, such as advantageous activity and/or low toxicity in vivo due to alternative mechanisms, are encompassed by the present invention.
Thus, the present invention relates to hydroxyalkyl starch (HAS) conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, said conjugate having a structure according to the following formula
HAS′(L-M)n
wherein M is a residue of a cytotoxic agent, and wherein the cytotoxic agent comprises a primary hydroxyl group, L is a linking moiety (linking the HAS derivative and M), HAS′ is a residue of the hydroxyalkyl starch derivative, n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight MW above the renal threshold, preferably a MW greater than or equal to 60 kDa, and a molar substitution MS in the range of from 0.6 to 1.5, and wherein the linking moiety L is linked to a primary hydroxyl group of the cytotoxic agent.
Further, the present invention also relates to a method for preparing a hydroxyalkyl starch (HAS) conjugate comprising a hydroxyallyl starch derivative and a cytotoxic agent, said conjugate having a structure according to the following formula
HAS′(-L-M)n
wherein
M is a residue of a cytotoxic agent, said cytotoxic agent comprising a primary hydroxyl group, L is a linking moiety, HAS′ is a residue of the hydroxyalkyl starch derivative, and n is equal or greater than 1, said method comprising
Moreover, the present invention relates to a hydroxyalkyl starch conjugate obtainable or obtained by the above-mentioned method.
The term “linked to the primary hydroxyl group of the cytotoxic agent” as used in the context of the present invention is denoted to mean that the cytotoxic agent is reacted via its primary group. The resulting conjugated residue of the cytotoxic agent M is thus linked via an —O— group to the linking moiety -L- wherein the oxygen of this —O— group corresponds to the oxygen of the reacted primary hydroxyl group cytotoxic agent.
Further, the present invention relates to a pharmaceutical compound or composition comprising the hydroxyalkyl starch conjugate or the hydroxyalkyl starch conjugate obtainable or obtained by the above-mentioned method. In addition, the present invention relates to the hydroxyalkyl starch conjugate as described above, or the pharmaceutical composition as described above, for the use as a medicament, in particular for the treatment of cancer. Moreover, the present invention relates to the use of the hydroxyalkyl starch conjugate as described above, or the pharmaceutical composition as described above for the manufacture of a medicament for the treatment of cancer. Moreover, the present invention relates to a method of treating a patient suffering from cancer comprising administering a therapeutically effective amount of the hydroxyalkyl starch conjugate as described above, or the pharmaceutical composition as described above.
In the context of the present invention, the term “hydroxyalkyl starch” (HAS) refers to a starch derivative having a constitution according to the following formula (III)
wherein the explicitly shown ring structure is either a terminal or a non-terminal saccharide unit of the HAS molecule and wherein HAS″ is a remainder, i.e. a residual portion of the hydroxyalkyl starch molecule, said residual portion forming, together with the explicitly shown ring structure containing the residues Raa, Rbb and Rcc and Rrr the overall HAS molecule. In formula (III), Raa, Rbb and Rcc are independently of each other hydroxyl, a linear or branched hydroxyalkyl group or —O—HAS″, in particular Raa, Rbb and Rcc are independently of each other —[O—(CRwRx)—(CRyRz)]x—OH or —O—HAS″, wherein Rw, Rx, Ry and Rz are independently of each other selected from the group consisting of hydrogen and alkyl, x is an integer in the range of from 0 to 20, preferably in the range of from 0 to 4. Preferably, Raa, Rbb and Rcc are independently of each other —O—HAS″ or —[O—CH2—CH2]s—OH with s being in the range of from 0 to 4. In particular, Raa, Rbb and Rcc are independently of each other —OH, —O—CH2—CH2—OH (2-hydroxyethyl), or —O—HAS″. Residue Rrr is —O—HAS″ in case the explicitly shown ring structure is a non-terminal saccharide unit of the HAS molecule. In case the explicitly shown ring structure is a terminal saccharide unit of the HAS molecule, Rrr is —OH, and formula (III) shows this terminal saccharide unit in its hemiacetal form. This hemiacetal form, depending on e.g. the solvent, may be in equilibrium with the free aldehyde form as shown in the scheme below:
The term O—HAS″ as used in the context of the residue Rrr as described above is, in addition to the remainder HAS″ shown at the left hand side of formula (III), a further remainder of the HAS molecule which is linked as residue Rrr to the explicitly shown ring structure of formula (III)
and forms, together with the residue HAS″ shown at the left hand side of formula (III) and the explicitly shown ring structure the overall HAS molecule.
Each remainder HAS″ discussed above comprises, preferably essentially consists of—apart from terminal saccharide units—one or more repeating units according to formula (IIIa)
According to the present invention, the HAS molecule shown in formula (III) is either linear or comprises at least one branching point, depending on whether at least one of the residues Raa, Rbb and Rcc of a given saccharide unit comprises yet a further remainder —O—HAS″. If none of the Raa, Rbb and Rcc of a given saccharide unit comprises yet a further remainder —O—HAS″, apart from the HAS″ shown on the left hand side of formula (III), and optionally apart from HAS″ contained in Rrr, the HAS molecule is linear.
Hydroxyalkyl starch comprising two or more different hydroxyalkyl groups is also conceivable. The at least one hydroxyalkyl group comprised in the hydroxyalkyl starch may contain one or more, in particular two or more, hydroxyl groups. According to a preferred embodiment, the at least one hydroxyalkyl group contains only one hydroxyl group.
The term “hydroxyalkyl starch” as used in the present invention also includes starch derivatives wherein the alkyl group is suitably mono- or polysubstituted. Such suitable substituents are preferably halogen, especially fluorine, and/or an aryl group. Yet further, instead of alkyl groups, HAS may comprise also linear or branched substituted or unsubstituted alkenyl groups.
Hydroxyalkyl starch may be an ether derivative of starch, as described above. However, besides of said ether derivatives, also other starch derivatives are comprised by the present invention, for example derivatives which comprise esterified hydroxyl groups. These derivatives may be, for example, derivatives of unsubstituted mono- or dicarboxylic acids with preferably 2 to 12 carbon atoms or of substituted derivatives thereof. Especially useful are derivatives of unsubstituted monocarboxylic acids with 2 to 6 carbon atoms, especially derivatives of acetic acid. In this context, acetyl starch, butyryl starch and propynyl starch are preferred.
Furthermore, derivatives of unsubstituted dicarboxylic acids with 2 to 6 carbon atoms are preferred. In the case of derivatives of dicarboxylic acids, it is useful that the second carboxy group of the dicarboxylic acid is also esterified. Furthermore, derivatives of monoalkyl esters of dicarboxylic acids are also suitable in the context of the present invention. For the substituted mono- or dicarboxylic acids, the substitute group may be preferably the same as mentioned above for substituted alkyl residues. Techniques for the esterification of starch are known in the art (cf. for example Klemm, D. et al., Comprehensive Cellulose Chemistry, vol. 2, 1998, Wiley VCH, Weinheim, N.Y., especially Chapter 4.4, Esterification of Cellulose (ISBN 3-527-29489-9)).
According to a preferred embodiment of the present invention, a hydroxyalkyl starch (HAS) according to the above-mentioned formula (III)
is employed. The saccharide units comprised in HAS″, apart from terminal saccharide units, may be the same or different, and preferably have the structure according to the formula (IIIa)
as shown above.
According to the invention, the term “hydroxyalkyl starch” is preferably a hydroxyethyl starch, hydroxypropyl starch or hydroxybutyl starch, wherein hydroxyethyl starch is particularly preferred.
Thus, according to the present invention, the hydroxyalkyl starch (HAS) is preferably a hydroxyethyl starch (HES), the hydroxyethyl starch preferably having a structure according to the following formula (III)
wherein Raa, Rbb and Rcc are independently of each other selected from the group consisting of —O—HES″, and —[O—CH2—CH2]s—OH, wherein s is in the range of from 0 to 4 and wherein HAS″, is, in case the hydroxyalkyl starch is hydroxyethyl starch, the remainder of the hydroxyethyl starch and could be abbreviated with HES″. Residue Rrr is either —O—HAS″ (which, in case the hydroxyalkyl starch is hydroxyethyl starch, could be abbreviated with —O—HES″) or, in case the formula (III) shows the terminal saccharide unit of HES, Rrr is —OH. For the sake of consistency, the abbreviation “HAS” is used throughout all formulas in the context of the present invention, and if HAS is concretized as HES, it is explicitly mentioned in the corresponding portion of the text.
In the context of the present invention, the term “hydroxyalkyl starch derivative” refers to a derivative of starch being functionalized with at least one functional group Z1, said group being a functional group capable of being linked to (reacted with) a further compound, in particular to the linking moiety L comprised in the structural unit -L-M which in turn is comprised in above-defined conjugate having a structure according to the following formula
HAS′(-L-M)n.
In accordance with the above-mentioned definition of HAS, the hydroxyalkyl starch derivative preferably comprises at least one structural unit according to the following formula (I)
wherein at least one of Ra, Rb or Rc comprises the functional group Z1 and wherein Ra, Rb and Rc are, independently of each other, selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]x—OH, —[O—(CRwRx)—(CRyRz)]y—Z1, —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-Z1, wherein Rw, Rx, Ry and Rz are independently of each other selected from the group consisting of hydrogen and alkyl, y is an integer in the range of from 0 to 20, preferably in the range of from 0 to 4, x is an integer in the range of from 0 to 20, preferably in the range of from 0 to 4, F1 is a functional group, p is 0 or 1, L1 is a linking moiety and Z1 is a functional group which is capable of being linked to a further compound, in particular to the linking moiety L comprised in the structural unit -L-M.
In particular, a hydroxyalkyl starch derivative which comprises at least one structural unit according to the following formula (I)
has preferably a structure according to the following formula (IV)
wherein Rr is —O—HAS″ or, in case the ring structure of formula (IV) shows the terminal saccharide unit of HAS, Rr is —OH, and wherein HAS″ is a remainder of the hydroxyalkyl starch derivative.
Analogously to the above-discussed definition of the term HAS″ in the context of the hydroxyalkyl starch as such, the term “remainder of the hydroxyalkyl starch derivative” is denoted to mean a linear or branched chain of the hydroxyalkyl starch derivative, being linked to the oxygen groups shown in formula (IV) or being comprised in the residues Ra, Rb or Rc of formula (I), wherein said linear or branched chains comprise at least one structural unit according to formula (I),
wherein at least one of Ra, Rb or Rc comprises the functional group Z1 and/or one or more structural units of the formula (Ib)
wherein Ra, Rb and Rc are, independently of each other, selected from the group consisting of —O—HAS″ and —[O—(CRwRx)—(CRyRz)]x—OH, wherein Rw, Rx, Ry, Rz are as described above.
In case the hydroxyalkyl starch derivative has a linear starch backbone, none of Ra, Rb or Rc comprises a further group —O—HAS″. In case at least one of Ra, Rb or Rc is —O—HAS″, the hydroxyalkyl starch derivative comprises at least one branching point.
In particular, in case, the structural unit is the reducing sugar moiety of the hydroxyalkyl starch derivative, the terminal structural unit has a structure according to the following formula (Ia):
wherein Rr is —OH or a group comprising the functional group Z1. Residue Rr is preferably selected from the group consisting of —OH, —Z1 and —[F1]p-L1-Z1, most preferably Rr is —OH, the reducing end of the hydroxyalkyl starch thus being present in unmodified form.
In the above-mentioned formula (Ia), the bond represents a bond with non-defined stereochemistry, i.e. this term represents a bond encompassing both possible stereochemistries. Preferably, the stereochemistry in most building blocks, preferably in all building blocks of the HAS derivative is defined according to the formulas (Ib) and (IVa)
According to a preferred embodiment of the present invention, the hydroxyalkyl starch (HAS) derivative is a hydroxyethyl starch (HES) derivative.
Therefore, the present invention also describes a hydroxyalkyl starch derivative as described above, and a method for preparing said hydroxyalkyl starch derivative, and a conjugate comprising said hydroxyalkyl starch derivative and a cytotoxic agent, and a conjugate obtained or obtainable by the above-mentioned method wherein the conjugate comprises said hydroxyalkyl starch derivative and a cytotoxic agent, wherein the hydroxyalkyl starch derivative is a hydroxyethyl starch derivative.
Accordingly, in case the hydroxyalkyl starch (HAS) is hydroxyethyl starch (HES), the HAS derivative preferably comprises at least one structural unit, preferably 3 to 100 structural units, according to the following formula (I)
wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—CH2—CH2]s—OH, —[O—CH2—CH2]t—Z1 and —[O—CH2—CH2]t—[F1]p-L1-Z1, wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—Z1 or —[O—CH2—CH2]t—[F1]p-L1-Z1, wherein s is in the range of from 0 to 4, wherein t is in the range of from 0 to 4, and wherein p is 0 or 1.
As regards the amount of functional groups Z1 present in a given hydroxyalkyl starch derivative, preferably 0.15% to 2% of all residues Ra, Rb and Rc present in the hydroxyalkyl starch derivative contain the functional group Z1.
More preferably, 0.15% to 2% of all residues Ra, Rb and Rc present in the hydroxyalkyl starch derivative have the structure —[O—(CRwRx)—(CRyRz)]y—Z1 or —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-Z1.
According to a particularly preferred embodiment, Ra, Rb and Rc are selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]x—OH and —[O—(CRwRx)—(CRyRz)]y—Z1, wherein 0.15% to 2% of all residues Ra, Rb and Rc present in the hydroxyalkyl starch derivative have the structure —[O—(CRwRx)—(CRyRz)]y—Z1.
According to an alternative preferred embodiment, Ra, Rb and Rc are selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]x—OH and —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-Z1, wherein 0.15% to 2% of all residues Ra, Rb and Rc present in the hydroxyalkyl starch derivative have the structure —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-Z1.
The Term “Residue of the Hydroxyalkyl Starch Derivative”
The term “residue of the hydroxyalkyl starch derivative” (HAS′) refers to a hydroxyalkyl starch derivative being incorporated into a hydroxyalkyl starch conjugate. Within the meaning of the present invention the term “a conjugate comprising a hydroxyalkyl starch derivative” thus refers to a conjugate comprising a residue of a hydroxyalkyl starch derivative being incorporated into the conjugate and thus being linked to the linking moiety L comprised in the conjugate having a structure according the following formula
HAS′(-L-M)n
Upon incorporation into the conjugate, the hydroxyalkyl starch derivative is coupled via at least one of its functional groups Z1 to the crosslinking compound L (which is further reacted with the cytotoxic agent) or to the derivative of the cytotoxic agent having the structure -L-M, as described hereinabove and hereinunder, thereby forming a covalent linkage between the residue of the hydroxyalkyl starch derivative and L or -L-M, wherein the functional group X is formed upon reaction of Z1 with L or -L-M, respectively.
Analogously to the above-discussed definition of the term “hydroxyalkyl starch derivative”, the term “residue of a hydroxyalkyl starch derivative” refers to a derivative of starch being linked via at least one functional group X via a linking moiety to a further compound, in particular via the linking moiety L comprised in the structural unit -L-M which in turn is comprised in above-defined conjugate having a structure according to the following formula
HAS′(-L-M)n.
In accordance with the above-mentioned definition of the hydroxyalkyl starch derivative, the residue of the hydroxyalkyl starch derivative preferably comprises at least one structural unit according to the following formula (I)
wherein Ra, Rb and Rc are, independently of each other, selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]x—OH, —[O(CRwRx)—(CRyRz)]y—X— and —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-X—, and wherein at least one of Ra, Rb or Rc comprises the functional group —[O—(CRwRx)—(CRyRz)]x—X— or —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-X, and wherein Rw, Rx, Ry and Rz are independently of each other selected from the group consisting of hydrogen and alkyl, y is an integer in the range of from 0 to 20, preferably in the range of from 0 to 4, x is an integer in the range of from 0 to 20, preferably in the range of from 0 to 4, F1 is a functional group, p is 0 or 1, L1 is a linking moiety and X is a functional group which is linked to a further compound, in particular to the linking moiety L comprised in the structural unit -L-M.
Besides the at least one structural unit according to formula (I).
wherein at least one of Ra, Rb or Rc comprises the functional group —[O—(CRwRx)—(CRyRz)]x—[F1]p-L1-X— or —[O—(CRwRx)—(CRyRz)]y—X—, the residue of the hydroxyalkyl starch preferably comprises one or more structural units of the formula (Ib)
wherein Ra, Rb and Rc are, independently of each other, selected from the group consisting of —O—HAS″ and —[O—(CRwRx)—(CRyRz)]x—OH.
As disclosed above, preferably 0.15% to 2% of all residues Ra, Rb and Rc present in the hydroxyalkyl starch derivative contain the functional group Z1. Further, preferably all functional groups Z1 being present in a given hydroxyalkyl starch derivative are coupled according to the coupling reaction of step (b) as defined hereinabove, thereby forming the covalent linkage via functional group X. Consequently, preferably 0.15% to 2% of all residues Ra, Rb and Rc present in the residue of the hydroxyalkyl starch derivative contain the functional group X. Thus, preferably 0.15% to 2% of all residues Ra, Rb and Rc present in the residue of the conjugate of the present invention contain the functional group X.
However, in case the hydroxyalkyl starch derivative comprises at least two functional groups Z1, it may be possible that in step (b) not all of these functional groups Z1 reacted with the crosslinking compound L, which in turn is reacted (either prior to, or after the reaction with the HAS derivative) with the cytotoxic agent, giving a conjugate in which the HAS derivative is linked via the linking moiety L to the residue of the cytotoxic agent M. Thus, embodiments are encompassed in which not all functional groups are reacted with the at least one crosslinking compound L, preferably the at least bifunctional crosslinking compound L, or with the derivative of the cytotoxic agent -L-M. The residue of the hydroxyalkyl starch derivative present in the conjugate of the invention may thus comprise at least one unreacted functional group Z1. Further, in case the hydroxyalkyl starch derivative is reacted with the crosslinking compound L which comprises the functional groups K1 and K2 as described above, prior to the coupling reaction to the cytotoxic agent, the residue of the hydroxyalkyl starch derivative present in the conjugate of the invention may comprise at least one unreacted functional group K2. All conjugates mentioned hereinunder and above, may comprise such unreacted groups.
To avoid possible side effects due to the presence of such unreacted functional groups Z1 and/or unreacted functional groups K2, the hydroxyalkyl starch conjugate may be further reacted with a suitable compound allowing for capping Z1 and/or K2 with a capping reagent D* in a preferably subsequent step (c) as described hereinunder in detail.
Thus, a hydroxyalkyl starch derivative comprised in a conjugate according to the invention mentioned hereinunder or above may comprise at least one structural unit according to formula (I),
wherein one or more of Ra, Rb or Rc is —[O—(CRwRx)—(CRyRz)]y—X-(L)beta-D or —[O—(CRwRx)—(CRyRz)]y—[F1]-L1-X-(L)beta-D, wherein D is a capping group, L is the linking moiety comprised in the conjugate, as described above, beta is 0 or 1, preferably 0, and X is the functional group being formed upon reaction of at least one functional group Z1 with a capping reagent D* thereby forming the structural unit X-D (in this case beta is 0) or X is the functional group which is formed upon reaction of Z1 with the crosslinking compound L, as described above, which in turn may be reacted via its functional group K2 with a capping reagent D*, as described above, thereby forming the structural unit -L-D.
As regards the amount of functional groups X being linked to the functional moiety -L-M present in a given hydroxyalkyl starch conjugate, preferably at least 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 95% most preferably at least 99%, of all functional groups X present in the conjugate of the invention are linked to the functional moiety -L-M.
Alternatively, the conjugates of the present invention may also be described by the formula
[D-(L)beta-]gammaHAS*(-L-M)n
wherein beta is 0 or 1, preferably 0, and wherein generally 0≦gamma<n, preferably wherein 0≦gamma<<<n, especially preferably wherein gamma is 0, wherein the residue of the hydroxyalkyl starch derivative HAS* comprises at least one structural unit according to formula (I),
wherein at least one of Ra, Rb or Rc comprises the functional group X, and wherein the residue of the hydroxyalkyl starch HAS* preferably comprises one or more structural units of the formula (Ib)
wherein Ra, Rb and Rc are, independently of each other, selected from the group consisting of —O—HAS″ and —[O—(CRwRx)—(CRyRz)]x—OH, and wherein HAS* comprises no structural units —[O—(CRwRx)—(CRyRz)]y—X-(L)beta-D or —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-X-(L)beta-D.
HAS, in particular HES, is mainly characterized by the molecular weight distribution, the degree of substitution and the ratio of C2:C6 substitution. There are two possibilities of describing the substitution degree.
The degree of substitution (DS) of HAS is described relatively to the portion of substituted glucose monomers with respect to all glucose moieties.
The substitution pattern of HAS can also be described as the molar substitution (MS), wherein the number of hydroxyethyl groups per glucose moiety is counted.
In the context of the present invention, the substitution pattern of the hydroxyalkyl starch (HAS), preferably HES, is referred to as MS, as described above, wherein the number of hydroxyalkyl groups present per sugar moiety is counted (see also Sommermeyer et al., 1987, Krankenhauspharmazie, 8(8): 271-278, in particular page 273). The MS is determined by gaschromatography after total hydrolysis of the hydroxyalkyl starch molecule.
The MS values of the respective hydroxyalkyl starch, in particular hydroxyethyl starch starting materials, are given since it is assumed that the MS value is not affected during the derivatization procedures as well as during the coupling step of the present invention.
The MS value corresponds to the degradability of the hydroxyalkyl starch via alpha-amylase. The higher the MS value, the lower the degradability of the hydroxyalkyl starch. It was surprisingly found that the MS of the hydroxyalkyl starch derivative present in the conjugates according to the invention should preferably be in the range of from 0.6 to 1.5 to provide conjugates with advantageous properties. Without wanting to be bound to any theory, it is believed that a MS in the above mentioned range combined with the specific molecular weight range of the conjugates results in conjugates with an optimized enrichment of the cytotoxic agent in the tumor and/or residence time in the plasma allowing for a controlled release of the cytotoxic agent prior to the degradation of the polymer and the subsequent removal of polymer fragments through the kidney.
According to a preferred embodiment of the present invention, the molar substitution MS is in the range of from 0.70 to 1.45, more preferably in the range of 0.80 to 1.40, more preferably in the range of from 0.90 to 1.35, such as 0.90, 0.95, 1.0, 1.05, 1.1, 1.15, 1.2, 1.25, 1.3 or 1.35.
Thus, the present invention also relates to a method for preparing a conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, as described above, and a conjugate obtained or obtainable by said method, wherein the hydroxyalkyl starch derivative has a MS in the range of from 0.70 to 1.45, preferably in the range of 0.80 to 1.40, more preferably in the range of from 0.90 to 1.35.
Likewise, the present invention also relates to a hydroxyalkyl starch (HAS) conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, as described above, wherein the hydroxyalkyl starch derivative has a molar substitution MS in the range of from 0.70 to 1.45, preferably in the range of from 0.80 to 1.40, more preferably in the range of from 0.90 to 1.35. Likewise, the present invention relates to a pharmaceutical composition comprising a hydroxyalkyl starch conjugate, as described above, or a hydroxyalkyl starch conjugate obtained or obtainable by the above described method, wherein the hydroxyalkyl starch derivative has a molar substitution MS in the range of from 0.70 to 1.45, preferably in the range of from 0.80 to 1.40, more preferably in the range of from 0.90 to 1.35.
As far as the ratio of C2:C6 substitution is concerned, i.e. the degree of substitution (DS) of HAS, said substitution is preferably in the range of from 2 to 20, more preferably in the range of from 2 to 15 and even more preferably in the range of from 3 to 12, with respect to the hydroxyalkyl groups.
HAS and in particular HES compounds are present as polydisperse compositions, wherein each molecule differs from the other with respect to the polymerization degree, the number and pattern of branching sites, and the substitution pattern. HAS and in particular HES is therefore a mixture of compounds with different molecular weight. Consequently, a particular HAS and in particular a HES is determined by average molecular weight with the help of statistical means.
In this context the number average molecular weight is defined by equation 1:
where ni is the number of molecules of species i of molar mass Mi.
Mw is the weight average molecular weight, defined by equation 2:
where ni is the number of molecules of species i of molar mass Mi and
Preferably, the hydroxyalkyl starch derivative, in particular the hydroxyethyl starch derivative comprised in the conjugate, as described above, has a mean molecular weight MW (weight mean) above the renal threshold.
The renal threshold is determined according to the method described by Waitzinger et al. (Clin. Drug Invest. 1998; 16: 151-160) and reviewed by Jungheinrich et al. (Clin. Pharmacokinet. 2006; 44(7): 681-699). Preferably, the renal threshold is denoted to mean molecular weight MW above 40 kDa.
More preferably, the hydroxyalkyl starch derivative, in particular the hydroxyethyl starch derivative comprised in the conjugate, as described above, has a mean molecular weight MW above 45 kDa, more preferably above 50 kDa, more preferably above 60 kDa.
More preferably the hydroxyalkyl starch derivative, in particular the hydroxyethyl starch derivative, according to the invention, has a mean molecular weight MW (weight mean) in the range of from 80 to 1200 kDa, preferably in the range of from 90 to 800 kDa.
The term “mean molecular weight” as used in the context of the present invention relates to the weight as determined according to MALLS (multiple angle laser light scattering) GPC method as described in example 7.
Therefore, the present invention also relates to a method as described above, for preparing a hydroxyalkyl starch derivative, as well as to a method for preparing a hydroxyalkyl starch conjugate, wherein the hydroxyalkyl starch derivative has a mean molecular weight MW above the renal threshold, preferably a MW greater than or equal to 60 kDa, more preferably in the range of from 80 to 1200 kDa, preferably in the range of from 90 to 800 kDa. Likewise, the present invention relates to a hydroxyalkyl starch conjugate, as described above, comprising a hydroxyalkyl starch derivative, as well as to a hydroxyalkyl starch conjugate obtained or obtainable by the above-mentioned method, wherein the hydroxyalkyl starch derivative has a mean molecular weight MW above the renal threshold, preferably a MW greater than or equal to 60 kDa, more preferably a mean molecular weight MW in the range of from 80 to 1200 kDa, more preferably in the range of from 90 to 800 kD.
According to an especially preferred embodiment, the hydroxyalkyl starch derivative has a MS in the range of from 0.70 to 1.45 and a mean molecular weight MW in the range of from 80 to 1200 kDa, more preferably a molar substitution MS in the range of from 0.80 to 1.40 and a mean molecular weight MW in the range of from 90 to 800 kDa, more preferably a molar substitution in the range of from 0.90 to 1.35, more preferably a mean molecular weight MW in the range of from 90 to 800 kDa and a MS in the range of from 0.95 to 1.35.
As regards integer n, as described above and below, according to a preferred embodiment of the present invention, n is in the range of from 2 to 300, preferably of from 2 to 100, more preferably of from 3 to 100.
The amount of M, present in the conjugates of the invention, can further be described by the drug loading (also: drug content). The “drug loading” as used in the context of the present invention is calculated as the mean molecular weight of the cytotoxic agent measured in mg drug, i.e. cytotoxic agent, per 1 g of the conjugate.
The drug loading is determined by measuring the absorbance of M (thus the cytotoxic agent bound to HAS) at a specific wavelength in a stock solution, and calculating the content using the following equation (Lambert Beer's law):
where ε is the extinction coefficient of the cytotoxic agent at the specific wavelength, which is obtained from a calibration curve of the cytotoxic agent dissolved in the same solvent which is used as in the stock solution (given in cm2/μmol), at the specific wavelength, A is the absorption at this specific wavelength, measured in a UV-VIS spectrometer, A0 is the absorption of a blank sample and d the width of the cuvette (equals the slice of absorbing material in the path of the beam, usually 1 cm). The appropriate wavelength for the determination of drug loading is derived from a maximum in the UV-VIS-spectra, preferably at wavelengths above 230 nm.
With a known concentration of conjugate in the sample (cconjugate) and the concentration of drug in the sample determined by Lambert Beer's law, the loading in micromol/g can be calculated according to the following equation:
The loading (in mg/g) may finally be determined taking into account the molecular weight of the cytotoxic agent as shown in the following equation:
Loading[mg/g]=Loading[μmol/g]*MWdrug[μg/μmol]/1000
As regards the drug loading, according to a preferred embodiment of the present invention, the drug loading of the conjugates is preferably in the range of from 40 to 1100 umol drug/g, more preferably in the range of from 80 to 800 μmol drug/g, more preferably in the range of from 110 to 700 mmol drug/g and most preferably in the range of from 150 to 600 μmol drug/g (-L-M).
The term “cytotoxic agent” as used in the context of the present invention refers to natural or synthetic substances, which inhibit the cell growth or the cell division in vivo. The term is intended to include chemotherapeutic agents, antibiotics and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof.
The term “residue of the cytotoxic agent M” as used in the context of the present invention refers to the cytotoxic agent being linked to L via a group —O—, said group being derived from a primary hydroxyl group being present in the cytotoxic agent.
Preferably, the term “cytotoxic agent” is a natural or synthetic substance which inhibits the cell growth or the cell division of a tumor in vivo. Most preferably, the cytotoxic agent is a chemotherapeutic agent. The therapeutic use of these preferred cytotoxic agents, most preferably of the chemotherapeutic agents, is based on the difference in the rate of cell division and cell growth of tumor cells compared to normal cells. Among others, tumor cells differ from normal cells in that tumor cells are no longer subject to physiological growth control and therefore have an increased rate of cell division. Since the toxic activity of cytotoxic agents is usually primarily directed against proliferating cells, such cytotoxic agents can be used for inhibiting a development or progression of a neoplasm in vivo, particularly a malignant (cancerous) lesion, such as a carcinoma, sarcoma, lymphoma, or leukemia. Inhibition of metastasis is frequently also a property of the cytotoxic agents encompassed by the present invention.
With respect to the chemistry used in the context of the present invention, any cytotoxic agent, preferably any chemotherapeutic agent, known to those skilled in the art can be incorporated into the conjugates according to the present invention provided that this cytotoxic agent, preferably the chemotherapeutic agent, comprises a primary hydroxyl group. Preferably the cytotoxic agent is an agent for the treatment of cancer.
Preferably, the cytotoxic agent is selected from the group consisting of a primary hydroxyl group containing—tubulin inhibitors, such as tubulin inhibitors or tubulin stabilizers, vinca alcaloids, topoisomerase I inhibitors (e.g. camptothecin analogues such as DRF-1042), topoisomerase II inhibitors, tubulin stabilizers such as peloruside A, dictyostatin, discondermolide, taxane derivatives or members of the epothilone family such as epothilone E and F, DNA intercalators such as mitoxantrone and the anthracycline family (doxorubicin, epirubicin), antimetabolites such as clofarabine, nelarabine, cytarabine, cladribine, decitabine, azacitidine, floxuridine, pentostatin or gemcitabine, mitotic inhibitors such as halichondrin B and eribulin, protein kinase inhibitors including rapamcyin analogues such as temsirolimus and everolimus, hormone analogues such as octreotide, alkylating agents such as streptozocin and DNA damaging agents such as bleomycin, vascular disrupting agents, colchinol-derivatives and HSP-90 inhibitors. The following cytotoxic agents encompassed by the present invention are mentioned by way of example:
According to a preferred embodiment of the invention, the cytotoxic agent is an antimetabolite, more preferably a nucleoside analogue, such as clofarabine, nelarabine, cytarabine, cladribine, decitabine, azacitidine, floxuridine, pentostatin or gemcitabine.
More preferably, the cytotoxic agent is a cytidine analogue having one of the following structures:
wherein Q is selected from the group consisting of C—H, C—F, C—CH3 and N, and wherein R′ and R″ are independently of each other selected from the group consisting of OH, H and F.
Most preferably the cytotoxic agent is selected from the group consisting of cytarabine, decitabine, azacitidine, floxuridine and gemcitabine (see structures below):
Accordingly, the present invention preferably relates to a hydroxyalkyl starch conjugate as described above, as well as to a method for preparing a hydroxyalkyl starch conjugate and the respective conjugate obtained or obtainable by said method, the conjugate comprising a residue of a cytotoxic agent, said cytotoxic agent being selected from the group consisting of clofarabine, nelarabine, cytarabine, cladribine, decitabine, azacitidine, floxuridine, pentostatin or gemcitabine, most preferably of cytarabine, decitabine, azacitidine, floxuridine and gemcitabine.
Most preferably, the cytotoxic agent is gemcitabine.
According to a further preferred embodiment of the invention, the cytotoxic agent is a kinase inhibitor including rapamycin and rapamcyin analogues, perferably the cytotoxic agent is a rapamycin analogue, in particular, temsirolimus or everolimus.
Antimetabolites, in particular nucleoside analogues have been found to be effective anti-cancer agents. However, to date, their use is limited due to their non specific toxicity and to their short residence time in the plasma. It is herein proposed that this drawback can be overcome by the conjugates according to the present invention, thus, by conjugates, wherein a hydroxyalkyl starch derivative, as described above, is linked via a linking moiety L to a group —O— derived from the primary hydroxyl group of a cytotoxic agent, preferably to a group —O— derived from the primary hydroxyl group of an antimetabolite.
Thus, preferably, the present invention also relates to a conjugate, as described above, as well as to a conjugate obtained or obtainable by a method, as described above, the conjugate having a structure according to one of the following formulas:
wherein Q is selected from the group consisting of C—H, C—F, C—CH3 and N, and wherein R′ and R″ are independently of each other selected from the group consisting of OH, H and F.
The following particularly preferred structures shall be mentioned:
According to the invention, the cytotoxic agent is preferably linked via a cleavable linker to the hydroxyalkyl starch derivative.
The expression “cleavable linker” refers to any linker which can be cleaved physically or chemically and preferably releases the cytotoxic agent in unmodified form. Examples for physical cleavage may be cleavage by light, radioactive emission or heat, while examples for chemical cleavage include cleavage by redox-reactions, hydrolysis, pH-dependent cleavage or cleavage by enzymes.
According to a preferred embodiment of the present invention, the cleavable linker comprises one or more cleavable bonds, preferably hydrolytically cleavable bonds, the cleavage, in particular the hydrolysis, of which releases the cytotoxic agent in vivo. Preferably the bond between linker moiety L and the group —O— derived from the primary hydroxyl group of the cytotoxic agent is a cleavable linkage.
Thus, the present invention also relates to a conjugate as described above, as well as to a conjugate obtained or obtainable by the above described method, wherein the linking moiety L and the residue of the cytotoxic agent M are linked via the group —O— derived from the primary hydroxyl group of the cytotoxic agent, wherein said linkage between —O— and the lining moiety L is cleaved, preferably is hydrolyzed, in vivo and allows for the release of the cytotoxic agent, preferably in unmodified form.
Preferably, the linking moiety L has a structure -L′-F3—, wherein F3 is the functional group linking L′ with M, and wherein the linkage between F3 and the group —O— derived from the primary hydroxyl group of M is cleaved in vivo and releases the (residue of the) cytotoxic agent. L′ is a linking moiety linking the functional group F3 with the hydroxyalkyl starch derivative.
There are in principle no restrictions as to the nature of the functional group F3 provided that this group forms together with the primary hydroxyl group of the cytotoxic agent a functional moiety capable of being cleaved in vivo.
Thus, the present invention also relates to a conjugate as described above, as well as to a conjugate obtained or obtainable by the above described method, wherein the bond between the functional group F3 and the functional group —O— of the residue of the cytotoxic agent M (said group being derived from the primary hydroxyl group of the cytotoxic agent) is a cleavable linkage, which is cleaved in vivo so as to release the cytotoxic agent.
Beside the —C(═Y)— function, this accounts, inter alia, for groups F3 which form together with the group —O— of the residue of the cytotoxic agent M (derived from the primary hydroxyl group of the cytotoxic agent) the structural unit —F3—O—, with —F3—O— being a carbonate, thiocarbonate, xanthogenate, carbamate, or thiocarbamate of the type —YY—C(═Y)—O— with YY being —O—, —S— or —NH— and Y being O, S or NH.
Preferably, the functional group F3 is selected from the group consisting of —C(═Y)— and —YY—C(═Y)—, with Y being O, NH or S and with YY being —O—, —S— or NH—. In particular, the functional group F3 is —C(═Y)—, with Y being O, NH or S. Together with the group O— derived from the primary hydroxyl group of the cytotoxic agent, the functional group F3 therefore preferably forms a —C(═Y)—O— bond with Y being O, NH or S, in particular with Y being O or S, more preferably with Y being 0, and wherein L′ is a linking moiety linking the functional group F3 with the hydroxyalkyl starch derivative.
Therefore, the present invention also relates to a hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, said conjugate having a structure according to the following formula HAS′(-L-M)n, wherein the linking moiety L has a structure -L′-F3—, wherein F3 is a functional group linking L′ with the residue of the cytotoxic agent M, thereby forming a —F3—O— group, preferably wherein F3 is a —C(═Y)— group, with Y being O, NH or S, and wherein F3 is linked to the primary hydroxyl group of the cytotoxic agent, i.e. to the group —O— derived from the primary hydroxyl group of the cytotoxic agent, thereby forming a —C(═Y)—O— bond with Y being O, NH or S, in particular with Y being O or S, more preferably with Y being O, and wherein L′ is a linking moiety. Likewise, the present invention relates to a method for preparing a conjugate having a structure HAS′(-L-M)n, wherein L has a structure -L′-F3—, wherein F3 is a functional group linking L′ with M, preferably wherein F3 is a —C(═Y)— group, with Y being O, NH or S, and wherein the structural unit —F3—O— is formed upon reaction of the crosslinking compound L with the primary hydroxyl group of the cytotoxic agent. Likewise, the present invention relates to a conjugate obtained or obtainable by the method, as described above.
Accordingly, the present invention also relates to a conjugate, as described above, as well as to a conjugate, obtained or obtainable by a method, as described above, the conjugate having a structure according to one of the following formulas:
wherein Q is selected from the group consisting of C—H, C—F, C—CH3 and N, and wherein R′ and R″ are independently of each other selected from the group consisting of OH, H and F; more preferably according to the following formula
According to a preferred embodiment of the present invention, the functional group F3 and the hydroxyalkyl starch derivative are separated by a suitable linking moiety L′, as described above. The term linking moiety L′ as used in this context of the present invention relates to any suitable chemical moiety bridging F3 and the hydroxyalkyl starch derivative.
In general, there are no particular restrictions as to the chemical nature of the linking moiety L′ with the proviso that L′ provides suitable chemical properties for the novel conjugates for their intended use.
Preferably, L′ is a linking moiety such as an alkyl, alkenyl, alkylaryl, arylalkyl, aryl, heteroaryl, alkylheteroaryl or heteroarylalkyl group.
Within the meaning of the present invention, the term “alkyl” relates to non-branched alkyl residues, branched alkyl residues, cycloalkyl residues, as well as residues comprising one or more heteroatoms or functional groups, such as, by way of example, —O—, —S—, —NH—, —NH—C(═O)—, —C(═O)—NH—, and the like. The term also encompasses alkyl groups which are further substituted by one or more suitable substituents. The term “substituted alkyl” as used in this context of the present invention preferably refers to alkyl groups being substituted in any position by one or more substituents, preferably by 1, 2, 3, 4, 5 or 6 substituents, more preferably by 1, 2 or 3 substituents. If two or more substituents are present, each substituent may be the same or may be different from the at least one other substituent. There are in general no limitations as to the substituent. The substituents may be, for example, selected from the group consisting of aryl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonato, phosphinato, amino, acylamino, including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido, amidino, nitro, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, trifluoromethyl, cyano, azido, cycloalkyl such as e.g. cyclopentyl or cyclohexyl, heterocycloalkyl such as e.g. morpholino, piperazinyl or piperidinyl, alkylaryl, arylalkyl and heteroaryl. Preferred substituents of such organic residues are, for example, halogens, such as fluorine, chlorine, bromine or iodine, amino groups, hydroxyl groups, carbonyl groups, thiol groups and carboxyl groups.
The term “alkenyl” as used in the context of the present invention refers to unsaturated alkyl groups having at least one double bond. The term also encompasses alkenyl groups which are substituted by one or more suitable substituents.
The term “alkynyl” refers to unsaturated alkyl groups having at least one triple bond. The term also encompasses alkynyl groups which are substituted by one or more suitable substituents.
Within the meaning of the present invention, the term “aryl” refers to, but is not limited to, optionally suitably substituted 5- and 6-membered single-ring aromatic groups as well as optionally suitably substituted multicyclic groups, for example bicyclic or tricyclic aryl groups. The term “aryl” thus includes, for example, optionally substituted phenyl groups or optionally suitably substituted naphthyl groups. Aryl groups can also be fused or bridged with alicyclic or heterocycloalkyl rings which are not aromatic so as to form a polycycle, e.g., benzodioxolyl or tetraline.
The term “heteroaryl” as used within the meaning of the present invention includes optionally suitably substituted 5- and 6-membered single-ring aromatic groups as well as substituted or unsubstituted multicyclic aryl groups, for example bicyclic or tricyclic aryl groups, comprising one or more, preferably from 1 to 4 such as 1, 2, 3 or 4, heteroatoms, wherein in case the aryl residue comprises more than 1 heteroatom, the heteroatoms may be the same or different. Such heteroaryl groups including from 1 to 4 heteroatoms are, for example, benzodioxolyl, pyrrolyl, furanyl, thiophenyl, thiazolyl, isothiazolyl, imidazolyl, triazolyl, tetrazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxazolyl, benzothiazolyl, benzoimidazolyl, benzothiophenyl, methylenedioxyphenylyl, napthyridinyl, quinolinyl, isoquinolinyl, indolyl, benzofuranyl, purinyl, deazapurinyl, or indolizinyl.
The term “substituted aryl” and the term “substituted heteroaryl” as used in the context of the present invention describes moieties having substituents replacing a hydrogen on one or more atoms, e.g. C or N, of an aryl or heteroaryl moiety. Again, there are in general no limitations as to the substituent. The substituents may be, for example, selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonato, phosphinato, amino, acylamino, including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido, amidino, nitro, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, trifluoromethyl, cyano, azido, cycloalkyl such as e.g. cyclopentyl or cyclohexyl, heterocycloalkyl such as e.g. morpholino, piperazinyl or piperidinyl, alkylaryl, arylalkyl and heteroaryl. Preferred substituents of such organic residues are, for example, halogens, such as fluorine, chlorine, bromine or iodine, amino groups, hydroxyl groups, carbonyl groups, thiol groups and carboxyl groups.
The term “alkylaryl” as used in the context of any linking moiety described in the present invention is denoted to mean a linking moiety having the structure alkyl-aryl-, thus being linked on one side via the alkyl group and on the other side via the aryl group, wherein this term is meant to also encompass linking moieties such as alkyl-aryl-alkyl- linking moieties. The term “alkylaryl group”, when used in the context of any substituent described hereinunder and above, is denoted to mean a residue being linked via the alkyl portion, said alkyl portion being further substituted with an aryl moiety.
The term “arylalkyl” as used in the context of any linking moiety described in the present invention is denoted to mean a linking moiety having the structure aryl-alkyl-, thus being linked on one side via the aryl group and on the other side via the alkyl group, wherein this term is meant to also encompass linking moieties such as aryl-alkyl-aryl- linking moieties. The term “arylalkyl group”, when used in the context of any substituent described hereinunder and above, is denoted to mean a residue being linked via the aryl portion, said aryl portion being further substituted with an alkyl moiety.
The term “alkylheteroaryl” as used in the context of any linking moiety described in the present invention is denoted to mean a linking moiety having the structure alkyl-heteroaryl-, thus being linked on one side via the alkyl group and on the other side via the heteroaryl group, wherein this term is meant to also encompass linking moieties such as alkyl-heteroaryl-alkyl- linking moieties. The term “alkylheteroaryl group”, when used in the context of any substituent described hereinunder and above, is denoted to mean a residue being linked via the alkyl portion, said alkyl portion being further substituted with a heteroaryl moiety.
The term “heteroarylalkyl” as used in the context of any linking moiety described in the present invention is denoted to mean a linking moiety having the structure heteroaryl-thus being linked on one side via the heteroaryl group and on the other side via the alkyl group, wherein this term is meant to also encompass linking moieties such as heteroaryl-alkyl-heteroaryl- linking moieties. The term “heteroarylalkyl group”, when used in the context of any substituent described hereinunder and above, is denoted to mean a residue being linked via the heteroaryl portion, said heteroaryl portion being further substituted with an alkyl moiety.
Without wanting to be bound to any theory, it is believed that the efficacy and/or unspecific toxicity of the conjugates of the invention can further be favorably controlled by providing linking moieties L′ which have an advantageous influence on the respective release rate of the cytotoxic agent in vivo.
The term “advantageous influence on the release rate” as used herein shall describe an influence allowing for a release rate which generates suitable amounts of the cytotoxic agent in a suitable time period so that therapeutic levels of the cytotoxic agent are delivered prior to excretion of the conjugate or conjugate fragments through the kidney or inactivation of the cytotoxic agent comprised in the conjugate by alternative mechanisms in the body. The term “suitable amounts” as used in this context of the present invention shall describe an amount with which the desired therapeutic effect of the cytotoxic agent is achieved, preferably together with an unspecific toxicity of the cytotoxic agent as low as possible.
In the context of the present invention, it is assumed that the release rates can, inter alia, be tailored to specific needs by choosing a suitable electron-withdrawing group and/or a suitable sterically demanding group and/or an unsubstituted linear alkyl group in close proximity to the functional group F3.
The term “present in close proximity to” as used in the context of the present invention is preferably denoted to mean a group which is present in alpha, beta, or gamma position to the functional group F3.
The term “electron-withdrawing group” is recognized in the art, and denotes the tendency of a functional group to attract valence electrons from neighboring atoms by means of a difference in electronegativity with respect to the neighboring atom (inductive effect) or by withdrawal of π-electrons via conjugation (mesomeric effect).
The term “sterically demanding group” is denoted to mean a group, being sterically more demanding than a hydrogen, preferably a substituent such as an alkyl, aryl or heteroaryl group, or a side chain of a natural or unnatural amino acid.
Without wanting to be bound to any theory, it is believed that the higher the tendency of the electron-withdrawing group to attract valence electrons, the faster the cytotoxic agent is released in vivo.
Further, it is believed that the more sterically demanding the group present in close proximity, more preferably in alpha position, the slower the release rate and the longerthe residence time in the plasma allowing an accumulation in tumor tissue and preventing the premature clearance of the low molecular weight cytotoxic agent, through the kidney.
Accordingly, depending on the specific needs, the following embodiments are described:
The electron-withdrawing group, if present, may be either part of the linking moiety L′ or, according to an alternative embodiment, may be present in the hydroxyalkyl starch derivative, provided that the electron-withdrawing group is present in close proximity to the functional group F3, as described above.
Preferably, the electron-withdrawing group is a moiety selected from the group consisting of —O—, —S—, —SO—, —SO2—, —NRe—, —C(═Ye)—, —NRe—C(═Ye)—, —C(═Ye)—NRe, —NO2 comprising groups such as —CH(NO2)—, —CN comprising groups, such as —CH(CN)—, aryl groups, heteroaryl groups, cyclic imide groups and at least partially fluorinated alkyl moieties, wherein Ye is either O, S or NRe, and wherein Re is one of hydrogen, alkyl, aryl, arylalkyl, heteroaryl, alkylaryl, alkylheteroaryl or heteroarylalkyl group, and the like.
Within the meaning of the present invention, the term “at least partially fluorinated alkyl moiety” refers to, optionally substituted, alkyl groups, such as non-branched alkyl residues, branched alkyl residues, cycloalkyl residues, as well as residues comprising one or more heteroatoms or functional groups, such as, by way of example, —O—, —S—, —NH—, —NH—C(═O), —C(═O)—NH—, and the like, having at least one of the hydrogen atoms replaced with a fluorine atom. In some fluorinated alkyl groups, all the hydrogen atoms are replaced with fluorine atoms, i.e., the fluorinated alkyl group is a perfluoroalkyl group. The following groups are mentioned, by way of example: —CH2F, CF3, —CHF2, —CF2—, —CHF—, —CH2—CF3, —CH2—CHF2 and —CH2—CH2F.
Within the context of the present invention, the term “cyclic imide groups” is denoted to mean a cyclic structural unit according to the general formula:
wherein the ring structure is preferably a 5-membered ring, 6-membered ring or 7-membered ring. Most preferably the cyclic imide is a succinimide- having the following structure
Preferably the electron-withdrawing group, if present, is selected from the group consisting of NH—C(═O)—, —C(═O)—NH—, —NH—, —O—, —S—, —SO—, —SO2— and -succinimide-. More preferably the electron-withdrawing group is selected from the group consisting of —C(═O)—NH—, —NH—, —O—, —S—, —SO2— and -succinimide-.
Thus, the present invention also relates to a conjugate, as described above, as well as a conjugate obtained or obtainable by the above-described method, wherein the conjugate comprises an electron-withdrawing group, preferably in alpha or beta position to each functional group F3, more particular in alpha position to each functional group F3, wherein the electron-withdrawing group is a group selected from the group consisting of —NH—C(═O)—, —C(═O)—NH—, —NH—, —O—, —S—, —SO—, —SO2— and -succinimide-.
According to a particularly preferred embodiment of the present invention, the linking moiety L′ has a structure according to the following formula —[F2]q-[L2]g-[E]e-[CRmRn]f-, wherein E is an electron-withdrawing group, L2 is a linking moiety, F2 is a functional group, f is in the range of from 1 to 20, g is 0 or 1, q is 0 or 1, e is 0 or 1, and wherein Rm and Rn are, independently of each other, H, aryl, alkyl or the side chain of a natural or unnatural amino acid, preferably H or alkyl.
Thus, the conjugate, described above, has a structure according to the formula
HAS′(—[F2]q-[L2]g-[E]e-[CRmRn]f—F3-M)n,
more preferably according to one of the following formulas
most preferably according to the following formula
According to the first preferred embodiment of the invention, an electron-withdrawing group E is present in linking moiety L′. In this case, integer e is 1.
Preferably E, if present, is selected from the group consisting of —O—, —S—, —SO—, —SO2—, —NRe—, —C(═Ye)—, —NRe—C(═Ye)—, —C(═Ye)—NRe—, —CH(NO2)—, —CH(CN)—, aryl groups, heteroaryl groups, cyclic imide groups and at least partially fluorinated alkyl moieties, more preferably of the group consisting of —C(═O)—NH—, —NH—(C═O)—, —O—, —S—, —SO—, —SO2— and -succinimide-, more preferably E, if present, is selected from the group consisting of —NH—C(═O), —C(═O)—NH—, -succinimide-, —O— and S—.
Accordingly, the following conjugate structures are thus preferred: HAS′(—[F2]q-[L2]g-C(═O)—NH—[CRmRn]f—F3-M)n, HAS′(—[F2]q-[L2]g—NH—C(═O)—[CRmRn]f—R3-M)n, HAS′(—[F2]q—O—[CRmRn]f—F3-M)n, HAS′(—[F2]q—[L2]g—S—[CRmRn]f—F3-M)n, HAS′(—[F2]q-[L2]g-succinimide-[CRmRn]f—F3-M)n. More preferably, the electron-withdrawing group E is selected from the group consisting of —NH—C(═O), —C(═O)—NH—, -succinimide-, —O— and —S— and the functional group F3 is a —C(═Y)— group, the hydroxyalkyl starch conjugate thus having preferably a structure selected from the group consisting of HAS′(—[F2]q-[L2]q-C(═C)—NH—[CRmRn]f—C(═Y)-M)n, HAS′(—[F2]q-[L2]g-NH—(C═O)—[CRmRn]f—C(═Y)-M)n, HAS′(—[F2]q—[L2]g—O—[CRmRn]f—C(═Y)-M)n, HAS′(—[F2]-[L2]g-S—[CRmRn]f—C(═Y)-M)n, HAS′(—[F2]q-[L2]g-succinimide-[CRmRn]f—C(═Y)-M)n, wherein Y is preferably selected from O or S, in particular wherein Y is O.
According to an alternative preferred embodiment the functional group F2 is an electron-withdrawing group present in close proximity to the functional group F3. In this case, F2 may for example be a group such as —C(═O)—NH—, —NH—, —O—, —S— or -succinimide-. In case F2 is an electron-withdrawing group present in close proximity to the functional group F3, which is in alpha, beta or gamma position to the functional group F3, F2 may be present instead of E or in addition to E.
According to this embodiment, the following conjugate structures are thus particularly preferred: HAS′(—C(═O)—NH-[L2]g-[E]e-[CRmRn]f—F3-M)n, HAS′(—NH-[L2]g-[E]e-[CRmRn]f—F3-M)n, HAS′(—O-[L2]g-[E]e-[CRmRn]f—F3-M)n, HAS′(—S[L2]g-[E]e-[CRmRn]f—F3-M)n and HAS′(-succinimide-[L2]g-[E]e-[CRmRn]f—F3-M)n, more preferably F3 is C(═Y)— and the conjugate structures are selected from the group consisting of HAS′(—C(═O)—NH—[L2]g-[E]e-[CRmRn]f—C(═Y)-M)n, HAS′(—NH—[L2]g-[E]e-[CRmRn]f—C(═Y)-M)n, HAS′(—S-[L2]g-[E]e-[CRmRn]f—C(═Y)-M)n, HAS′(—O-[L2]g-[E]e-[CRmRn]f—C(═Y)-M)n and HAS′(-succinimide-[L2]g-[E]e[CRmRn]f—C(═Y)-M)n, wherein Y is preferably selected from O or S, in particular wherein Y is O.
According to an alternative embodiment, the electron-withdrawing group, if present in the linking moiety L′, may also be present in the linking moiety L2.
Further, the electron-withdrawing group, if present, may also be present in the structural unit [CRmRn]f. It is recalled that integer f of the structural unit [CRmRn]f is preferably in the range of from 1 to 3 and Rm and Rn are, independently of each other, H, aryl or alkyl or the side chain of a natural or unnatural amino acid, preferably H or alkyl. Since the term “alkyl” as used in the context of the present invention also encompasses alkyl groups which are further substituted, the electron-withdrawing group may also be present in at least one of Rm or Rn, such as, e.g. in the form of a —CH2F, —CHF2 or —CF3 group or the like.
According to a further preferred embodiment of the present invention, the electron-withdrawing group, if present, is not present in the linking moiety L′ but is instead part of the hydroxyalkyl starch derivative (HAS′). In this case e is 0 and the integers q, g and f are chosen so that the electron-withdrawing group is preferably present in the hydroxyalkyl starch derivative in a position being in close proximity to the functional group F3, as described above, preferably in alpha or beta position to the functional group F3.
The sterically demanding group, if present, is preferably present in the structural unit —[CRmRn]f, as described in detail hereinunder.
In general, there are no particular restrictions as to the chemical nature of the linking moiety L2. The term “linking moiety L2” as used in the context of the present application, relates to any suitable chemical moiety bridging F2 and E, in case q and e are 1, or bridging F2 and the structural unit [CRmRn]f in case q is 1, e is 0 and f is in the range of from 1 to 10, or bridging E and the hydroxyalkyl starch derivative in case q is 0 and e is 1. Thus L2 may, inter alia, be alkyl, alkenyl, alkylaryl, arylalkyl, aryl, heteroaryl, alkylheteroaryl or heteroarylalkyl group. The respective residues may comprise one or more substituents as described above.
Preferably, L2 is an alkyl group comprising 1 to 20, preferably 1 to 10, more preferably 1 to 8, more preferably, 1 to 6, such as 1, 2, 3, 4, 5 or 6, more preferably 1 to 4, more preferably from 1 to 3, and most preferably from 2 to 3 carbon atoms. According to the definition of the term “alkyl”, the above mentioned alkyl groups may be substituted.
In particular, L2 comprises at least one structural unit according to the following formula
wherein L2a and L2b are independently of each other H or an organic residue selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkylaryl, heteroaryl, heteroarylalkyl, alkylheteroaryl, hydroxyl, and halogen, such as fluorine, chlorine, bromine, or iodine.
More preferably, L2 has a structure according to the following formula
with L2a and L2b being selected from the group consisting of H, methyl or hydroxyl, with nL being preferably in the range of from 1 to 8, more preferably of from 1 to 6, more preferably of from 1 to 4, more preferably of from 1 to 3, and most preferably of from 1 to 2. According to an even more preferred embodiment, the spacer L2 consists of the structural unit according to the following formula
wherein integer n1 is from 1 to 8, more preferably in the range of from 1 to 6, more preferably in the range of from 1 to 4, more preferably from 1 to 3, and most preferably from 1 to 2. Therefore, according to a preferred embodiment of the present invention, L2 has a structure selected from the group consisting of —CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—, —CH2—CH2—, —CH2—, more preferably L2 is selected from the group consisting of —CH2—, —CH2—CH2—, —CH2—CH2—CH2—.
According to one preferred embodiment of the present invention, the present invention also relates to a conjugate, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, wherein the conjugate has a structure selected from the group consisting of the following formulas HAS′(—[F2]q—[CH2]g—[E]e—[CRmRn]f—F3-M)n, HAS′(—[F2]q—[CH2—CH2]g-[E]e—[CRmRn]f—F3-M)n, HAS′(—[F2]q—[CH2—CH2—CH2]g[E]e-[CRmRn]f—F3-M)n, HAS′(—[F2]q—[CH2—CH2—CH2—CH2]c[E]e[CRmRn]f—F3-M)n, HAS′(—[F2]q—[CH2—CH2—CH2—CH2—CH2]g-[E]e-[CRmRn]f—F3-M)n, HAS′(—[F2]q—[CH2—CH2—CH2—CH2—CH2]g-[E]e-[CRmRn]f—F3-M)n, more preferably the conjugate is selected from the following structures: HAS′(-[F2][CH2]g[E]e-[CRmRn]f—F3-M)n, HAS′(-[F2]q—[CH2—CH2]g-[E]e-[CRmRn]f—F3-M)n and HAS′(—[F2]q—[CH2—CH2—CH2]g-[E]e-[CRmRn]f—F3-M)a, more preferably from the group consisting of HAS′([F2]yCH2-[E]e-[CRmRn]f—F3-M)n, HAS′(—[F2]q—CH2—CH2-[E]e-[CRmRn]f—F3-M)n and HAS′(-[F2]q—CH2—CH2—CH2—[E]e—[CRmRn]f—F3-M)n.
Most preferably g is 1, i.e. L2 is present, and L2 is —CH2—, —CH2—CH2— or —CH2—CH2—CH2—.
The functional group F2, if present, is a functional group linking the hydroxyalkyl starch derivative with the linking moiety L2, in case g is 1, or with the electron-withdrawing group E in case g is 0 and e is 1, or with the structural unit [CRmRn]f, in case g and e are 0.
There are, in general, no particular restrictions as regards the chemical nature of the functional group F2 provided that a stable bond is formed linking the hydroxyalkyl starch derivative with L2, E or the structural unit [CRmRn]f, respectively. The stable bond may also be a bond which is eventually cleaved in vivo. As described above, the functional group F2 may serve as electron-withdrawing group in close proximity to the functional group F3 to provide an optimized hydrolysis rate of the linkage between F3 and the cytotoxic agent.
Preferably, F2 is a group consisting of —Y1—, —C(═Y2)—, —C(═Y2)—NRF2—,
wherein Y1 is selected from the group consisting of —S—, —O—, —NH—, —NH—NH—, —CH2—CH2—SO2—NRF2—, —CH2—CHOH—, and cyclic imides, such as succinimide, and wherein Y2 is selected from the group consisting of NH, S and O, and wherein RF2 is selected from the group consisting of hydrogen, alkyl, alkylaryl, arylalkyl, aryl, heteroaryl, alkylheteroaryl or heteroarylalkyl group.
More preferably, F2 is a group consisting of —Y1—, —C(═Y2)—, —C(═Y2)—NRF2—,
Preferably, F2 is selected from the group consisting of S—, —NH—NH—, and succinimide-, more preferably F2 is succinimide- or —S—, most preferably succinimide-.
The functional group F2 is suitably chosen depending on the functional group —X— being present in the hydroxyalkyl starch derivative.
Thus, according to one preferred embodiment of the invention, the present invention also relates to the conjugate as described above, wherein in the structural unit [F2]q, q is 1 and F2 is —S— or succinimide-, the conjugate having a structure HAS′(-succinimide-[L2]g-[E]e-[CRmRn]f—F3-M)n or HAS′(—S—[L2]g—[E]e—[CRmRn]f—F3-M)n, more preferably HAS′(-succinimide-[L2]g—[E]e—[CRmRn]f—F3-M)n.
Furthermore, the functional group F2 may form together with a functional group of the hydroxyalkyl starch a 1,2,3-triazole ring. In the event that the functional group F2 forms together with a functional group of the hydroxyalkyl starch derivative a 1,2,3-triazole, inter alia, the following structures are conceivable for this structural building block.
In case the conjugate comprises a triazole linking group, preferably the functional group F2 forms together with the functional group X present in the residue of the hydroxyalkyl starch derivative a 1,2,3-triazole. Preferably such a triazole group is formed via a 1,3-dipolar cycloaddition between an azide and a terminal or internal alkynyl group to give a 1,2,3-triazole. For example in case Z1 is an alkynyl group or azide and the crosslinking compound L bears a functional group K2 being the respective azide or alkynyl, a triazole linkage may be formed upon reaction of the crosslinking compound L with the hydroxyalkyl starch derivative.
As regards the structural unit [CRmRn]f, integer f is in the range of from 1 to 20, preferably in the range of from 1 to 10, such 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, more preferably in the range of from 1 to 5, and Rm and Rn are, independently of each other, H, alkyl, aryl or a side chain of a natural or unnatural amino acid, preferably H or alkyl. In case integer f is greater than 1, each repeating unit [CRmRn] may be the same or may be different from each other.
Preferably, Rm and Rn are, independently of each other, selected from H or branched or linear alkyl chains, comprising 1 to 10, preferably 1 to 8, more preferably 1 to 5, most preferably 1 to 3 carbon atoms. More preferably Rm and Rn are, independently of each other, selected from the group consisting of H, methyl, ethyl, propyl, butyl, sec-butyl and tert-butyl, more preferably Rm and Rn are, independently of each other, H or methyl.
By way of example, the following preferred structures for the structural unit [CRmRn]f are mentioned: —CH2—CH2—CH2—CH2—, CH2—CH2—CH2—CH2—CH2—, CH2—CH2—CH2—, —CH2—CH2—, —CH2—, —CH(CH3)—, —CH(CH2CH3)—, —CH(CH(CH3)2)—, —CH(CH3)—CH2—, —CH2—CH(CH3)—, —CH(CH3)—CH2—CH2—, —CH2—CH(CH3)—CH2—, —CH2—CH2—CH(CH3)—, —CH2—CH2—CH2—CH(CH3)—, —CH2—CH2—CH2—CH2—CH(CH3)—, —C(CH3)2—, —CH(CH3)—CH(CH3)—, —CH(CH3)—CH(CH3)—CH2—, —CH2—CH(CH3)—CH(CH3)—, —CH(CH3)—CH2—CH(CH3)—.
According to one preferred embodiment of the present invention, Rm and Rn are both H. The structural unit [CRmRn]f is thus preferably CH2—CH2—CH2—CH2—CH2—, CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—, CH2—CH2— or CH2—. Thus, the present invention also relates to the conjugate as described above, the conjugate having a structure selected from the group consisting of HAS′([F2]q-[L2]g-[E]e-CH2—CH2—CH2—CH2—CH2—F3-M)n, HAS′(—[F2]q-[L2]g[E]e-CH2—CH2—CH2—CH2—F3-M)n, HAS′(-[F2]q-[L1]g-[E]e-CH2—CH2—CH2—F3-M)n, HAS′(—[F2]g-[L2]q-[E]e-CH2—CH2—F3-M)n and HAS′(—[F2]q-[L2]g-[E]e-CH2—F3-M)n.
According to another preferred embodiment, at least one of Rm or Rn of at least one repeating unit of the structural unit [CRmRn]f is a sterically demanding group, more preferably an alkyl group, most preferably at least one of Rm or Rn is present in alpha, beta or gamma position, more preferably in alpha position. Most preferably, at least one of Rm or Rn is a methyl group. Preferably, the structural unit [CRmRn]f is a group having the structure
—[—CRmRn]f-1—CH(CH3)— or —[CRmRn]f-1—C(CH3)2—.
Thus, the present invention also relates to a conjugate, as described above, as well as to a conjugate obtained or obtainable by the above described method, the conjugate having a structure according to the formula
HAS′(—[F2]q-[L2]g-[E]e-[CRmRn]f-1—C(CH3)2—F3-M)n,
or
HAS′(—[F2]q-[L2]g-[E]e-[CRmRn]f-1—CH(CH3)—F3-M)n
more preferably according to one of the following formulas
most preferably according to the following formula
According to an alternative embodiment, the structural unit -[E]e-[CRmRn]f—F3— is a residue derived from a natural or unnatural amino acid being linked to the linking moiety L2, wherein e is 1 and E is —C(═O)—NH— and wherein one of Rm and Rn is the side chain of a natural or unnatural amino acid. Alternatively, e is 0 and g is 0 and the structural unit —[F2]q—[CRmRn]f—F3— is a residue of a natural or unnatural amino acid, wherein one of Rm and Rn is the side chain of a natural or unnatural amino acid.
The term “residue of an amino acid” is denoted to mean an amino acid being incorporated into the linker L or an amino acid being the linker L and being incorporated into the conjugate of the invention, respectively, wherein the residue of an amino acid has a structure according to the following formula:
The term “side chain of a natural or unnatural amino acid” refers to the residue being linked to the alpha carbon atom of a natural or unnatural amino acid, in this case the C atom of the structural unit —[CRmRn]f—. The term “natural amino acid” refers to naturally occurring amino acids or residues which typically occur in proteins including their stereoisomeric forms. Natural amino acids include alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr) and valine (Val). The term unnatural amino acid includes any conceivable amino acid. This term includes amino acids bearing a side chains comprising acidic, basic, neutral and/or aromatic moieties. Conceivable amino acids to be mentioned are, for example, azetidine carboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4-diaminoisobutyric acid, desmosine, 2,2′-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylglycine, N-methylisoleucine, N-methylvaline, norvaline, norleucine, ornithine, naphthylalanine, diaminopropionic acid, N-(fluoropropionyl)-diaminobutyric acid, N-fluorobenzoyl-diaminobutyric acid, N-fluorobenzoyl-diaminopropionic acid, citrulline and pipecolic acid.
By way of example, the following preferred linking moieties L are mentioned:
In accordance with the above-mentioned definition of HAS, the residue of the hydroxyalkyl starch derivative preferably comprises at least one structural unit according to the following formula (I)
wherein at least one of Ra, Rb or Rc comprises the functional group —X— and wherein Ra, Rb and Rc are, independently of each other, selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]x—OH, —[O—(CRwRx)—(CRyRz)]y—X—, —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-X—, wherein Rw, Rx, Ry and Rz are independently of each other selected from the group consisting of hydrogen and alkyl, y is an integer in the range of from 0 to 20, preferably in the range of from 0 to 4, F1 is a functional group, p is 0 or 1, L1 is a linking moiety and —X— is a functional group linking the hydroxyalkyl starch derivative and the linking moiety L. Preferably X is formed upon reaction of Z1 with the crosslinking compound L. HAS″ is a remainder of the hydroxyalkyl starch derivative, as described above.
The amount of functional groups X present in the residue of the hydroxyalkyl starch derivative being incorporated into the conjugate of the invention corresponds to the amount of functional groups Z1 present in the corresponding hydroxyalkyl starch derivative prior to the conjugation of said derivative to the crosslinking compound L or the structural unit -L-M. Thus, preferably 0.15% to 2% of all residues Ra, Rb and Rc present in the hydroxyalkyl starch derivative contain the functional group Z1. More preferably, 0.15% to 2% of all residues Ra, Rb and Rc present in the hydroxyalkyl starch derivative have the structure —[O—(CRwRx)—(CRyRz)]y—X— or —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-X—. According to a particularly preferred embodiment, Ra, Rb and Rc are selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]xOH and —[O—(CRwRx)—(CRyRz)]y—X—, wherein 0.15% to 2% of all residues Ra, Rb and Rc present in the hydroxyalkyl starch derivative have the structure —[O—(CRwRx)—(CRyRz)]y—X—. According to an alternative preferred embodiment, Ra, Rb and Rc are selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]x—OH and —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-X—, wherein 0.15% to 2% of all residues Ra, Rb and Rc present in the hydroxyalkyl starch derivative have the structure —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-X—.
According to a preferred embodiment of the present invention, the hydroxyalkyl starch derivative is a hydroxyethyl starch derivative. Therefore, the present invention also describes a conjugate, comprising a residue of a hydroxyalkyl starch derivative, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, wherein the conjugate comprises a residue of a hydroxyethyl starch derivative and a cytotoxic agent, the residue of HES derivative preferably comprises at least one structural unit, according to the following formula (I)
wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—CH2—CH2]s—OH, —[O—CH2—CH2]t—X— and —[O—CH2—CH2]t—[F1]p-L1-X—, wherein t is in the range of from 0 to 4, and wherein s is in the range of from 0 to 4, p being 0 or 1, and wherein at least one of Ra, Rb and Rc comprises the functional group X, and wherein X is linked to the linking moiety L comprised in the conjugate of the present invention.
According to a preferred embodiment of the present invention, this linkage between X and L is obtained by coupling a hydroxyalkyl starch derivative being functionalized with at least one functional group Z1, as described above, to the crosslinking compound L comprising the functional group K2 or a derivative of a cytotoxic agent -L-M comprising the functional group K2, thereby obtaining a covalent linkage between HAS′ and L, wherein, as result, the residue of the hydroxyalkyl starch is linked via the functional group X to the linking moiety L. Further preferred embodiments as to this method are described below.
Preferably all functional groups X present in a given hydroxyalkyl starch derivative comprised in a conjugate according to the invention, are linked to the linking moiety L, most preferably to the structural unit -L-M.
X is a functional group linking the hydroxyalkyl starch derivative with the linking moiety L, wherein L is preferably -L′-F3—, and wherein more preferably L′ is —[F2]q-[L2]g-[E]e-[CRmRn]f—. Thus, X is a linking group preferably linking the hydroxyalkyl starch derivative with the functional group F2 in case q is 1, or with the linking moiety L2 in case q is 0 and g is 1, or with the electron-withdrawing group E in case q and g are 0 and e is 1, or with the structural unit [CRmRn]f in case q, g, e are 0 and f is in the range of from 1 to 20, preferably in the range of from 1 to 10.
In general, there exists no limitation regarding the functional group X provided that the functional group X is able to link the hydroxyalkyl starch derivative with the linking moiety L. According to a preferred embodiment of the present invention, and depending on the respective group of the linking moiety L being linked to X, X is selected from the group consisting of —Yxx—, —C(═Yx)—, —C(═Yx)—NRxx, —CH2—CH2—C(═Yx)—NRxx—
wherein Yxx is selected from the group consisting of —S—, —O—, —NH—, —NH—NH—, —CH2—CH2—SO2—NRxx—, and cyclic imides, such as succinimide, and wherein Yx is selected from the group consisting of NH, S and O, and wherein Rxx is selected from the group consisting of hydrogen, alkyl, alkylaryl, arylalkyl, aryl, heteroaryl, alkylheteroaryl or heteroarylalkyl group.
Furthermore, the functional group X may form together with a functional group of the linking moiety L, such as with the functional group F2, a 1,2,3-triazole ring, as described hereinabove.
More preferably X is selected from the group consisting of Yxx, —C(═Yx)—, —C(═Yx)—NRxx—, —CH2—CH2—C(═Yx)—NRxx—
More preferably X is selected from the group consisting of —O—, —S—, —NH— and —NH—NH—. Most preferably X is —S—.
Therefore, the present invention also describes a conjugate, comprising a residue of a hydroxyalkyl starch derivative, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, wherein the conjugate comprises a residue of a hydroxyalkyl starch derivative and a cytotoxic agent, the residue of the hydroxyalkyl starch derivative preferably comprises at least one structural unit according to the following formula (I)
wherein at least one of Ra, Rb and Rc is —[O—(CRwRx)—(CRyRz)]y—S— or —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-S—, preferably wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—S— or —[O—CH2—CH2]t—[F1]p-L1-S—.
According to one preferred embodiment of the present invention, at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—S—. Thus, the following hydroxyalkyl starch derivatives may be mentioned as preferred embodiments of the invention:
According to another preferred embodiment of the present invention, at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—[F1]p-L1-S—. Thus, the following hydroxyalkyl starch derivatives may be mentioned as preferred embodiments of the invention:
According to a preferred embodiment of the invention, the linking moiety L is directly linked to the functional group X of the hydroxyalkyl starch derivative and, on the other side, directly linked to a the group —O— derived from the primary hydroxyl group of the cytotoxic agent.
According to a more preferred embodiment of the invention, the linking moiety L is -L′-—C(═O)— and the conjugate has a structure according to the following formula:
wherein Q is selected from the group consisting of C—H, C—F, C—CH3 and N, and R′ and R″ are independently of each other selected from the group consisting of OH, H and F, more preferably according to the following formula
wherein the hydroxyalkyl starch comprises at least one structure according to the following formula (I)
wherein at least one of Ra, Rb and Rc is —[O—(CRwRx)—(CRyRz)]y—S— or —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-S—, preferably wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—S— or —[O—CH2—CH2]t—[F1]p-L1S— and wherein the linking moiety L′ is linked to the functional group —S—.
F1 is a functional group, which, if present, is preferably selected from the group consisting of —Y7—, —Y7—C(═Y6)—, —C(═Y6)—, —Y7—C(═Y6)—Y8—, —C(═Y6)—Y8—, wherein —Y7— is selected from the group consisting of —NRY7—, —O—, —S—, -succinimide-, —NH—NH—, —NH—O—, —CH═N—O—, —O—N═CH—, —CH═N—, —N═CH—, —Y8— is selected from the group consisting of —NRY8—, —S—, —O—, —NH—NH— and Y6 is selected from the group consisting of NRY6, O and S, wherein RY6 is H or alkyl, preferably H, and wherein RY7 is H or alkyl, preferably H, and wherein RY8 is H or alkyl, preferably H.
According to a preferred embodiment of the present invention the functional group F1 is, if present, selected from the group consisting of —NH—, —O—, —S—, —NH—C(═O)—, —O—C(═O)—NH—, —NH—C(═S)—, —O—C(═O)—, —C(═O)—, —NH—C(═O)—NH—, —NH—NH—C(═O)—, NH—, —NH—C(═O)—NH—NH—, more preferably F1 is, if present, —O— or —O—C(═O)—NH—.
Therefore, the present invention also describes a conjugate, comprising a hydroxyalkyl starch derivative, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, the hydroxyalkyl starch derivative preferably comprising at least one structural unit according to the following formula (I)
wherein at least one of Ra, Rb and Rc is —[O—(CRwRx)—(CRyRz)]y—X— or —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-X—, preferably wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—X— or —[O—CH2—CH2]t—[F1]p-L1-X—, more preferably wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—S— or —[O—CH2—CH2]t—[F1]p-L1-S—, wherein F1, if present, is preferably —O— or —O—C(═O)—NH—.
Thus, the following preferred conjugates are described, comprising a hydroxyalkyl starch derivative, as described above, wherein the hydroxyalkyl starch derivative comprises at least one structural unit according to the following formula (I)
wherein in each unit, independently of each other unit, at least one of Ra, Rb and Rc is
The term “linking moiety L1” as used in this context of the present invention relates to any suitable chemical moiety bridging X with the functional group F1 or the building block —[O—(CRwRx)—(CRyRz)]y— or the sugar backbone of the hydroxyalkyl starch derivative.
In general, there are no particular restrictions as to the chemical nature of the spacer L1 with the proviso that L1 provides for a stable linkage between the functional group —X— and the hydroxyalkyl starch building block. Preferably, L1 is an alkyl, alkenyl, alkylaryl, arylalkyl, aryl, heteroaryl, alkylheteroaryl or heteroarylalkyl group. As described above, the terms alkyl, alkenyl, alkylaryl, arylalkyl, aryl, heteroaryl, alkylheteroaryl or heteroarylalkyl group, also encompass groups which are substituted by one or more suitable substituent.
According to a preferred embodiment of the present invention, the linking moiety L1 is a spacer comprising at least one structural unit according to the following formula —{[CRdRf]h—[F4]u—[CRddRff]z}alpha-, wherein F4 is a functional group, preferably selected from the group consisting of —S—, —O— and —NH—, preferably wherein F4 is —O— or —S—, more preferably wherein F4 is —S—. The integer h is preferably in the range of from 1 to 20, more preferably of from 1 to 10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, more preferably of from 1 to 5, most preferably of from 1 to 3. Integer z is in the range of from 0 to 20, more preferably of from 0 to 10, such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, more preferably of from 0 to 3, most preferably of from 0 to 2, such as 0, 1 or 2. Integer u is 0 or 1. Integer alpha is in the range of from 1 to 10, preferably of from 1 to 5, such as 1, 2, 3, 4, 5, more preferably 1 or 2. As regards residues Rd, Rf, Rdd and Rff, these residues are, independently of each other, preferably selected from the group consisting of halogens, alkyl groups, H or hydroxyl groups. The repeating units of —[CRdRf]h— may be the same or may be different. Likewise, the repeating units of —[CRddRff]z— may be the same or may be different. Likewise in case integer alpha is greater than 1, the groups F4 in each repeating unit may be the same or may be different. Further, in case alpha is greater than 1, integer h in each repeating unit may be the same or may be different, integer z in each repeating unit may be the same or may be different and integer u in each repeating unit may be the same or may be different. Thus, in case alpha is greater than 1, each repeating unit of [CRdRf]h—[F4]u—[CRddRff]z may be the same or may be different. Most preferably, Rd, Rf, Rdd and Rff are independently of each other H, alkyl or hydroxyl.
According to one embodiment of the present invention, u and z are 0, the linking moiety L1 thus corresponds to the structural unit —[CRdRf]h—.
According to an alternative embodiment of the present invention u is 1. According to this embodiment z is preferably greater than 0, preferably 1 or 2.
Thus, the following preferred structures for the linking moiety L1 are mentioned, by way of example: —{[CRdRf]h—F4—[CRddRff]z}alpha- and —[CRdRf]h—.
Thus, by way of the example, the following especially preferred linking moieties L1 are mentioned:
According to one preferred embodiment, Rd, Rf and, if present, Rdd and Rff are preferably H or hydroxyl, more preferably at least one of Rd and Rf of at least one repeating unit of —[CRdRf]h— is OH, wherein even more preferably, in this case, both Rdd and Rf are H, if present. In particular, in this case, L1 is selected from the group consisting of —CH2—CHOH—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—CH2—, —CH2—CHOH—CH2—NH—CH2—CH2— and —CH2—CHOH—CH2—NE-CH2—CH2—CH2—, more preferably from the group consisting of —CH2—CHOH—CH2—, —CH2—CHOH—CH2—S—CH2—CH2— and —CH2—CHOH—CH2—S—CH2—CH2—CH2—.
According to an alternative preferred embodiment, both residues Rd and Rf are H, and Rdd and Rff are, if present, H as well. In particular, in this case, L1 is selected from the group consisting of: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—S—CH2—CH2—, —CH2—CH2—S—CH2—CH2—, —CH2—CH2—CH2—O—CH2—CH2— and —CH2—CH2—O—CH2—CH2—.
Therefore, the present invention also describes a hydroxyalkyl starch derivative, comprising at least one structural unit according to the following formula (I)
wherein at least one of Ra, Rb and Rc has a structure according to the following formula —[O—CH2—CH2]t—[F1]p-L1-X—, wherein the linking moiety L1 is selected from the group consisting of —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—S—CH2—CH2—, —CH2—CH2—S—CH2—CH2—, —CH2—CH2—O—CH2—CH2—, —CH2—CH2—O—CH2—CH2—O—CH2—CH2—, —CH2—CHOH—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—CH2—, —CH2—CHOH—CH2—NH—CH2—CH2—, —CH2—CHOH—CH2—NH—CH2—CH2—CH2—, —CH2—CHOH—CH2—O—CH2—CHOH—CH2—, —CH2—CHOH—CH2—O—CH2—CHOH—CH2—S—CH2—CH2—, —CH2—CH(CH2OH)— and —CH2—CH(CH2OH)—S—CH2—CH2—, more preferably from the group consisting of —CH2—CHOH—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—CH2—, —CH2—CHOH—CH2—NH—CH2—CH2— and —CH2—CHOH—CH2—NH—CH2—CH2—CH2—, more preferably from the group consisting of —CH2—CHOH—CH2—, —CH2—CHOH—CH2—S—CH2—CH2— and —CH2—CHOH—CH2—S—CH2—CH2—CH2—.
Further, the present invention also relates to a conjugate, comprising a hydroxyalkyl starch derivative, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, wherein the conjugate comprises a hydroxyalkyl starch derivative and a cytotoxic agent, wherein the hydroxyalkyl starch derivative preferably comprises at least one structural unit according to the following formula (I)
wherein at least one of Ra, Rb and has a structure according to the following formula [O—CH2—CH2]t—[F1]p-L1-X—, wherein L1 is selected from the group consisting of —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2LS-CH2—CH2—, —CH2—CH2—S—CH2—CH2—, —CH2—CH2—O—CH2—CH2—, —CH2—CH2—O—CH2—CH2—O—CH2—CH2—, —CH2—CHOH—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—CH2—, —CH2—CHOH—CH2—NH—CH2—CH2—, —CH2—CHOH—CH2—NH—CH2—CH2—CH2—, —CH2—CHOH—CH2—O—CH2—CHOH—CH2—, —CH2—CHOH—CH2—O—CH2—CHOH—CH2—S—CH2—CH2—, —CH2—CH(CH2OH)— and —CH2—CH(CH2OH)—S—CH2—CH2—, more preferably from the group consisting of —CH2—CHOH—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—CH2—, —CH2—CHOH—CH2—NH—CH2—CH2— and —CH2—CHOH—CH2—NH—CH2—CH2—CH2—, more preferably from the group consisting of —CH2—CHOH—CH2—, —CH2—CHOH—CH2—S—CH2—CH2— and —CH2—CHOH—CH2—S—CH2—CH2—CH2—.
In the following, conjugate structures are mentioned, which comprise a particularly preferred combination of HAS′ and different structural units -L-M.
According to a first especially preferred embodiment of the present invention, the hydroxyalkyl starch conjugate comprises a residue of hydroxyalkyl starch derivative comprising at least one structural unit according to the following formula (I)
wherein in each unit, independently of each other unit, at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—X— and X is —S—. The hydroxyalkyl starch conjugate further comprises the structural unit -L-M having the structure —[F2]q-[L2]g-[E]e-[CRmRn]f—F3-M wherein q is 0, g is 0 and e is 0.
Accordingly, in this preferred embodiment, the functional group X is directly linked to the structural unit —[CRmRn]f—. Integer f is preferably in the range of from 1 to 5.
Thus, the present invention also relates to a conjugate, comprising a hydroxyalkyl starch derivative, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, wherein the conjugate comprises a hydroxyalkyl starch derivative and a cytotoxic agent, the conjugate having a structure according to the following formula
HAS′(—[F2]q-[L2]g-[E]e-[CRmRn]f—F3-M)n
wherein q is 0, g is 0, e is 0, and wherein HAS′ preferably comprises at least one structural unit according to the following formula (I)
wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—X— and X is —S— and the functional group X is directly linked to the —[CRmRn]f— group, and wherein integer f is 1, 2, 3, 4 or 5.
According to one preferred embodiment, integer f is 1, so that X is present in alpha position to the functional group F3. Accordingly, the present invention also relates to a conjugate, comprising a hydroxyalkyl starch derivative, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, wherein the conjugate comprises a hydroxyalkyl starch derivative and a cytotoxic agent, the conjugate having a structure according to the following formula
HAS′(—[F2]q-[L2]g-[E]e-[CRmRn]f—F3-M)n
wherein q is 0, g is 0, e is 0, wherein HAS′ preferably comprises at least one structural unit according to formula (I)
wherein in each unit, independently of each other unit, at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—X— and X is —S— and the functional group X is directly linked to the —[CRmRn]f— group, and wherein the hydroxyalkyl starch derivative comprises at least n functional groups X, and wherein f is 1. Rm and Rn are, independently of each other, H or alkyl, most preferably Rm and Rn are H or methyl.
Thus, according to this embodiment, the conjugate, or the conjugate obtained or obtainable by the above-mentioned method, preferably has a structure according to one of the following formulas
HAS′(—CH(CH3)—F3-M)n or HAS′(—C(CH3)2—F3-M)n,
or according to the following formula
HAS′(—CH2—F3-M)n.
Particularly preferably F3 in the above mentioned formula is —C(═O)—, as described above.
The present invention thus also relates to a conjugate, comprising a hydroxyalkyl starch derivative, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, the conjugate having a structure according to one of the following formulas
more preferably according to the following formula
wherein HAS′ comprises at least one structural unit according to the following formula (I)
wherein in each unit, independently of each other unit, at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—X— and —X— is —S— and the functional group —X— is directly linked to the —CH2—C(═O)-group, as shown in the formulas above.
According to an alternative embodiment, the hydroxyalkyl starch conjugate comprises a hydroxyalkyl starch derivative comprising at least one structural unit according to the following formula (I)
wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—X— and X is —S—, thus at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—S—, and wherein the conjugate further comprises the moiety -L-M, wherein -L-M has the structure (—[F2]q-[L2]g-[E]e-[CRmRn]f—F3-M)n, as described above, and wherein e is 1 and E is preferably —S— or —O—.
According to this embodiment, X is directly linked to the functional group F2 with q and g preferably both being 1. As described above, the functional group F2 is, if present, preferably selected from —S— and -succinimide-, preferably succinimide-.
Thus, according to this embodiment, the conjugate, or the conjugate obtained or obtainable by the above-mentioned method, has in particular a structure according to one of the following formulas
HAS′(-succinimide-L2-O—[CRmRn]f—F3-M)n
or
HAS′(-succinimide-L2-S—[CRmRn]f—F3-M)n
wherein HAS′ comprises at least one structural unit according to the following formula (I), wherein in each unit, independently of each other unit, at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—X— and X is —S— and wherein the succinimide is directly linked to X, thereby forming a
bond.
Particularly preferably F3 in the above mentioned formula is —C(═O)—.
As regards, the linking moiety L2 according to this preferred embodiment, L2 is preferably an alkyl group, as described above. More preferably L2 is selected from the group consisting of —CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—, —CH2—CH2—, —CH2—, more preferably L2 is selected from the group consisting of —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, most preferably L2 is —CH2—CH2—.
Accordingly, the present invention also relates to a conjugate, comprising a residue of a hydroxyalkyl starch derivative, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, wherein the conjugate comprises a hydroxyalkyl starch derivative and a cytotoxic agent, the conjugate having a structure according to the following formula
HAS′(-succinimide-CH2—CH2-E-[CRmRn]f—C(═O)-M)n
more preferably a structure according to one of the following formulas
HAS′(-succinimide-CH2—CH2—O—[CRmRn]f—C(═O)-M)n and
HAS′(-succinimide-CH2—CH2—S—[CRmRn]f—C(═O)-M)n
wherein HAS′ preferably comprises at least one structural unit according to the formula (I), wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—X— and X is —S— and wherein the functional group X is directly linked to the succinimide group, thereby forming a
bond and wherein most preferably all functional groups X present in a given hydroxyalkyl starch derivative comprised in a conjugate according to the invention, are directly linked to the succinimide group.
According to a further especially preferred embodiment of the present invention, the hydroxyalkyl starch conjugate comprises a residue of a hydroxyalkyl starch derivative which comprises at least one structural unit according to the following formula (Ib)
wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—[F1]p-L1-X— with X being —S—, preferably with p being 1 and F1 being —O—, thus at least one of Ra, Rb and Rc has preferably the structure —[O—CH2—CH2]t—O-L1-S—, and wherein t is in the range of from 0 to 4, and wherein L1 is a group, as described above, preferably an alkyl group. Most preferably the linking moiety L1 is a spacer comprising at least one structural unit according to the formula —{[CRdRf]h—[F4]u—[CRddRff]z}alpha-, as described above, wherein F4, if present, is preferably selected from the group consisting of —S—, —O— and —NH—, more preferably wherein F4, if present, is —O— or —S—, more preferably wherein F4 is —S—. According to this fourth especially preferred embodiment of the present invention, preferably at least one of Rd and Rf of at least one repeating unit of —[CRdRf]h— is —OH. More preferably, Rd and Rf are either H or OH, wherein at least one of Rd and Rf of at least one repeating unit of —[CRdRf]h— is —OH, wherein the repeating units may be the same or may be different. Most preferably Rdd and Rff are, if present, H as well.
Particularly preferably, L1 has a structure selected from the group consisting of —CH2—CHOH—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—, —CH2—CHOH—CH2—S—CH2—CH2—CH2—, —CH2—CHOH—CH2—NH—CH2—CH2—, —CH2—CHOH—CH2—NH—CH2—CH2—CH2—, CH2—CHOH—CH2—O—CH2—CHOH—CH2—, —CH2—CHOH—CH2—O—CH2—CHOH—CH2—S—CH2—CH2—, more preferably from the group consisting of —CH2—CHOH—CH2—, —CH2—CHOH—CH2—S—CH2—CH2— and —CH2—CHOH—CH2—S—CH2—CH2—CH2—, most preferably L1 is —CH2—CHOH—CH2—S—CH2—CH2—.
The hydroxyalkyl starch conjugate according to this fourth preferred embodiment, preferably further comprises the structural unit -L-M having the structure
—[F2]q-[L2]g-[E]e-[CRmRn]f—F3-M
wherein q and g and e are 0.
In this preferred embodiment, —X— is directly linked to the structural unit —[CRmRn]f—, and integer f is preferably in the range of from 1 to 5.
Accordingly, the present invention also relates to a conjugate, comprising a hydroxyalkyl starch derivative, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, wherein the conjugate comprises a hydroxyalkyl starch derivative and a cytotoxic agent, the conjugate having a structure according to the following formula
HAS′(—[F2]q-[L2]g-[E]e-[CRmRn]f—F3-M)n
wherein q is 0, g is 0, e is 0, and wherein HAS′ preferably comprises at least one structural unit according to the following formula (Ib)
wherein at least one of Ra, Rb and Rc is [O—CH2—CH2]t—[F1]p-L1-X— with X being —S—, preferably with p being 1 and F1 being —O—, thus at least one of Ra, Rb and Rc has preferably the structure —[O—CH2—CH2]t—O-L1-S—, wherein t is in the range of from 0 to 4, and wherein L1 is preferably —CH2—CHOH—CH2—SCH2—CH2—, and wherein the functional group X is directly linked to the —[CRmRn]f— group, and wherein integer f is 1, 2, 3, 4 or 5. According to one preferred embodiment, f is 1 and Rm and Rn are, independently of each other, H or alkyl, most preferably Rm and Rn are H or methyl.
The present invention thus also relates to a conjugate, comprising a hydroxyalkyl starch derivative, as described above, as well as a conjugate obtained or obtainable by the above-mentioned method, the conjugate having a structure according to one of the following formulas
wherein Q is selected from the group consisting of C—H, C—F, C—CH3 and N, and R′ and R″ are independently of each other selected from the group consisting of OH, H and F, more preferably according to the following formula
and wherein HAS′ preferably comprises at least one structural unit according to the following formula (Ib)
wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—[F1]p-L1-X— with X being —S—, preferably with p being 1 and F1 being —O—, thus at least one of Ra, Rb and Rc has preferably the structure —[O—CH2—CH2]t—O-L1-S—, wherein t is in the range of from 0 to 4, and wherein L′ is preferably —CH2—CHOH—CH2—SCH2—CH2—.
Further preferred embodiments of the present invention are described in table 1:
The way how to read this table is illustrated on the basis of entry 1:
The conjugate according to entry 1, comprises a hydroxyalkyl starch comprising at least one structural unit according to formula (I)
wherein at least one of Ra, Rb or Rc is —[O—CH2—CH2]t—S—, and wherein in the above mentioned structure, [F2]q is -succinimide- and q is 1, integer g is 0, thus L2 is absent, and integer e is 0, thus E is absent. Thus, the following structure results:
with the structural unit —[CRmRn]f— being selected from the group consisting of CH2—CH2—CH2—CH2—, CH2—CH2—CH2—CH2—CH2—, CH2—CH2—CH2—, CH2—CH2—, CH2—, —CH(CH3)—, —CH(CH3)—CH2—, —CH2—CH(CH3)—, —CH(CH3)—CH2—CH2—, —CH2—CH(CH3)—CH2—, —CH2—CH2—CH(CH3)—, —CH2—CH2—CH2—CH(CH3)—, —CH2—CH2—CH2—CH2—CH(CH3)—, —C(CH3)2—, —CH(CH3)—CH(CH3)—, —CH(CH3)—CH(CH3)—CH2—, —CH2—CH(CH3)—CH(CH3)—, —CH(CH3)—CH2—CH(CH3)—, —CH(CH2CH3)—, —CH(CH(CH3)2)—.
As described above, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, said conjugate having a structure according to the following formula HAS′(-L-M)n wherein M is a residue of a cytotoxic agent, wherein the cytotoxic agent comprises a primary hydroxyl group, L is a linking moiety, HAS′ is a residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, said method comprising the steps
The term “at least bifunctional crosslinking compound L” as used in the context of the present invention refers to an at least bifunctional compound comprising the functional groups K1 and K2.
Besides the functional group K1 and the functional group K2 the at least bifunctional crosslinking compound may optionally contain further functional groups, which may be used, for example, for the attachment of radiolabels, or the like. Hereinunder and above, the “at least bifunctional crosslinking compound L” is also referred to as “crosslinking compound L”.
The crosslinking compound L is reacted via its functional group K1 with the primary hydroxyl group of the cytotoxic agent thereby forming a covalent linkage. On the other side, the crosslinking compound L is reacted via its functional group K2 with the functional group Z1 of the hydroxyalkyl starch derivative, thereby forming a covalent linkage as well.
The crosslinking compound L can be reacted with a cytotoxic agent either prior to or subsequent to the reaction with the hydroxyalkyl starch derivative. Preferably the crosslinking compound L is coupled to the cytotoxic agent prior to the reaction with the hydroxyalkyl starch derivative.
Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, said conjugate having a structure according to the following formula HAS′(-L-M)n, wherein M is a residue of a cytotoxic agent, wherein the cytotoxic agent comprises a primary hydroxyl group, L is a linking moiety, HAS′ is a residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, preferably wherein n is in the range of from 3 to 100, said method comprising the steps
Further, the present invention relates to a hydroxyalkyl starch conjugate obtained or obtainable by said method.
Upon reaction of the crosslinking compound L with the hydroxyalkyl starch derivative and the cytotoxic agent the hydroxyalkyl starch conjugate HAS′(-L-M) is formed. In said conjugate, HAS′ and M are linked via the linking moiety L, wherein said linking moiety L is the linking moiety derived from the at least bifunctional crosslinking compound L.
Preferably, the at least bifunctional crosslinking compound L has a structure according to the following formula
K2-L′-K1
wherein L′ is a linking moiety, K2 is the functional group capable of being reacted with the functional group Z1 of the hydroxyalkyl starch derivative and K1 is the group capable of being reacted with the cytotoxic agent, as described above.
Accordingly, the functional group K1 is a group capable of being coupled to a primary hydroxyl group of the cytotoxic agent. Upon reaction of the functional group K1 with the primary hydroxyl group, preferably the linking unit —F3—O—, as described above, is formed. Preferably, K1 is a functional group with which (upon reaction with the hydroxyl group) a covalent linkage between L, preferably L′ and M, is formed which is cleavable in vivo as described above.
The crosslinking compound L may be reacted with either the cytotoxic agent or the hydroxyalkyl starch in an initial step. Preferably, the crosslinking compound L is reacted with the primary hydroxyl group of the cytotoxic agent prior to the reaction with the hydroxyalkyl starch derivative, thereby forming a derivative of the cytotoxic agent, the derivative of the cytotoxic agent preferably having the structure K2-L′-F3-M.
Thus, the present invention also describes a method for preparing a hydroxyalkyl starch conjugate, as described above, wherein step (b) comprises the steps
Further, the present invention relates to a hydroxyalkyl starch conjugate obtained or obtainable by said method.
Preferably K1 comprises the structural unit C(═Y)—, with Y being O, NH or S. Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, wherein the cytotoxic agent is reacted with the at least one crosslinking compound L via the functional group K1 comprised in the crosslinking compound L, wherein said functional group K1 comprises the structural unit C(═Y)—, with Y being O, NH or S, more preferably Y being O. Further, the present invention relates to a hydroxyalkyl starch conjugate obtained or obtainable by said method.
According to a particular preferred embodiment K1 is a carboxylic acid group or a reactive carboxy group.
The term “reactive carboxy group” as used in this context of the present invention is intended to mean an activated carboxylic acid derivative that reacts readily with electrophilic groups, such as the —OH group of the cytotoxic agent, optionally in the presence of a suitable base, in contrast to those groups that require a further catalyst, such as a coupling reagent, in order to react. The term “activated carboxylic acid derivative” as used herein preferably refers to acid halides such as acid chlorides and also refers to activated ester derivatives including, but not limited to, formic and acetic acid derived anhydrides, anhydrides derived from alkoxycarbonyl halides such as isobutyloxycarbonylchloride and the like, isothiocyanates or isocyanates, anhydrides derived from reaction of the carboxylic acid with N,N′-carbonyldiimidazole and the like, and esters derived from activation of the corresponding carboxylic acid with a coupling reagent. Such coupling reagents include, but are not limited to, HATU (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate); HOAt, HBTU (O-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate); TBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate); TFFH(N,N,N″,N″-tetramethyluronium-2-fluoro-hexafluorophosphate); BOP (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate); PyBOP (benzotriazol-1-yl-oxy-trispyrrolidino-phosphonium hexafluorophosphate); EEDQ (2-ethoxy-1-ethoxycarbonyl-1,2-dihydro-quinoline); DCC (dicyclohexylcarbodiimide); DIPCDI (diisopropylcarbodiimide); HOBt (1-hydroxybenzotriazole); NHS (N-hydroxysuccinimide); MSNT (1-(mesitylene-2-sulfonyl)-3-nitro-1H-1,2,4-triazole); aryl sulfonyl halides, e.g. triisopropylbenzenesulfonyl chloride, EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, CDC (1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide), Pyclop, T3P, CDI, Mukayama's reagent, HODhbt, HAPyU, TAPipU, TPTU, TSTU, TNTU, TOTU, BroP, PyBroP, BOI, TOO, NEPIS, BBC, BDMP, BOMI, AOP, BDP, PyAOP, TDBTU, BOP—Cl, CIP, DEPBT, Dpp-Cl, EEDQ, FDPP, HOTT, TOTT, PyCloP.
In case, K1 is a carboxylic acid group, the coupling between the cytotoxic agent and the crosslinking compound L is preferably carried out in the presence of at least one coupling reagent, wherein the coupling reagent is preferably selected from the group of coupling reagents mentioned above. In case a coupling reagent is used, most preferably EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) is used. Additionally additives promoting the activation of the carboxylic acid, such as DMAP (4-(dimethylamino)-pyridine), may be used.
The coupling between the cytotoxic agent and the crosslinking compound L is preferably carried out in the presence of a suitable base, preferably an organic base, most preferably an amino group comprising base, most preferably a base selected from the group consisting of diisopropylamine (DIEA), triethylamine (TEA), N-methylmorpholine, N-methylimidazole, 1,4-diazabicyclo[2.2.2]octane (DABCO), N-methylpiperidine, N-methylpyrrolidine, 2,6-lutidine, collidine, pyridine, 4-dimethylaminopyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
As regards the reaction conditions used in this coupling step, preferably, the reaction is carried out in an organic solvent, such as N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO), acetonitrile, acetone, dimethyl acetamide (DMA), dimethyl formamide (DMF), formamide, tetrahydrofuran (THF), 1,4-dioxane, diethyl ether, tert.-butyl methyl ether (MTBE), dichloromethane (DCM), chloroform, tetrachloromethane and mixtures of two or more thereof. More preferably, the reaction is carried out in dichloromethane.
The temperature of the coupling reaction is preferably in the range of from 0 to 100° C., more preferably of from 5 to 50° C., and especially preferably of from 15 to 30° C. During the course of the reaction, the temperature may be varied, preferably in the above given ranges, or held essentially constant.
The derivative of the cytotoxic agent, which in particular has the following structure
K2-L′-F3-M,
may be subjected to at least one isolation and/or purification step prior to the reaction with the hydroxyalkyl starch derivative.
In the context of the present invention, K2 is a functional group capable of being reacted with a functional group Z1 of the hydroxyalkyl starch derivative, and Z1 is the respective functional group capable of being reacted with the functional group K2. Upon reaction of K2 with Z1 the functional unit —X—[F2]q— is formed, with X and —[F2]q— being as , described above in the context of the conjugate structures.
Such functional groups Z1 and K2 may be suitably chosen. By way of example, one of the groups Z1 and K2, i.e. Z1 or K2, may be chosen from the group consisting of the functional groups according to the following list while the other group, K2 or Z1, is suitably selected and capable of forming a chemical linkage with Z1 or K2, wherein K2 or Z1 is also preferably selected from the following list:
Preferably, Z1 is selected from the group consisting of aldehyde, keto, hemiacetal, acetal, alkynyl, azide, carboxy groups, alkenyl, thiol reactive groups, such as maleimide, halogen acetyl, pyridyl disulfides, haloacetamides, vinyl sulfones and vinyl pyridines, —SH, —NH2, —O—NH2, —NH—O-alkyl, —(C=G)-NH—NH2, -G—(C=G)-NH—NH2, —NH—(C=G)-NH—NH2, and —SO2—NH—NH2, where G is O or S and, if G is present twice, it is independently O or S.
Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, wherein K2 is reacted with the functional group Z1, wherein Z1 is selected from the group consisting of aldehyde groups, keto groups, hemiacetal groups, acetal groups, alkynyl groups, azide groups, carboxy groups, alkenyl groups, thiol reactive groups, —SH, —NH2, —O—NH2, —NH—O-alkyl, —(C=G)-NH—NH2, -G—(C=G)-NH—NH2, —NH—(C=G)-NH—NH2, and —SO2—NH—NH2, where G is O or S and, if G is present twice, it is independently O or S. Further, the present invention also relates to the conjugate obtained or obtainable by said method.
By way of example, in the following Table 2, suitable combinations of Z1 and K2 are mentioned:
According to a preferred embodiment of the present invention, the functional group Z1 is a thiol group. Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, wherein in step (a) a derivative is formed comprising at least one thiol group, preferably comprising multiple thiol groups, the derivative having a mean molecular weight MW above the renal threshold, preferably a MW greater than or equal to 60 kDa, more preferably in the range of from 80 to 1200 kDa, preferably more of from 90 to 800 kD, and a molar substitution MS in the range of from 0.6 to 1.5. The present invention further relates to the conjugate obtained or obtainable by said method.
In case Z1 is a thiol group, K2 is preferably a thiol reactive group, preferably a group selected from the group consisting of pyridyl disulfides, maleimide group, haloacetyl groups, haloacetamides, vinyl sulfones and vinyl pyridines. Preferably, K2 is a thiol-reactive group selected from the group consisting of the following structures:
wherein Hal is a halogen, such as Cl, Br, or I, and LG is a leaving group (or nucleofuge). The term “leaving group”, as used in this context of the present invention, is denoted to mean a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage upon reaction with the functional group Z1. Examples are, inter alia, halogens or sulfonic esters. Examples for sulfonic esters are, inter alia, the mesyl and tosyl group.
More preferably, K2 is a thiol-reactive group selected from the group consisting of the following structures:
more preferably from the following structures
Thus, the present invention also describes a method for preparing a hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent said conjugate having a structure according to the following formula HAS′(-L-M)n, wherein M is a residue of a cytotoxic agent, and wherein the cytotoxic agent comprises a primary hydroxyl group, L is a linking moiety, HAS′ is a residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1,
said method comprising the steps
and wherein K1 comprises the structural unit —C(═Y)—, with Y being O, NH or S, more preferably Y is O, preferably, wherein K1 is a carboxylic acid group or a reactive carboxy group. Further, the present invention also relates to the respective conjugate obtained or obtainable by said method.
Preferably, the at least bifunctional crosslinking compound L has a structure according to the following formula,
K2-[L2]g-[E]e-[CRmRn]f—K1.
Thus, in step (b) of the present invention, the hydroxyalkyl starch derivative according to step (a) is preferably reacted with a crosslinking compound L, with L having the structure
K2-[L2]g-[E]e-[CRmRn]f—K1,
wherein the crosslinking compound L is coupled to Z1 comprised in the hydroxyalkyl starch derivative via the functional group K2, and wherein each cytotoxic agent is coupled via the primary hydroxyl group to the hydroxyalkyl starch derivative via the functional group K1 thereby forming a conjugate having the structure
HAS′(—[F2]q-[L2]g-[E]e-[CRmRn]f—F3-M)n.
with F2, L2, E, q, g, e and —[CRmRn]f being as described hereinabove, preferably wherein E is an electron-withdrawing group selected from the group consisting of —O—, —S—, —SO—, —SO2—, —NRe—, -succinimide-, —C(═Ye)—, —NRe—C(═Ye)—, —C(═Ye)—NRe—, —CH(NO2)—, —CH(CN)—, aryl moieties or an at least partially fluorinated alkyl moiety, wherein Ye is either O, S or NRe, and Re is hydrogen or alkyl, more preferably wherein E is selected from the group consisting of —NH—C(═O)—, —C(═O)NH—, —NH—, —O—, —S—, —SO—, SO2 and -succinimide-, L2 is a linking moiety, preferably an alkyl, alkenyl, alkylaryl, arylalkyl, heteroaryl, alkylheteroaryl, heteroarylalkyl or aryl group, f is in the range of from 1 to 20, g is 0 or 1, e is 0 or 1, and wherein Rm and Rn are, independently of each other, H or alkyl or a side chain of a natural or unnatural amino acid, preferably H or alkyl, more preferably H or methyl.
By way of example, the following preferred crosslinking compounds L are mentioned in table 3:
As regards, the provision of the hydroxyalkyl starch derivative according to step (a), preferably step (a) comprises the introduction of at least one functional group Z1 into the hydroxyalkyl starch by
The term “at least one suitable linker comprising a precursor of the functional group Z1” as used in context of the present invention is denoted to mean a linker comprising a functional group which is capable of being transformed in at least one further step to give the functional group Z1. The term “precursor” used in the context of “displacing the hydroxyl group of hydroxyalkyl starch with a precursor”, is denoted to mean a reagent, which is capable of displacing the hydroxyl group, thereby forming a functional group Z1 or a group, which can be modified in at least one further step to give the functional group Z1.
According to a preferred embodiment of the present invention, the present invention relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, wherein the hydroxyalkyl starch derivative comprises at least one structural unit according to the following formula (I)
wherein at least one of Ra, Rb or Rc comprises the functional group Z1, wherein Ra, Rb and Rc are, independently of each other, selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]x—OH, —[O—(CRwRx)—(CRyRz)]y—Z1, —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-Z1, wherein Rw, Rx, Ry and Rz are independently of each other selected from the group consisting of hydrogen and alkyl, y is an integer in the range of from 0 to 20, preferably in the range of from 0 to 4, x is an integer in the range of from 0 to 20, preferably in the range of from 0 to 4, F1 is a functional group, p is 1 or 0, and L1 is a linking moiety,
and wherein step (a) comprises
Furthermore, the present invention relates to a conjugate obtained or obtainable by said method.
According to a preferred embodiment of the present invention, the present invention relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, as well as to a conjugate obtained or obtainable by said method, wherein the hydroxyalkyl starch derivative provided in step (a2) comprises at least one structural unit according to the following formula (I)
wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—CH2—CH2]s—OH, —[O—CH2—CH2]t—Z1 and —[O—CH2—CH2]t—[F1]p-L1-Z1, with p being 0 or 1, and wherein at least one of Ra, Rb and Rc comprises the functional group Z1, and wherein t is in the range of from 0 to 4, wherein s is in the range of from 0 to 4.
Hydroxyalkyl starches having the desired properties are preferably produced from waxy maize starch or potato starch by acidic hydrolysis and reaction with ethylene oxide and purification by ultrafiltration.
Step (a2)(i)
According to a first preferred embodiment of the present invention, the functional group Z1 is introduced by coupling the hydroxyalkyl starch via at least one hydroxyl group to at least one suitable linker comprising the functional group Z1 or a precursor of the functional group Z1.
Organic chemistry offers a wide range of reactions to modify hydroxyl groups with linker constructs bearing functionalities such as aldehyde, keto, hemiacetal, acetal, alkynyl, azide, carboxy, alkenyl, and thiol reactive groups, such as maleimide, halogen, acetal, pyridyl, disulfides, haloacetamides, vinyl sulfones, vinyl pyridines, —SH, —NH2, —O—NH2, —NH—O-alkyl, —(C=G)-NH—NH2, -G-(C=G)-NH—NH2, —NH—(C=G)-NH—NH2, and —SO2—NH—NH2, wherein G is O, NH or S, preferably O or S, and if present twice may be the same or may be different from each other. However, the hydroxyalkyl starch's polymeric nature and the abundance of hydroxyl groups present in the hydroxyalkyl starch usually strongly promote the number of possible side reactions such as inter- and intramolecular crosslinking. Therefore, a method was needed to functionalize the polymer under maximum retention of its molecular characteristics such as solubility, molecular weight and polydispersity. It was surprisingly found that when using the method according to this preferred embodiment, possible side reactions such as inter- and intramolecular crosslinking can be significantly diminished.
According to a preferred embodiment of the present invention, in step (a2)(i), the hydroxyalkyl starch is coupled to a linker comprising a functional group Z2, said functional group Z2 being capable of being coupled to a hydroxyl group of the hydroxyalkyl starch, thereby forming a covalent linkage between the first linker and the hydroxyalkyl starch. Further, the linker preferably comprises the functional group Z1 or a precursor thereof. According to a particularly preferred embodiment, the linker comprises a precursor of the functional group Z1 which is transformed in at least one further step to give the functional group Z1.
The functional group Z2 is a functional group capable of being coupled to at least one hydroxyl function of the hydroxyalkyl starch or to an activated hydroxyl function of hydroxyalkyl starch, thereby forming a covalent linkage F1.
According to a preferred embodiment, the functional group Z2 is a leaving group or a nucleophilic group. According to an alternative embodiment the functional group Z2 is an epoxide.
According to a first preferred embodiment, Z2 is a leaving group, preferably a leaving group being attached to a CH2-group comprised in the at least one suitable linker which is reacted in step (a2)(ii) with the hydroxyalkyl starch. The term “leaving group” as used in this context of the present invention is denoted to mean a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage upon reaction with the hydroxyl group of the hydroxyalkyl starch, thereby forming a covalent bond between the oxygen atom of the hydroxyl group and the carbon atom formerly bearing the leaving group. Common leaving groups are, for example, halides such as chloride, bromide and iodide, and sulfonates such as tosylates, mesylates, fluorosulfonates, triflates and the like. According to a preferred embodiment of the present invention, the functional group Z2 is a halide leaving group. Thus, upon reaction of the hydroxyl group with the functional group Z2, preferably a functional group F1 is formed, which is preferably —O—.
Alternatively, Z2 may also be an epoxide group, which reacts with a hydroxyl group of HAS in a ring opening reaction, thereby forming a covalent bond.
According to another embodiment, Z2 is a nucleophile, thus a group capable of forming a covalent bond with an electrophile by donating both bonding electrons. In case Z2 is a nucleophile, the method preferably comprises an initial step, in which at least one hydroxyl function of hydroxyalkyl starch is activated, thereby forming an electrophilic group. For example, the hydroxyl group may be activated by reacting at least one hydroxyl function with a reactive carbonyl compound, as described in detail below.
Thus, the present invention also describes a method, as described above, wherein the functional group Z2 is a nucleophile, said nucleophile being capable of being reacted with at least one activated hydroxyl function of hydroxyalkyl starch, as described above, wherein the hydroxyl group is initially activated with a reactive carbonyl compound prior to coupling the hydroxyalkyl starch in step (a2)(ii) to the at least one suitable linker comprising the functional group Z2 and the functional group Z1 or a precursor of the functional group Z1.
The term “reactive carbonyl compound” as used in this context of the present invention, refers to carbonyl dication synthons having a structure R** —(C═O)—R*, wherein R* and R** may be the same or different, and wherein R* and R** are both leaving groups. As leaving groups halides, such as chloride, and/or residues derived from alcohols, may be used. The term “residue derived from alcohols”, refers to R* and/or R** being a unit O—Rff or —O—Rgg, with —O—Rff and —O—Rgg preferably being residues derived from alcohols such as N-hydroxy succinimide or sulfo-N-hydroxy succinimide, suitably substituted phenols such as p-nitrophenol, o,p-dinitrophenol, o,o′-dinitrophenol, trichlorophenol such as 2,4,6-trichlorophenol or 2,4,5-trichlorophenol, trifluorophenol such as 2,4,6-trifluorophenol or 2,4,5-trifluorophenol, pentachlorophenol, pentafluorophenol, heterocycles such as imidazol or hydroxyazoles such as hydroxy benzotriazole may be mentioned. Reactive carbonyl compounds containing halides are phosgene, related compounds such as diphosgene or triphosgene, chloroformic esters and other phosgene substitutes known in the art. Especially preferred are carbonyldiimidazol (CDI), N,N′-disuccinimidyl carbonate and sulfo-N,N′-disuccinimidyl carbonate, or mixed compounds such as p-nitrophenyl chloroformate.
Preferably, the reactive carbonyl compound having the structure R** —(C═O)R* is selected from the group consisting of phosgene, diphosgene, triphosgene, chloroformates and carbonic acid esters, more preferably from the group consisting of p-nitrophenylchloroformate, pentafluorophenylchloroformate, N,N′-disuccinimidyl carbonate, sulfo-N,N′-disuccinimidyl carbonate, dibenzotriazol-1-yl carbonate and carbonyldiimidazol.
Preferably upon reaction of at least one hydroxyl group with the reactive carbonyl compound R** —(C═O)—R* prior to the coupling step according to step (a2)(ii) an activated hydroxyalkyl starch derivative is formed, which comprises at least one structural unit, according to the following formula (Ib)
wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—CH2—CH2]s—OH and —[O—CH2—CH2]t—O—C(═O)—R*, wherein t is in the range of from 0 to 4, and wherein s is in the range of from 0 to 4, and wherein at least one of Ra, Rb and Rc comprises the group —[O—CH2—CH2]t—O—C(═O)—R*, and wherein R* is a leaving group, preferably a group selected from the group consisting of p-nitrophenoxy, 2,4-dichlorophenoxy, 2,4,6-trichlorophenoxy, trichloromethoxy, imidazolyl,azides and halides, such as chloride or bromide.
According to this embodiment, according to which the hydroxyalkyl starch is activated to give a hydroxyalkyl starch derivative comprising a reactive —O—C(═O)—R* group, Z2 is preferably a nucleophilic group, such as a group comprising an amino group. Possible groups are, for example, NHRZ2, —NH2, —O—NH2, —NH—O-alkyl, —(C=G)-NH—NH2, -G-(C=G)-NH—NH2, —NH—(C=G)-NH—NH2, and —SO2—NH—NH2 wherein G is O or S, and if present twice in one structural unit, may be the same or may be different, and wherein RZ2 is an alkyl group, preferably methyl. More preferably Z2 is NH2 or —NHRZ2, most preferably —NH2.
As described above, besides the functional group Z2, the linker comprises either the functional group Z1 or a precursor thereof.
Preferably, the linker further comprises the functional group W, this functional group being a group capable of being transformed in at least one further step to give the functional group Z1. Preferably W is an epoxide or a functional group which is transformed in a further step to give an epoxide or W has the structure Z1-PG, with PG being a suitable protecting group.
According to a first preferred embodiment, in step (a2)(i), a first linker is used comprising the functional group W, wherein W is an epoxide or a functional group which is transformed in a further step to give an epoxide.
Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, and a hydroxyalkyl starch conjugate obtained or obtainable by said method, wherein step (a2)(i) comprises step (I)
Preferably, the first linker has the structure Z2-LW-W, wherein Z2 is a functional group capable of being reacted with at least one hydroxyl group of hydroxyalkyl starch, as described above, and wherein LW is a linking moiety.
Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, and a hydroxyalkyl starch conjugate obtained or obtainable by said method, wherein step (a2)(i) comprises step (I)
According to one embodiment of the present invention, the functionalization of at least one hydroxyl group of hydroxyalkyl starch to give the epoxide comprising hydroxyalkyl starch, is carried out in a one-step procedure, wherein at least one hydroxyl group is reacted with a first linker, as described above, wherein the first linker comprises the functional group W, and wherein W is an epoxide.
Therefore, the present invention also describes a method for preparing a hydroxyalkyl starch conjugate, as described above, as well as to a hydroxyalkyl starch conjugate obtained or obtainable by said method, wherein in step (a2)(i)(I) the hydroxyalkyl starch is reacted with a linker comprising a functional group Z2 capable of being reacted with a hydroxyl group of the hydroxyalkyl starch, thereby forming a covalent linkage, the linker further comprising a functional group W, wherein the functional group W is an epoxide.
This linker has in this case a structure according to the following formula
such as, for example, epichlorohydrine.
Upon reaction of this linker with at least one hydroxyl group of hydroxyalkyl starch, a hydroxyalkyl starch derivative is formed comprising at least one structural unit according to the following formula (Ib)
wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]x—OH and
preferably wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—CH2—CH2]s—OH and
and wherein t is in the range of from 0 to 4 and wherein s is in the range of from 0 to 4 (i.e. p is 1), and wherein at least one of Ra, Rb and Rc comprises the group
According to a preferred embodiment of the invention, the epoxide is generated in a two step procedure, comprising the steps (I) and (II)
It was surprisingly found that this two step procedure is superior to the one step procedure in that higher loadings of the hydroxyalkyl starch with epoxide groups can be achieved and/or undesired side reactions such as inter- and intra-molecular crosslinking can be substantially avoided.
Preferably the functional group W is an alkenyl group. In this case, step (II) preferably comprises the oxidation of the alkenyl group to give an epoxide and transforming the epoxide to give the functional group Z1.
According to a preferred embodiment, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, wherein the hydroxyalkyl starch, preferably the hydroxyethyl starch, is coupled in step (a2)(i) via at least one hydroxyl group to at least one suitable linker, the linker having the structure Z2-LW-W, wherein upon reaction of a hydroxyl group of the hydroxyalkyl starch with the linker, the leaving group Z2 departs, thereby forming a covalent linkage between the hydroxyalkyl starch and the linking moiety LW, and wherein the functional group F1 which links the hydroxyalkyl starch and the linking moiety LW, is an —O— bond. Likewise, the present invention also relates to the respective hydroxyalkyl starch conjugates obtained or obtainable by said method.
According to the present invention, the term “linking moiety Lw” as used in the context of the present invention relates to any suitable chemical moiety bridging the functional group Z2 and the functional group W.
In general, there are no particular restrictions as to the chemical nature of the linking moiety Lw with the proviso that Lw has particular chemical properties enabling carrying out the inventive method for the preparation of the novel derivatives comprising the functional group Z1, i.e. in particular, in case W is a functional group to be transformed to an epoxide, the linking moiety LW has suitable chemical propertibs enabling the transformation of the chemical moiety W to the functional group Z1. According to a preferred embodiment of the present invention, LW bridging W and HAS′ comprises at least one structural unit according to the following formula
wherein Rvv and Rww are independently of each other H or an organic residue selected from the group consisting of alkyl, alkenyl, alkylaryl, arylalkyl, aryl, heteroaryl, alkylheteroaryl and heteroarylalkyl groups.
Preferably, Lw is an optionally substituted, non-branched alkyl residue such as a group selected from the following groups:
According to a first preferred embodiment of the present invention, the functional group W is an alkenyl group, wherein the first linker Z2-LW-W has a structure according to the following formula
Z2-Lw-CH═CH2
preferably with Z2 being a leaving group or an epoxide.
Thus preferred structures of the first linker are by way of example, the following structures:
Hal-CH2—CH═CH2, such as Cl—CH2—CH═CH2 or Br—CH2—CH═CH2 or I—CH2—CH═CH2 sulfonic esters such as TsO—CH2—CH═CH2 or MsO—CH2—CH═CH2 epoxides such as
More preferably Z2 in the first linker Z2-LW-W is a leaving group, most preferably the first linker Z2-LW-W has a structure according to the following formula
Hal-LW-CH═CH2.
According to an especially preferred embodiment of the present invention, the linker Z2-LW-W has a structure according to the following formula
Hal-CH2—CH═CH2
with Hal being a halogen, preferably the halogen being I, Cl, or Br, more preferably Br.
Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, wherein in step (a2)(ii) the hydroxyalkyl starch, preferably the hydroxyethyl starch, is coupled via at least one hydroxyl group to at least one suitable linker having the structure Hal-CH2—CH═CH2, wherein upon reaction of the hydroxyalkyl starch with the linker, a hydroxyalkyl starch derivative is formed comprising at least one structural unit according to the following formula (Ib)
wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]x—OH and —[O—(CRwRx)—(CRyRz)]y—O—CH2—CH═CH2, and wherein at least one of Ra, Rb and Rc comprises the group —[O—(CRwRx)—(CRyRz)]y—O—CH2—CH═CH2, preferably wherein Ra, Rb and Rc are independently of each other selected form the group consisting of —OH, —O—HAS″, —[O—CH2—CH2]s—OH and —[O—CH2—CH2]t—O—CH2—CH═CH2, wherein t is in the range of from 0 to 4, wherein s is in the range of from 0 to 4, and wherein at least one of Ra, Rb and Rc comprises the group —[O—CH2—CH2]t—O—CH2—CH═CH2, and wherein the functional group —O— linking the CH2—CH═CH2 group to the hydroxyalkyl starch is formed upon reaction of the linker Hal-CH2—CH═CH2 with a hydroxyl group of the hydroxyalkyl starch. Likewise, the present invention also relates to a hydroxyalkyl starch conjugate obtained or obtainable by the above-mentioned method.
As regards, the reaction conditions used in this step (I), wherein the hydroxyalkyl starch is reacted with the first linker, in particular wherein the first linker comprises the functional group W with W being an alkenyl, in principle any reaction conditions known to those skilled in the art can be used. Preferably, the reaction is carried out in an organic solvent, such as N-methylpyrrolidone, dimethyl acetamide (DMA), dimethyl formamide (DMF), formamide, dimethyl sulfoxide (DMSO) or mixtures of two or more thereof. More preferably, the reaction is carried out in anhydrous solvents or solvent mixtures.
Preferably, the hydroxyalkyl starch is dried prior to use, by means of heating to constant weight at a temperature range from 50 to 80° C. in a drying oven or with related techniques.
The temperature of the reaction is preferably in the range of from 5 to 55° C., more preferably in the range of from 10 to 30° C., and especially preferably in the range of from 15 to 25° C. During the course of the reaction, the temperature may be varied, preferably in the above given ranges, or held essentially constant.
The reaction time for the reaction of HAS with the linker Z2-LW-W may be adapted to the specific needs and is generally in the range of from 1 h to 7 days, preferably 2 hours to 24 hours, more preferably 3 hours to 18 hours.
More preferably, the reaction is carried out in the presence of a base. The base may be added together with the linker Z2-LW-W, or may be added prior to the addition of the linker, to pre-activate the hydroxyl groups of the hydroxyalkyl starch. Preferably, a base, such as alkali metal hydrides, alkali metal hydroxides, alkali metal carbonates, amine bases such as diisopropylethyl amine (DIEA) and the like, amidine bases such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), amide bases such as lithium diisopropylamide (LDA) or alkali metal hexamethyldisilazyl bases (e.g. LiHMDS) may be used. Most preferably the hydroxyalkyl starch is pre-activated with sodium hydride prior to the addition of the first linker Z2-LW-W.
The derivative comprising the functional group W, preferably the alkenyl group, may be isolated prior to transforming this group in at least one further step to give an epoxide comprising hydroxyalkyl starch derivative. Isolation of this polymer derivative comprising the functional group W may be carried out by a suitable process which may comprise one or more steps. According to a preferred embodiment of the present invention, the polymer derivative is first separated from the reaction mixture by a suitable method such as precipitation and subsequent centrifugation or filtration. In a second step, the separated polymer derivative may be subjected to a further treatment such as an after-treatment like ultrafiltration, dialysis, centrifugal filtration or pressure filtration, ion exchange chromatography, reversed phase chromatography, HPLC, MPLC, gel filtration and/or lyophilization. According to an even more preferred embodiment, the separated polymer derivative is first precipitated, subjected to centrifugation, re-dissolved and finally subjected to ultrafiltration.
Preferably, the precipitation is carried out with an organic solvent such as ethanol, isopropanol, acetone or tetrahydrofurane (THF). The precipitated derivative is subsequently subjected to centrifugation and subsequent ultrafiltration using water or an aqueous buffer solution having a concentration preferably from 1 to 1000 mmol/I, more preferably from 1 to 100 mmol/I, and more preferably from 10 to 50 mmol/l such as about 20 mmol/l, a pH value in the range of preferably from 3 to 10, more preferably of from 4 to 8, such as about 7. The number of exchange cycles preferably is in the range of from 5 to 50, more preferably of from 10 to 30, and even more preferably of from 15 to 25, such as about 20. Most preferably the obtained derivative comprising the functional group W is further lyophilized until the solvent content of the reaction product is sufficiently low according to the desired specifications of the product.
In case W is an alkenyl, the method preferably further comprises step (II), that is the oxidation of the alkenyl group to give an epoxide group. As to the reaction conditions used in the epoxidation (oxidation) step (II), in principle, any known method to those skilled in the art can be applied to oxidize an alkenyl group to yield an epoxide.
The following oxidizing reagents are mentioned, by way of example, metal peroxysulfates such as potassium peroxymonosulfate (Oxone®) or ammonium peroxydisulfate, peroxides such as hydrogen peroxide, tert.-butyl peroxide, acetone peroxide (dimethyldioxirane), sodium percarbonate, sodium perborate, peroxy acids such as peroxoacetic acid, meta-chloroperbenzoic acid (MCPBA) or salts like sodium hypochlorite or hypobromite.
According to a particularly preferred embodiment of the present invention, the epoxidation is carried out with potassium peroxymonosulfate (Oxone®) as oxidizing agent.
Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, wherein step (a2)(i) comprises
Further, the present invention also relates to a hydroxyalkyl starch conjugate obtained or obtainable by said method.
According to an even more preferred embodiment of the present invention, the reaction with potassium peroxymonosulfate (Oxone®) is carried out in the presence of a suitable catalyst. Catalysts may consist of transition metals and their complexes, such as manganese (Mn-salene complexes are known as Jacobsen catalysts), vanadium, molybdenium, titanium (Ti-dialkyltartrate complexes are known as Sharpless catalysts), rare earth metals and the like. Additionally, metal free systems can be used as catalysts. Acids such as acetic acid may form peracids in situ and epoxidize alkenes. The same accounts for ketones such as acetone or tetrahydrothiopyran-4-one, which react with peroxide donors under formation of dioxiranes, which are powerful epoxidation agents. In case of non-metal catalysts, traces of transition metals from solvents may lead to unwanted side reactions, which can be excluded by metal chelation with EDTA.
Preferably, said suitable catalyst is tetrahydrothiopyran-4-one.
Upon epoxidation, in step (II) a hydroxyalkyl starch derivative is formed comprising at least one structural unit according to the following formula (Ib)
wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—(CRwRx)—(CRyRz)]x—OH
and wherein at least one of Ra, Rb and comprises the group
preferably wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—CH2—CH2]s—OH and
and wherein t is in the range of from 0 to 4 and wherein s is in the range of from 0 to 4 (i.e. p is 1) and wherein at least one of Ra, Rb and Rc comprises the group
According to a preferred embodiment, the epoxidation of the alkenyl-modified hydroxyalkyl starch derivatives is carried out in aqueous medium, preferably at a temperature in the range of from 0 to 80° C., more preferably in the range of from 0 to 50° C. and especially preferably in the range of from 10 to 30° C.
During the course of the epoxidation reaction, the temperature may be varied, preferably in the above-given ranges, or held essentially constant. The term “aqueous medium” as used in the context of the present invention refers to a solvent or a mixture of solvents comprising water in an amount of at least 10% per weight, preferably at least 20% per weight, more preferably at least 30% per weight, more preferably at least 40% per weight, more preferably at least 50% per weight, more preferably at least 60% per weight, more preferably at least 70% per weight, more preferably at least 80% per weight, even more preferably at least 90% per weight or up to 100% per weight, based on the weight of the solvents involved. The aqueous medium may comprise additional solvents like formamide, dimethylformamide (DMF), dimethylsulfoxide (DMSO), alcohols such as methanol, ethanol or isopropanol, acetonitrile, tetrahydrofurane or dioxane. Preferably, the aqueous solution contains a transition metal chelator (disodium ethylenediaminetetraacetate, EDTA, or the like) in the concentration ranging from 0.01 to 100 mM, preferably from 0.01 to 1 mM, most preferably from 0.1 to 0.5 mM, such as about 0.4 mM.
The pH value for the reaction of the HAS derivative with potassium peroxymonosulfate (Oxone®) may be adapted to the specific needs of the reactants. Preferably, the reaction is carried out in buffered solution, at a pH value in the range of from 3 to 10, more preferably of from 5 to 9, and even more preferably of from 7 to 8. Among the preferred buffers, carbonate, phosphate, borate and acetate buffers as well as tris(hydroxymethyl)aminomethane (TRIS) may be mentioned. Among the preferred bases, alkali metal bicarbonates may be mentioned.
According to the invention, the epoxide-modified HAS derivative may be purified or isolated in a further step prior to the transformation of the epoxide group to the functional group Z1.
The separated derivative is optionally lyophilized.
After the purification step, the HAS derivative is preferably obtained as a solid. According to a further conceivable embodiment of the present invention, the HAS derivative solutions or frozen HAS derivative solutions may be mentioned.
The epoxide comprising HAS derivative is preferably reacted in a subsequent step (III) with at least one suitable reagent to yield the HAS derivative comprising the functional group Z1. Preferably, the epoxide is reacted with a nucleophile comprising the functional group Z1 or a precursor thereof. Preferably, the nucleophile reacts with the epoxide in a ring opening reaction and yields a HAS derivative comprising at least one structural unit according to the following formula (Ib)
wherein at least one of Ra, Rb and Rc is —[O—(CRwRx)—(CRyRz)]y—[F1]p-Lw-CHOH—CH2—Nuc, preferably wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—[F1]p-Lw-CHOH—CH2—Nuc, wherein the residue Nuc is the remaining part of the nucleophile covalently linked to the hydroxyalkyl starch after being reacted with the epoxide.
Any nucleophile capable of reacting with the epoxide thereby forming a covalent linkage and comprising the functional group Z1 or a precursor thereof may be used. As nucleophile, for example, linker compounds comprising at least one nucleophilic functional group capable of reacting with the epoxide and at least one functional group W capable of being transformed to the functional Z1 can be used. Alternatively, a linker such as an at least bifunctional linker comprising a nucleophilic group such as a thiol group and further comprising the functional group Z1 may be used.
As described above, according to a particularly preferred embodiment of the present invention, Z1 is a thiol group.
According to a further preferred embodiment of the present invention, the nucleophilic group reacting with the epoxide is a thiol group.
Thus, the present invention also relates to a method as described above, wherein step (a2)(i) comprises
According to an especially preferred embodiment of the present invention, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as well as to a hydroxyalkyl starch conjugate obtained or obtainable by said method, as described above, wherein the epoxide is reacted with a nucleophile comprising the functional group Z1, with Z1 being a thiol group, and comprising a nucleophilic group, this group being a thiol. Thus, according to a preferred embodiment, the nucleophile is a dithiol.
The invention also relates to the respective derivative obtained or obtainable by said method, wherein said derivative is preferably transformed to the conjugate according of the invention, as described hereunder and above, said derivative preferably comprising at least one structural unit according to the following formula (Ib)
wherein at least one of Ra, Rb and Rc is —[O—(CRwRx)—(CRyRz)]y—[F1]p-L1-SH, preferably wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—[F1]p-L1-SH, wherein L1 is a linking moiety which is obtained when reacting the structural unit
with the nucleophile and which links the functional group F1 to the functional group Z1. According to the preferred embodiment, the linking moiety L1 has a structure selected from the groups below:
more preferably L1 has a structure according to the following formula
According to an alternative embodiment of the present method, the epoxide is reacted with a nucleophile suitable for the introduction of thiol groups such as thiosulfate, alkyl or aryl thiosulfonates or thiourea, preferably sodium thiosulfate. Thus, the present invention also relates to a method as described above as well as to a hydroxyalkyl starch derivative obtained or obtainable by said method, wherein the epoxide-modified hydroxyalkyl starch is reacted with a nucleophile, said nucleophile being thiosulfate, alkyl or aryl thiosulfonates or thiourea, preferably sodium thiosulfate.
Upon reaction of the thiosulfate with the epoxide in a ring opening reaction, preferably a hydroxyalkyl starch derivative is formed comprising at least one structural unit according to the following formula (Ib)
wherein at least one of Ra, Rb and Rc is —[O—(CRwRx)—(CRyRz)]x—[F1]p-Lw-CHOH—CH2—SSO3Na, preferably wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—[F1]p-Lw-CHOH—CH2—SSO3Na.
Preferably, this derivative is reduced in a subsequent step to yield the HAS derivative comprising the functional group Z1 with Z1 being —SH. Any suitable methods known to those skilled in the art can be used to reduce the respective intermediate shown above. Preferably, the thiosulfonate is reduced with sodium borohydride in aqueous solution.
According to a preferred embodiment of the present invention, the hydroxyalkyl starch derivative comprising the functional Z1, obtained by the above-described method, is purified in a further step. Again, the purification of the HAS derivative from step (III) can be carried out by any suitable method such as ultrafiltration, dialysis or precipitation or a combined method using for example precipitation and afterwards ultrafiltration. Furthermore, the HAS derivative may be lyophilized, as described above, using conventional methods, prior to step (b).
Carboxy Activated Hydroxyalkyl Starch with a Crosslinking Compound (Linker)
According to a second embodiment, in step (a2)(i), a linker is used, comprising the functional group Z1 or the functional group W, wherein W has the structure —Z1*-PG, with PG being a suitable protecting group. Preferably, in case this linker is used, the hydroxyalkyl starch is activated prior to the reaction using a reactive carbonate as described above.
Thus, the present invention also relates to a method, as described above, wherein step (a2)(i) comprises
The invention further relates to a conjugate obtained or obtainable by said method.
In particular, in step (a2)(i) the hydroxyalkyl starch is reacted with a linker comprising the functional group Z1 or a precursor thereof and a functional group Z2, the linker having the structure Z2-L′-Z1 or Z2-L1-Z1*-PG, with Z2 being a functional group capable of being reacted with the hydroxyalkyl starch or an activated hydroxyalkyl starch, preferably with an activated hydroxyalkyl starch, the method further comprising activating the hydroxyalkyl starch prior to the reaction with the linker using a reactive carbonate, and with Z1* being the protected form of the functional group Z1.
As described above, the linker preferably comprises a functional group Z2, which in this case, is preferably a nucleophile, such as a group comprising an amino group, more preferably a group selected from the group consisting of NHRZ2, —NH2, —O—NH2, —NH—O-alkyl, —(C=G)-NH—NH2, -G-(C=G)-NH—NH2, —NH—(C=G)-NH—NH2, and —SO2—NH—NH2 wherein G is O or S, and if present twice in one structural unit, may be the same or may be different, and wherein RZ2 is an alkyl group, preferably methyl. More preferably Z2 is NH2 or —NHRZ2, most preferably —NH2.
In this case, the linker has preferably a structure Z2-L1-Z1*-PG, wherein Z1* is in particular —S— (and the respective unprotected functional group Z1 a thiol group). According to this embodiment, the linking moiety L1 is preferably an optionally substituted alkyl group. More preferably, the linking moiety L1 is a spacer comprising at least one structural unit according to the formula -{[CRdRf]h—[F4]u—[CRddRff]z}alpha, as described above, wherein integer alpha is in the range of from 1 to 10, and wherein F4 is preferably selected from the group consisting of —S—, —O— and —NH—, more preferably wherein F4, if present, is —O— or —S—, more preferably wherein F4 is —S—. As described above, in the context of the preferred conjugates, residues Rd, Rf, Rdd and Rff are, independently of each other, preferably selected from the group consisting of halogens, alkyl groups, H or hydroxyl groups. More preferably, these residues are independently from each other H, alkyl or hydroxyl groups. Preferably, integer u and integer z of the formula —{[CRdRf]h—[F4]u—[CRddRff]z}alpha- are 0, and alpha is 1, the linking moiety L1 thus corresponds to the structural unit —[CRdRf]h—. The integer h is preferably in the range of from 1 to 20, more preferably of from 1 to 10, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, more preferably of from 1 to 5, most preferably of from 1 to 3. More preferably Rd and Rf are both H. Thus, by way of example, the following preferred linking moieties L1 are mentioned: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—, more preferably —CH2—CH2—, in the context of this second embodiment.
In case Z1 is a thiol group, and Z1* is —S—, the group PG is preferably a thiol protecting group, more preferably a protecting group forming together with Z1* a thioether (e.g. trityl, benzyl, allyl), a disulfide (e.g. S-sulfonates, S-tert.-butyl, S-(2-aminoethyl)), or a thioester (e.g. thioacetyl). In case the linker comprises a protecting group, the method further comprises a deprotection step.
In case the group Z1*-PG is a disulfide, and Z1* is —S—, the linker Z2-L1-S-PG is preferably a symmetrical disulfide, with PG having the structure —S-L1-Z2. As preferred linker compound, thus cystamine and the like, may be mentioned
In the context of this embodiment, the following linker compounds having the structure Z2-L1-Z1*—PG are mentioned by way of example: H2N—CH2—S-Trt, H2N—CH2—CH2—S-Trt, H2N—CH2—CH2—CH2—S-Trt, H2N—CH2—CH2—CH2—CH2S-Trt, H2N—CH2—CH2—CH2—CH2—CH2—S-Trt, H2N—CH2—CH2—S—S—CH2—CH2—NH2, H2N—CH2—CH2—S—S-tBu, wherein Trt is a trityl group.
Subsequent to the activation, the hydroxyalkyl starch is preferably reacted with the linker Z2-L1-Z1*-PG, thereby most preferably forming a derivative, comprising the functional group —Z1*-PG, more preferably this derivative comprises at least one structural unit according to the following formula (Ib)
wherein at least one of Ra, Rb and Rc is —[O—(CRwRx)—(CRyRz)]x—F1-L1-Z1*-PG, more preferably wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—CH2—CH2]s—OH, and —[O—CH2—CH2]t—F1-L1-Z1*-PG, wherein t is in the range of from 0 to 4, and wherein s is in the range of from 0 to 4, and wherein at least one of Ra, Rb and Rc comprises the group —[O—CH2—CH2]t—F1-L1-Z1-PG, and wherein F1 is the functional group being formed upon reaction of the group —O—C(═O)—R* with the functional group Z2. According to a preferred embodiment, the functional group Z2 is —NH2, thus F1 preferably has the structure —O—C(═O)—NH—.
The coupling reaction between the activated hydroxyalkyl starch and the linker, comprising the functional Z1 or the functional group W, wherein W has preferably the structure —Z1*—PG, with PG being a suitable protecting group, in principle any reaction conditions known to those skilled in the art can be used. Preferably, the reaction is carried out in an organic solvent, such as N-methylpyrrolidone, dimethyl acetamide (DMA), dimethyl formamide (DMF), formamide, dimethyl sulfoxide (DMSO), or mixtures of two or more thereof, preferably at a temperature in the range of from 5 to 80° C., more preferably of from 5 to 50° C. and especially preferably of from 15 to 30° C. The temperature may be held essentially constant or may be varied during the reaction procedure.
The pH value for this reaction may be adapted to the specific needs of the reactants. Preferably, the reaction is carried out in the presence of a base. Among the preferred bases pyridine, substituted pyridines, such as 4-(dimethylamino)-pyridine, 2,6-lutidine or collidine, tertiary amine bases such as triethyl amine, diisopropyl ethyl amine (DIEA), N-methyl morpholine, amidine bases such as 1,8-diazabicyclo[5.4.0]undec-7-ene or inorganic bases such as alkali metal carbonates may be mentioned.
The reaction time for the reaction of activated hydroxyalkyl starch with the linker Z2-L1-Z1*—PG or Z2-L1-Z1 may be adapted to the specific needs and is generally in the range of from 1 h to 7 days, preferably of from 2 hours to 48 hours, more preferably of from 4 hours to 24 hours.
The derivative comprising the functional group Z1*-PG or Z1, may be subjected to at least one further isolation and/or purification step. According to a preferred embodiment of the present invention, the polymer derivative is first separated from the reaction mixture by a suitable method such as precipitation and subsequent centrifugation or filtration. In a second step, the separated polymer derivative may be subjected to a further treatment such as an after-treatment like ultrafiltration, dialysis, centrifugal filtration or pressure filtration, ion exchange chromatography, reversed phase chromatography, HPLC, MPLC, gel filtration and/or lyophilization. According to an even more preferred embodiment, the separated polymer derivative is first precipitated, subjected to centrifugation, re-dissolved and finally subjected to ultrafiltration.
Preferably, the precipitation is carried out with an organic solvent such as ethanol, isopropanol, acetone or tetrahydrofurane (THF). The precipitated conjugate is subsequently subjected to centrifugation and subsequent ultrafiltration using water or an aqueous buffer solution having a concentration preferably from 1 to 1000 mmol/l, more preferably from 1 to 100 mmol/l, and more preferably from 10 to 50 mmol/l such as about 20 mmol/l, a pH value in the range of preferably from 3 to 10, more preferably of from 4 to 8, such as about 7. The number of exchange cycles preferably is in the range of from 5 to 50, more preferably of from 10 to 30, and even more preferably from 15 to 25, such as about 20.
Most preferably the obtained derivative is further lyophilized until the solvent content of the reaction product is sufficiently low according to the desired specifications of the product.
In case the linker comprises a protecting group (PG), the method preferably further comprises a deprotection step. The reaction conditions used are adapted to the respective protecting group used. According to a preferred embodiment of the invention, Z1 is a thiol group, and the group Z1*-PG is a disulfide, as described above. In this case, the deprotection step comprises the reduction of this disulfide bond to give the respective thiol group. This deprotection step is carried out using specific reducing agents. As possible reducing agents, complex hydrides such as borohydrides, especially sodium borohydride, and thiols, especially dithiothreitol (DTT) and dithioerythritol (DTE) or phosphines such as tris-(2-carboxyethyl)phosphine (TCEP) are mentioned. The reduction is preferably carried out using DTT.
The deprotection step is preferably carried out at a temperature in the range of from 0 to 80° C., more preferably of from 10 to 50° C. and especially preferably of from 20 to 40° C. During the course of the reaction, the temperature may be varied, preferably in the above-given ranges, or held essentially constant.
Preferably, the reaction is carried out in aqueous medium. The term “aqueous medium” as used in the context of the present invention refers to a solvent or a mixture of solvents comprising water in an amount of at least 10% per weight, preferably at least 20% per weight, more preferably at least 30% per weight, more preferably at least 40% per weight, more preferably at least 50% per weight, more preferably at least 60% per weight, more preferably at least 70% per weight, more preferably at least 80% per weight, even more preferably at least 90% per weight or up to 100% per weight, based on the weight of the solvents involved. The aqueous medium may comprise additional solvents like formamide, dimethylformamide (DMF), dimethylsulfoxide (DMSO), alcohols such as methanol, ethanol or isopropanol, acetonitrile, tetrahydrofurane or dioxane. Preferably, the aqueous solution contains a transition metal chelator (disodium ethylenediaminetetraacetate, EDTA, or the like) in a concentration ranging from 0.01 to 100 mM, preferably from 0.01 to 1 mM, most preferably from 0.1 to 0.5 mM, such as about 0.4 mM.
The pH value in the deprotection step may be adapted to the specific needs of the reactants. Preferably, the reaction is carried out in buffered solution, at a pH value in the range of from 3 to 14, more preferably of from 5 to 11, and even more preferably of from 7.5 to 8.5. Among the preferred buffers, carbonate, phosphate, borate and acetate buffers as well as tris(hydroxymethyl)aminomethane (TRIS) may be mentioned.
Again, at least one of the isolation steps/and or purification steps, as described above, may be carried out subsequent to the deprotection step. Most preferably, the obtained derivative is further lyophilized prior to step (b) until the solvent content of the reaction product is sufficiently low according to the desired specifications of the derivative.
Step (a2)(ii)
As regards step (a2)(ii) of the method according to the present invention, in this step, the functional group Z1 is introduced by displacing a hydroxyl group present in the hydroxyalkyl starch in a substitution reaction with a precursor of the functional group Z1 or with a bifunctional linker comprising the functional group Z1 or a precursor thereof.
Preferably, prior to the replacement of the hydroxyl group with the functional group Z1, the at least one hydroxyl group of the hydroxyalkyl starch is activated to generate a suitable leaving group. Preferably, a group RL is added to the at least one hydroxyl group thereby generating a group —O—RL, wherein the structural unit —O—RL is the leaving group.
Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, as well as to a hydroxyalkyl starch conjugate, obtained or obtainable by said method wherein in step (a2)(ii), prior to the substitution (displacement) of the hydroxyl group with the group comprising the functional group Z1 or a precursor thereof, a group RL is added to at least one hydroxyl group thereby generating a group —O—RL, wherein —O—RL is the leaving group.
The term “leaving group” as used in this context of the present invention is denoted to mean that the molecular fragment —O—RL departs when reacting the hydroxyalkyl starch derivative with a reagent, such as a crosslinking compound, comprising the functional group Z1 or a precursor thereof.
As regards, preferred leaving groups used in this context of the present invention, according to a preferred embodiment, the hydroxyl group is transformed to a sulfonic ester, such as a mesylic ester (—OMs), tosylic ester (—OTs), imsyl ester (imidazylsulfonyl ester) or a carboxylic ester such as trifluoroacetic ester.
Preferably, the at least one leaving group is generated by reacting at least one hydroxyl group of hydroxyalkyl starch, preferably in the presence of a base, with the respective sulfonyl chloride to give the sulfonic ester, preferably the mesylic ester.
Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate as described above, as well as to a hydroxyalkyl starch conjugate obtained or obtainable by said method, wherein in step (a2)(ii), prior to the substitution (displacement) of the hydroxyl group with the group comprising the functional group Z1 or a precursor thereof, a group RL is added to at least one hydroxyl group, thereby generating a group —O—RL, wherein —O—RL is —OMs or —OTs, and wherein the —O-Ms group is preferably introduced by reacting at least one hydroxyl group of hydroxyalkyl starch with methanesulfonyl chloride, and —OTs is introduced by reacting at least one hydroxyl group with toluenesulfonylchloride.
The addition of the group RL to at least one hydroxyl group of hydroxyalkyl starch, whereupon a group —O—RL is formed, is preferably carried out in an organic solvent, such as N-methylpyrrolidone, dimethyl acetamide (DMA), dimethyl formamide (DMF), formamide, dimethylsulfoxide (DMSO) and mixtures of two or more thereof, preferably at a temperature in the range of from −60 to 80° C., more preferably in the range of from −30 to 50° C. and especially preferably in the range of from −30 to 30° C. The temperature may be held essentially constant or may be varied during the reaction procedure. The pH value for this reaction may be adapted to the specific needs of the reactants. Preferably, the reaction is carried out in the presence of a base. Among the preferred bases pyridine, substituted pyridines such as collidine or 2,6-lutidine, tertiary amine bases such as triethylamine, diisopropyl ethyl amine (DIEA), N-methylmorpholine, N-methylimidazole or amidine bases such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and inorganic bases such as metal hydrides and carbonates may be mentioned. Especially preferred are substituted pyridines (collidine) and tertiary amine bases (DIEA, N-methylmorpholine). The reaction time for this reaction step may be adapted to the specific needs and is generally in the range of from 5 min to 24 hours, preferably of from 15 min to 10 hours, more preferably of from 30 min to 5 hours.
The derivative comprising the group —O—RL, may be subjected to at least one further isolation and/or purification step such as precipitation and/or centrifugation and/or filtration prior to the substitution reaction according to step (a2)(ii). Likewise, instead or additionally, the derivative comprising the —O—R1 group may be subjected to an after-treatment like ultrafiltration, dialysis, centrifugal filtration or pressure filtration, ion exchange chromatography, reversed phase chromatography, HPLC, MPLC, gel filtration and/or lyophilization. According to a preferred embodiment, the derivative comprising the O—RL is in situ reacted with the precursor of the functional group Z1 or with the bifunctional linker, comprising the functional group Z1 or a precursor thereof.
As described above, the at least one hydroxyl group, preferably the at least one O—RL group, more preferably the —OMs or OTs group, is displaced, in a substitution reaction, with the precursor of the functional group Z1 or with an at least bifunctional linker comprising the functional group Z1 or a precursor thereof.
According to a preferred embodiment of the present invention, the activated hydroxyl group, preferably the —O—RL group, more preferably the —OMs or —OTs group, is reacted with the precursor of the functional group Z1. The term “a precursor” as used in this context of the present invention is denoted to mean a reagent which is capable of displacing the group, thereby forming a functional group Z1 or a group, which can be modified in at least one further step to give the functional group Z1.
Thus, the present invention also relates to a method for preparing a hydroxyalkyl starch conjugate, as described above, as well as to a hydroxyalkyl starch conjugate, obtained or obtainable by said method wherein in step (a2)(ii), prior to the substitution (displacement) of the hydroxyl group with the group comprising the functional group Z1 or a precursor thereof, a group RL is added to at least one hydroxyl group, thereby generating a group —O—RL, wherein —O—RL is a leaving group, and subsequently —O—RL is replaced by a precursor of the functional group Z1, the method further comprising converting the precursor after the substitution reaction to the functional group Z1, and wherein Z1 is preferably a thiol group.
In case Z1 is an amine, reagents such as ammonia, hydrazine, acyl hydrazides, such as carbohydrazide, potassium phthalimide, azides, such as sodium azide, and the like, can be employed to introduce the functional group Z1.
In case Z1 is a thiol group, reagents such as thioacetic acid, alkyl or aryl thiosulfonates such as sodium benzenethiosulfonate, thiourea, thiosulfate or hydrogen sulfide can be employed as precursor to introduce the functional group Z1.
According to an especially preferred embodiment of the present invention, the hydroxyl group present in the hydroxyalkyl starch is first activated and then reacted with thioacetate, thereby replacing the hydroxyl group with the structure —S—C(═O)—CH3. A particularly preferred reagent is potassium thioacetate. Thus, the present invention also relates to a method, as described above, wherein in step (a2)(ii) the hydroxyl group present in the hydroxyalkyl starch is reacted with thioacetate giving a functional group having the structure S—C(═O)—CH3.
In this substitution step, in principle any reaction conditions known to those skilled in the art can be used. Preferably, the reaction is carried out in an organic solvent, such as N-methylpyrrolidone, dimethyl acetamide (DMA), dimethyl formamide (DMF), formamide, dimethyl sulfoxide (DMSO) and mixtures of two or more thereof. Preferably this step is carried out at a temperature in the range of from 0 to 80° C., more preferably of from 20 to 70° C. and especially preferably of from 40 to 60° C. The temperature may be held essentially constant or may be varied during the reaction procedure.
The pH value for this reaction may be adapted to the specific needs of the reactants. Optionally, the reaction is carried out in the presence of a scavenger, which reacts with the leaving group —O—RL, such as mercaptoethanol or the like.
The reaction time for the substitution step is generally in the range of from 1 hour to 7 days, preferably of from 3 to 48 hours, more preferably of from 4 to 18 hours.
The derivative obtained may be subjected to at least one further isolation and/or purification step, as described above.
Preferably, the derivative is subjected to at least one further step. In particular, in case the hydroxyl group present in the hydroxyalkyl starch is reacted with thioacetate, thereby replacing the hydroxyl group with the structure —S—C(═O)—CH3, the derivative is preferably saponified in a subsequent step to give the functional group Z1 with Z1 being an —SH group. Thus, the present invention also relates to a method as described above as well as to a conjugate obtained or obtainable by said method, wherein in step (a2)(ii), the hydroxyl group present in the hydroxyalkyl starch is reacted with thioacetate giving a functional group having the structure —S—C(═O)—CH3, wherein the method further comprises saponification of the group —S—C(═O)—CH3 to give the functional group Z1.
It has to be understood, that in case at least one hydroxyl group present in hydroxyalkyl starch, comprising the structural unit according to the following formula (II)
with Raa, Rbb and Rcc being independently of each other selected from the group consisting of —[O—(CRwRx)—(CRyRz)]x—OH and —O—HAS″, is displaced in a substitution reaction, the stereochemistry of the carbon atom which bears the respective hydroxyl function, which is displaced may be inverted.
Thus, in case at least one of Raa and Rbb in the above shown structural unit is OH, and in case, this at least one group is displaced by a precursor of the functional group Z1, thereby yielding a hydroxyalkyl starch derivative comprising the functional group Z1 in this structural unit, the stereochemistry of the carbon atoms bearing this functional group Z1 may be inverted.
Since, it cannot be excluded that such a substitution of secondary hydroxyl groups occur, in the method of the invention according to step (a2)(ii), the stereochemistry of the carbon atoms bearing the functional group Ra and Rc is not further defined, as shown in the structural unit according to the following formula (I)
However, without wanting to be bound to any theory, it is believed that mainly primary hydroxyl groups will be displaced in the substitution reaction according to step (a2)(ii). Thus, according to this theory, the stereochemistry of most carbon atoms bearing the residues Ra or Rc will not be inverted but the respective structural unit of the hydroxyalkyl starch will comprise the stereochemistry as shown in the formula (Ib)
The thioacetate is preferably saponified in at least one further step to give the thiol comprising hydroxyalkyl starch derivatives. As regards the saponification of the functional group —S—C(═O)—CH3, all methods known to those skilled in the art are encompassed by the present invention. This includes the use of at least one base (such as metal hydroxides) and strong nucleophiles (such as ammonia, amines, thiols or hydroxides) in order to saponify the present thioesters to give thiols. Preferred reagents are sodium hydroxide and ammonia.
Since thiols are well known to oxidize via the formation of disulfides, especially under basic conditions present in most saponification protocols, the molecular weight of the hydroxyalkyl starch derivative obtained may vary due to unspecific crosslinking. To prevent the formation of disulfides, preferably a reducing agent is added prior, during or after the saponification step. According to a preferred embodiment of the invention, a reducing agent is directly added to the saponification mixture in order to keep the forming thiol groups in their low oxidation state. Regarding the reduction of the thiol groups, all reduction methods known to those skilled in the art such as borohydrides, especially sodium borohydride, and thiols, especially dithiothreitol (DTT) and dithioerythritol (DTE) or phosphines such as tris-(2-carboxyethyl)phosphine (TCEP) are encompassed by the present invention. According to preferred embodiments of the present invention, dithiothreitol (DTT), dithioerythritol (DTE) or sodium borohydride are employed.
In an alternative embodiment of the reaction, aqueous sodium hydroxide is used as saponification agent together with sodium borohydride as reducing agent.
Optionally, mercaptoethanol can be used as an additive in this reaction.
Thus, the present invention also relates to a method, as described above, wherein in step (a2)(ii) the activated hydroxyl group present in the hydroxyalkyl starch is reacted with thioacetate giving a functional group having the structure —S—C(═O)—CH3, wherein the method further comprises saponifying the group —S—C(═O)—CH3 to give the functional group Z1, wherein the hydroxyalkyl starch derivative comprises at least one structural unit according to the following formula (I)
wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—CH2—CH2]s—OH, —[O—CH2—CH2]t—SH and wherein at least one Ra, Rb and Rc is —[O—CH2—CH2]t—SH and wherein t is in the range of from 0 to 4, and wherein s is in the range of from 0 to 4.
Again, the hydroxyalkyl starch derivative, comprising the functional group SH, obtained by the above-described preferred embodiment, may be isolated/and or purified prior to step (b) in a further step. Again, the purification/isolation of the HAS derivative from step (a2)(ii) can be carried out by any suitable method such as ultrafiltration, dialysis or precipitation or a combined method using for example precipitation and afterwards ultrafiltration.
Furthermore, the hydroxyalkyl starch derivative may be lyophilized, as described above, using conventional methods.
According to an especially preferred embodiment, the hydroxyalkyl starch derivative, obtained in step (a2)(ii), comprises at least one structural unit according to the following formula (I)
where in Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—CH2—CH2]s—OH, —[O—CH2—CH2]t—Z1, wherein t is in the range of from 0 to 4, and wherein s is in the range of from 0 to 4, and wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—Z1, with Z1 being —SH. This derivative is preferably reacted in step (b) with a crosslinking compound L having a structure according to the following formula KZ-[L2]g-[E]e-[CRmRn]f—K1 with g and e being 0, and wherein K2 is a halogene.
According to an especially preferred embodiment the hydroxyalkyl starch derivative obtained in step (a2)(ii) comprises at least one structural unit according to the following formula (I)
wherein Ra, Rb and Rc are independently of each other selected from the group consisting of —O—HAS″, —[O—CH2—CH2]s—OH, and —[O—CH2—CH2]t—Z1, wherein t is in the range of from 0 to 4, and wherein s is in the range of from 0 to 4, and wherein at least one of Ra, Rb and Rc is —[O—CH2—CH2]t—Z1, with Z1 being —SH. This derivative is preferably reacted in step (b) with a crosslinking compound L having a structure according to the formula K2-[L2]g-[E]e-[CRmRn]f—K1, wherein K2 is maleimide, and wherein upon reaction of Z1 with K2, a functional group —X—F2— is formed.
As already described above, the hydroxyalkyl starch derivative obtained according to step (a) is, optionally after at least one purification and/or isolation step, further reacted in step (b).
In step (b) the HAS derivative is coupled via the functional group Z1 to at least one cytotoxic agent via the at least bifunctional crosslinking compound L, wherein L comprises the functional groups K1 and K2, wherein L is coupled to Z1 via a functional group K2 comprised in L, and wherein each cytotoxic agent is coupled via the primary hydroxyl group to the HAS derivative via the functional group K1, comprised in L.
Thus, step (b) preferably comprises the steps (b1) and (b2)
As to the preferred reaction conditions used in step (b1), reference is made to the details given above.
As regards to the reaction conditions used in step (b2), in principle any reaction conditions known to those skilled in the art can be used. Preferably, the reaction is carried out in an aqueous reaction medium, preferably in a mixture comprising water and at least one organic solvent, preferably at least one water miscible solvent, in particular a solvent selected from the group such as N-methylpyrrolidone, dimethyl acetamide (DMA), dimethyl formamide (DMF), formamide, dimethyl sulfoxide (DMSO), acetonitrile, tetrahydrofurane (THF), dioxane, alcohols such as methanol, ethanol, isopropanol and mixtures of two or more thereof. More preferably, the reaction is carried out in DMF.
The temperature of the reaction is preferably in the range of from 5 to 55° C., more preferably of from 10 to 30° C., and especially preferably of from 15 to 25° C. During the course of the reaction, the temperature may be varied, preferably in the above given ranges, or held essentially constant.
The reaction time for the reaction of step (b2) may be adapted to the specific needs and is generally in the range of from 30 min to 2 days, preferably of from 1 hour to 18 hours, more preferably of from 2 hours to 6 hours.
The pH value for the reaction of step (b) may be adapted to the specific needs of the reactants. Preferably, the reaction is carried out in a buffered solution, at a pH value in the range of from 3 to 10, more preferably of from 5 to 9, and even more preferably of from 6 to 8. Among the preferred buffers, citrate buffers (pH 6.4), phosphate buffers (pH 7.5) and bicarbonate buffers (pH 8) may be mentioned.
As described above, the hydroxyalkyl starch may comprise more than one functional group Z1, such as multiple thiol groups. Preferably, all groups Z1 present in the hydroxyalkyl starch derivative participate in the coupling reaction in step (b2). However, it is also possible that in step (b2) not all of the functional groups Z1 are coupled to the at least bifunctional crosslinking compound L, or preferably with the derivative of the cytotoxic agent having the structure -L-M. Thus, in this case, the hydroxyalkyl starch conjugate according to step (b2) may comprise at least one unreacted functional group Z1.
To avoid side effects due to the presence of such unreacted functional groups Z1, the hydroxyalkyl starch conjugate may be further reacted, as described above, in a subsequent step to step (c) with a suitable capping reagent D*. In case Z1 is a thiol group, possible free thiol groups present in the conjugate, which may lead to unwanted side effects such as oxidative disulfide formation and consequently crosslinking, may be reacted, for example, with small molecules comprising a thiol reactive group. Examples of thiol reactive groups are given above. Preferred capping reagents D* thus in particular comprise a group selected from the group consisting of pyridyl disulfides, maleimide group, haloacetyl groups, haloacetamides, vinyl sulfones and vinyl pyridines. Preferably, the capping reagent D* comprises a thiol reactive group selected from the group consisting of the following structures:
wherein Hal is a halogen, such as Cl, Br, or I, and LG is a leaving group (or nucleofuge).
In particular D* is iodoacetic acid and/or ethylbromoacetate.
Optionally, a reducing agent such as tris-(2-carboxyethyl)phosphine (TCEP) may be added prior to the capping step in order to break existing disulfides and to keep thiols in their low oxidation state.
Thus, the present invention also describes a method, as described above, the method further comprises
(c) reacting the hydroxyalkyl starch conjugate with a capping reagent D*.
Likewise, in case the crosslinking compound L is either reacted with the hydroxyalkyl starch derivative prior to the coupling to the cytotoxic agent, or only in a subsequent step with the cytotoxic agent, the hydroxyalkyl starch conjugate may comprise at least one unreacted functional group Z1 and/or at least one unreacted group K1.
In this case, the present invention may comprise a further capping step
(c1) reacting the hydroxyalkyl starch conjugate with a further capping reagent D**, wherein D** may be the same or may differ from D*, depending on the nature of functional group to be capped.
Most preferably the hydroxyalkyl starch conjugate according to step (b) comprises no unreacted functional groups Z1 and/or no unreacted group K1.
Preferably, the hydroxyalkyl starch conjugate obtained according to step (b), optionally according to step (c) and/or (c1), is subjected to at least one isolation and/or purification step. Isolation of the conjugate may be carried out by a suitable process which may comprise one or more steps.
According to a preferred embodiment of the present invention, the conjugate is first separated from the reaction mixture by a suitable method such as precipitation and subsequent centrifugation or filtration. In a second step, the separated conjugate may be subjected to a further treatment such as an after-treatment like ultrafiltration, dialysis, centrifugal filtration or pressure filtration, ion exchange chromatography, reversed phase chromatography, HPLC, MPLC, gel filtration and/or lyophilization. According to an even more preferred embodiment, the separated polymer derivative is first precipitated, subjected to centrifugation, re-dissolved and finally subjected to ultrafiltration.
Preferably, the precipitation is carried out with an organic solvent such as ethanol or isopropanol. The precipitated conjugate is subsequently subjected to centrifugation and subsequent ultrafiltration using water or an aqueous buffer solution having a concentration preferably from 1 to 1000 mmol/l, more preferably from 1 to 100 mmol/l, and more preferably from 10 to 50 mmol/l such as about 20 mmol/l, a pH value in the range of preferably from 3 to 10, more preferably of from 4 to 8, such as about 5. The number of exchange cycles preferably is in the range of from 5 to 50, more preferably of from 10 to 30, and even more preferably of from 15 to 25, such as about 20.
Most preferably, the obtained conjugate is further lyophilized until the solvent content of the reaction product is sufficiently low according to the desired specifications of the product.
Furthermore, the present invention relates to a pharmaceutical composition comprising in a therapeutically effective amount a HAS conjugate, as described above, or a HAS conjugate obtained or obtainable by the above described method.
As far as the pharmaceutical compositions according to the present invention comprising the hydroxyalkyl starch conjugate, as described above, are concerned, the hydroxyalkyl starch conjugate may be used in combination with a pharmaceutical excipient. Generally, the hydroxyalkyl starch conjugate will be in a solid form which can be combined with a suitable pharmaceutical excipient that can be in either solid or liquid form. As excipients, carbohydrates, inorganic salts, antimicrobial agents, antioxidants, surfactants, buffers, acids, bases, and combinations thereof may be mentioned. A carbohydrate such as a sugar, a derivatized sugar such as an alditol, aldonic acid, an esterified sugar, and/or a sugar polymer may be present as an excipient. Specific carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoinositol, and the like. The excipient may also include an inorganic salt or buffer such as citric acid, sodium chloride, potassium chloride, sodium sulfate, potassium nitrate, sodium phosphate monobasic, sodium phosphate dibasic, and combinations thereof. The pharmaceutical composition according to the present invention may also comprise an antimicrobial agent for preventing or determining microbial growth, such as, e.g., benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate, thimersol, and combinations thereof.
The pharmaceutical composition according to the present invention may also comprise an antioxidant, such as, e.g., ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, and combinations thereof.
The pharmaceutical composition according to the present invention may also comprise a surfactant, such as, e.g., polysorbates, or pluronics sorbitan esters; lipids, such as phospholipids and lecithin and other phosphatidylcholines, phosphatidylethanolamines, acids and fatty esters; steroids, such as cholesterol; and chelating agents, such as EDTA or zinc.
The pharmaceutical composition according to the present invention may also comprise acids or bases such as, e.g., hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof, and/or sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumarate, and combinations thereof.
Generally, the excipient will be present in a pharmaceutical composition according to the present invention in an amount of 0.001 to 99.999 wt.-%, preferably from 0.01 to 99.99 wt.-%, more preferably from 0.1 to 99.9 wt.-%, in each case based on the total weight of the pharmaceutical composition.
The present invention also relates to a method of treating cancer, comprising administering to a patient suffering from cancer a therapeutically effective amount of the hydroxyalkyl starch conjugate as defined herein, or the hydroxyalkyl starch conjugate obtained or obtainable by the method according to the present invention, or the pharmaceutical composition according to the present invention.
The term “patient”, as used herein, relates to animals and, preferably, to mammals. More preferably, the patient is a rodent such as a mouse or a rat. Even more preferably, the patient is a primate. Most preferably, the patient is a human. It is, however, envisaged by the method of the present invention that the patient shall suffer from cancer.
The term “cancer”, as used herein, preferably refers to a proliferative disorder or disease caused or characterized by the proliferation of cells which have lost susceptibility to normal growth control. Preferably, the term encompasses tumors and any other proliferative disorders. Thus, the term is meant to include all pathological conditions involving malignant cells, irrespective of stage or of invasiveness. The term, preferably, includes solid tumors arising in solid tissues or organs as well as hematopoietic tumors (e.g. leukemias and lymphomas).
The cancer may be localized to a specific tissue or organ (e.g. in the breast, the prostate or the lung), and, thus, may not have spread beyond the tissue of origin. Furthermore the cancer may be invasive, and, thus may have spread beyond the layer of tissue in which it originated into the normal surrounding tissues (frequently also referred to as locally advanced cancer). Invasive cancers may or may not be metastatic. Thus, the cancer may be also metastatic. A cancer is metastatic, if it has spread from its original location to distant parts of the body. E.g., it is well known in the art that breast cancer cells may spread to another organ or body part, such as the lymph nodes.
Preferred cancers are biliary cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, gastrointestinal cancer, head and neck cancer, leukaemia, lymphoma, malignant melanoma, mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma and small cell lung cancer.
Moreover, it is also envisaged that the cancer is selected from cancer is selected from the group consisting of Acute Lymphoblastic Leukemia (adult), Acute Lymphoblastic Leukemia (childhood), Acute Myeloid Leukemia (adult), Acute Myeloid Leukemia (childhood), Adrenocortical Carcinoma, Adrenocortical Carcinoma (childhood), AIDS-Related Cancers, AIDS-Related Lymphoma, Anal Cancer, Appendix Cancer, Astrocytomas (childhood), Atypical Teratoid/Rhabdoid Tumor (childhood), Central Nervous System Cancer, Basal Cell Carcinoma, Bile Duct Cancer (Extrahepatic), Bladder Cancer, Bladder Cancer (childhood), Bone Cancer, Osteosarcoma and Malignant Fibrous Histiocytoma, Brain Stem Glioma (childhood), Brain Tumor (adult), Brain Tumor (childhood), Brain Stem Glioma (childhood), Central Nervous System Brain Tumor, Atypical Teratoid/Rhabdoid Tumor (childhood), Brain Tumor, Central Nervous System Embryonal Tumors (childhood), Astrocytomas (childhood) Brain Tumor, Craniopharyngioma Brain Tumor (childhood), Ependymoblastoma Brain Tumor (childhood), Ependymoma Brain Tumor (childhood), Medulloblastoma Brain Tumor (childhood), Medulloepitheliom Brain Tumor (childhood), Pineal Parenchymal Tumors of Intermediate Differentiation Brain Tumor (childhood), Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma Brain Tumor, (childhood), Brain and Spinal Cord Tumors (childhood), Breast Cancer , Breast Cancer (childhood), Breast Cancer (Male), Bronchial Tumors (childhood), Burkitt Lymphoma, Carcinoid Tumor (childhood), Carcinoid Tumor, Gastrointestinal, Carcinoma of Unknown Primary, Central Nervous System Atypical Teratoid/Rhabdoid Tumor (childhood), Central Nervous System Embryonal Tumors (childhood), Central Nervous System (CNS) Lymphoma, Primary Cervical Cancer, Cervical Cancer (childhood), Childhood Cancers, Chordoma (childhood), Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloproliferative Disorders, Colon Cancer, Colorectal Cancer (childhood), Craniopharyngioma (childhood), Cutaneous T-Cell Lymphoma, Embryonal Tumors, Central Nervous System (childhod), Endometrial Cancer, Ependymoblastoma (childhood), Ependymoma (childhood), Esophageal Cancer, Esophageal Cancer (childhood), Esthesioneuroblastoma (childhood), Ewing Sarcoma Family of Tumors, Extracranial Germ Cell Tumor (childhood), Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer, Intraocular Melanoma, Eye Cancer, Retinoblastoma, Gallbladder Cancer, Gastric (Stomach) Cancer, Gastric (Stomach) Cancer (childhood), Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cell Tumor (childhood), Germ Cell Tumor, Extracranial (childhood), Germ Cell Tumor, Extragonadal, Germ Cell Tumor, Ovarian, Gestational Trophoblastic Tumor, Glioma (adult), Glioma (childhood) Brain Stem, Hairy Cell Leukemia, Head and Neck Cancer, Heart Cancer (childhood), Hepatocellular (Liver) Cancer (adult) (Primary), Hepatocellular (Liver) Cancer (childhood) (Primary), Histiocytosis, Langerhans Cell, Hodgkin Lymphoma (adult), Hodgkin Lymphoma (childhood), Hypopharyngeal Cancer, Intraocular Melanoma, Islet Cell Tumors (Endocrine Pancreas), Kaposi Sarcoma, Kidney (Renal Cell) Cancer, Kidney Cancer (childhood), Langerhans Cell Histiocytosis, Laryngeal Cancer, Laryngeal Cancer (childhood), Leukemia, Acute Lymphoblastic (adult), Leukemia, Acute Lymphoblastic (childhood), Leukemia, Acute Myeloid (adult), Leukemia, Acute Myeloid (childhood), Leukemia, Chronic Lymphocytic, Leukemia, Chronic Myelogenous, Leukemia, Hairy Cell, Lip and Oral Cavity Cancer, Liver Cancer (adult) (Primary), Liver Cancer (childhood) (Primary), Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Non-Hodgkin Lymphoma, (adult), Non-Hodgkin Lymphoma, (childhood), Primary Central Nervous System (CNS) Lymphoma, Waldenstrm , Macroglobulinemia, Malignant Fibrous Histiocytoma of Bone and Osteosarcoma, Medulloblastoma (childhood), Medulloepithelioma (childhood), Melanoma, Intraocular (Eye)Melanoma, Merkel Cell Carcinoma, Mesothelioma (adult) Malignant, Mesothelioma (childhood), Metastatic Squamous Neck Cancer with Occult Primary, Mouth Cancer, Multiple Endocrine Neoplasia Syndromes (childhood), Multiple Myeloma/Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Myelogenous Leukemia, Chronic, Myeloid Leukemia (adult) Acute, Myeloid Leukemia (childhood) Acute, Myeloma, Multiple, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Nasopharyngeal Cancer (childhood), Neuroblastoma, Oral Cancer (childhood), Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Osteosarcoma and Malignant Fibrous, Histiocytoma of Bone, Ovarian Cancer (childhood), Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Pancreatic Cancer, Pancreatic Cancer (childhood), Pancreatic Cancer, Islet Cell Tumors, Papillomatosis (childhood), Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pharyngeal Cancer, Pineal Parenchymal Tumors of Intermediate Differentiation (childhood), Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors (childhood), Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Pleuropulmonary Blastoma, Pregnancy and Breast Cancer, Primary Central Nervous System (CNS) Lymphoma, Prostate Cancer, Rectal Cancer, Renal Cell (Kidney) Cancer, Renal Pelvis and Ureter Transitional Cell Cancer, Respiratory Tract Cancer with Chromosome 15 Changes, Retinoblastoma, Rhabdomyosarcoma (childhood), Salivary Gland Cancer, Salivary Gland Cancer (childhood), Sarcoma, Ewing Sarcoma Family of Tumors, Kaposi Sarcoma, Soft Tissue (adult)Sarcoma, Soft Tissue (childhood)Sarcoma, Uterine Sarcoma, Sezary Syndrome, Skin Cancer (Nonmelanoma), Skin Cancer (childhood), Skin Cancer (Melanoma), Merkel Cell Skin Carcinoma, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma (adult), Soft Tissue Sarcoma (childhood), Squamous Cell Carcinoma, see Skin Cancer (Nonmelanoma), Stomach (Gastric) Cancer, Stomach (Gastric) Cancer (childhood), Supratentorial Primitive Neuroectodermal Tumors (childhood), Cutaneous T-Cell Lymphoma, Testicular Cancer, Testicular Cancer (childhood), Throat Cancer, Thymoma and Thymic Carcinoma, Thymoma and Thymic Carcinoma (childhood), Thyroid Cancer, Thyroid Cancer (childhood), Transitional Cell Cancer of the Renal Pelvis and Ureter, T Gestational rophoblastic Tumor, Unknown Primary Site, Carcinoma of adult, Unknown Primary Site, Cancer of (childhood), Unusual Cancers of childhood, Ureter and Renal Pelvis, Transitional Cell Cancer, Urethral Cancer, Uterine Cancer, Endometrial, Uterine Sarcoma, Vaginal Cancer, Vaginal Cancer (childhood), Vulvar Cancer, Waldenstrm Macroglobulinemia and Wilms Tumor.
The terms “treating cancer” and “treatment of cancer”, preferably, refer to therapeutic measures, wherein the object is to prevent or to slow down (lessen) an undesired physiological change or disorder, such as the growth, development or spread of a hyperproliferative condition, such as cancer. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. It is to be understood that a treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
The term “administering” as used herein, preferably, refers to the introduction of the hydroxyalkyl starch conjugate as defined herein, the hydroxyalkyl starch conjugate obtained or obtainable by the method according to the present invention, or the pharmaceutical composition according to the present invention into cancer patients. Methods for administering a particular compound are well known in the art and include parenteral, intravascular, paracanceral, transmucosal, transdermal, intramuscular (i.m.), intravenous (i.v.), intradermal, subcutaneous (s.c.), sublingual, intraperitoneal (i.p.), intraventricular, intracranial, intravaginal, intratumoral, and oral administration. It is to be understood that the route of administration may depend on the cancer to be treated. Preferably, the hydroxyalkyl starch conjugate as defined herein, the hydroxyalkyl starch conjugate obtained or obtainable by the method according to the present invention, or the pharmaceutical composition according to the present invention are administered parenterally. More preferably, it is administered intravenously. Preferably, the administration of a single dose of a therapeutically effective amount of the aforementioned compounds is over a period of 5 min to 5 h.
Preferably, the conjugates are administered together with a suitable carrier, and/or a suitable diluent, such as preferably a sterile solution for i.v., i.m., i.p. or s.c. application.
The term “therapeutically effective amount”, as used herein, preferably refers to an amount of the hydroxyalkyl starch conjugate as defined herein, the hydroxyalkyl starch conjugate obtained or obtainable by the method according to the present invention, or the pharmaceutical composition according to the present invention that (a) treats the cancer, (b) attenuates, ameliorates, or eliminates the cancer. More preferably, the term refers to the amount of the cytotoxic agent present in the hydroxyalkyl starch conjugate as defined herein, the hydroxyalkyl starch conjugate obtained or obtainable by the method according to the present invention, or the pharmaceutical composition according to the present invention that (a) treats the cancer, (b) attenuates, ameliorates, or eliminates the cancer. How to calculate the amount of a cytotoxic agent present in the aforementioned conjugates or pharmaceutical composition is described elsewhere herein. It is particularly envisaged that the therapeutically effective amount of the aforementioned compounds shall reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, at least to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. Whether a particular amount of the aforementioned compounds exerts these effects (and, thus is pharmaceutically effective) can be determined by well known measures. Particularly, it can be determined by assessing cancer therapy efficacy. Cancer therapy efficacy, e.g., can be assessed by determining the time to disease progression and/or by determining the response rate. Thus, the required dosage will depend on the severity of the condition being treated, the patient's individual response, the method of administration used, and the like. The skilled person is able to establish a correct dosage based on his general knowledge.
Advantageously, it has been shown in the studies carried out in the context of the present invention that
i) the cytotoxic agent is less toxic when present in the conjugates described herein as compared to an agent not being present in a conjugate and/or
ii) that the use of said conjugate, or of the pharmaceutical composition comprising said conjugate allows for a more efficient treatment of cancer in a subject (see Example 2).
Moreover, the present invention relates to the hydroxyalkyl starch conjugate as defined above, or the hydroxyalkyl starch conjugate obtained or obtainable by the method according to the present invention, or the pharmaceutical composition according to the present invention for use as a medicament.
Moreover, the present invention relates to the hydroxyalkyl starch conjugate as defined above, or the hydroxyalkyl starch conjugate obtained or obtainable by the method according to the present invention, or the pharmaceutical composition according to the present invention for the treatment of cancer.
Also envisaged by the present invention is the hydroxyalkyl starch conjugate as defined above, or the hydroxyalkyl starch conjugate obtained or obtainable by the method according to the present invention, or the pharmaceutical composition according to the present invention for the treatment of cancer selected from the group consisting of biliary cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, gastrointestinal cancer, head and neck cancer, leukaemia, lymphoma, malignant melanoma, mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma and small cell lung cancer.
Finally, the present invention pertains to the use of the hydroxyalkyl starch conjugate as defined above, or the hydroxyalkyl starch conjugate obtained or obtainable by the method according to the present invention, or the pharmaceutical composition according to the present invention for the manufacture of a medicament for the treatment of cancer. Preferably, the cancer is selected from the group consisting of biliary cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, gastrointestinal cancer, head and neck cancer, leukaemia, lymphoma, malignant melanoma, mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma and small cell lung cancer.
How to administer the conjugates, compositions or medicaments has been explained elsewhere herein.
The following especially preferred embodiments are described:
HAS′(-L-M)n
—[F2]q-[L2]g-[E]e-[CRmRn]f—
HAS′(-L-N)n
K2-L′-K1
K2-[L2]g-[E]e-[CRmRn]f—K1
The following symbols are used:
▪=saline, ★=gemcitabine (Gemzar®), ⋄═CGt1.
The X-axis shows the time after start [d], the Y-axis shows the mean relative tumor volume, mean RTV [%].
Each measurement was carried out with a group of 8 mice. The conjugate CGt1 was administered at a dosage of 7.5 mg/kg body weight on days 9, 16, 23, 30, 24 and 40. Gemcitabine was administered at a dosage of 60 mg/kg body weight at days 9, 13, 16, 20, 23, 27, 30, 34 and 40. Median values are given. Further details are given in Table 11.
The following symbols are used:
▪=saline, ★=gemcitabine (Gemzar®), ⋄═CGt1.
The X-axis shows the time after start [d], the Y-axis shows the mean BWC [%]
Each measurement was carried out with a group of 8 mice. The conjugate CGt1 was administered at a dosage of 7.5 mg/kg body weight on days 9, 16, 23, 30, 24 and 40. Gemcitabine was administered at a dosage of 60 mg/kg body weight at days 9, 13, 16, 20, 23, 27, 30, 34 and 40. Median values are given. Further details are given in Table 11.
The following symbols are used: ▪=Saline, ★=gemcitabine (Gemzar®), ∘=CGt2, Δ=CGt6, ∇=CGt3, ⋄═CGt5.
The X-axis shows the time after tumor implantation [d], the Y-axis shows the relative tumor volume (RTV) [%].
Each measurement was carried out with a group of 8 mice. The conjugates were administered 5 to 9 times, each time at a dosage of 7.5 mg/kg body weight. Gemcitabine was administered 8 times at a dosage of 60 mg/kg body weight each. Median values are given. Further details are given in Table 12.
The following symbols are used: ▪=Saline, ★=gemcitabine (Gemzar®), ∘=CGt2, Δ=CGt6, ∇=CGt3, ⋄═CGt5.
The X-axis shows the time after tumor transplantation [d], the Y-axis shows the BWC [%].
Each measurement was carried out with a group of 8 mice. The conjugates were administered 5 to 9 times, each time at a dosage of 7.5 mg/kg body weight. Gemcitabine was administered 8 times at a dosage of 60 mg/kg body weight each. Median values are given. Further details are given in Table 12.
X-axis: time [h], Y-axis: conjugate [%].
The following symbols are used: ▪=CEv2, ♦=CEv1.
X-axis: time [h], Y-axis: conjugate [%].
The following symbols are used: ♦=CTm1, =CTm3, ▴=CTm2, X═CTm5.
X-axis: time [h], Y-axis: conjugate [%].
The following symbols are used: ♦=CGt9, ▪=CGt3, ▴=CGt8.
X-axis: time [h], Y-axis: conjugate [%].
The following symbols are used: ♦=CGt1, ▪=CCt2.
CEv2 vs. mice in the control group (untreated mice (saline)) as well as vs. mice treated with everolimus.
The following symbols are used: ▪=Saline, ×=Everolimus, ♦=CEv1, =CEv2,
The X-axis shows the days after treatment [d], the Y-axis shows the median relative tumor volume (RTV) [%].
Each measurement was carried out with a group of 5 mice. The conjugates were administered 5 times, each time at a dosage of 10 or 15 mg/kg body weight. Everolimus was administered 5 times, each time at a dosage of 10 or 15 mg/kg body weight each. Median values are given. Further details are given in Table 14.
The following symbols are used: The following symbols are used: ▪=Saline, ×=Everolimus, ♦=CEv1, =CEv2,
The X-axis shows the time after start, the Y-axis shows the median BWC [%].
Each measurement was carried out with a group of 5 mice. The conjugates were administered 5 times, each time at a dosage of 10 or 15 mg/kg body weight. Everolimus was administered 5 times, each time at a dosage of 10 or 15 mg/kg body weight each. Median values are given. Further details are given in Table 14.
The following symbols are used: ▪=saline, ×=temsirolimus, ♦=CTm1, ▴=CTm2, =CTm3.
The X-axis shows the days after treatment [d], the Y-axis shows the relative tumor volume (RTV) [%].
Each measurement was carried out with a group of 5 mice. The conjugates were administered 4 times, each time at a dosage of 20 mg/kg body weight. Temsirolimus was administered 4 times, each time at a dosage of 20 mg/kg body weight. Median values are given. Further details are given in Table 14.
The following symbols are used: ▪=saline, ×=temsirolimus, ♦=CTm1, ▴=CTm2, =CTm3.
The X-axis shows the time after treatment [d], the Y-axis shows the mean body weight [% of start value.
Each measurement was carried out with a group of 5 mice. The conjugates were administered 4 times, each time at a dosage of 20 mg/kg body weight. Temsirolimus was administered 4 times, each time at a dosage of 20 mg/kg body weight. Median values are given. Further details are given in Table 14.
The following symbols are used: ▪=saline, ★=gemcitabine (Gemzar®), ∇=CGt10, Δ=CGt9, ⋄=CGt7.
The X-axis shows the time after treatment [d], the Y-axis shows the median relative tumor volume.
Each measurement was carried out with a group of 9 mice. Conjugates were administered 3 times, each time at a dosage of 3 mg/kg for CGt10 and CGt7 and 7.5 mg/kg for CGt9. gemcitabine (Gemzar®) was administered 3 times, each time at a dosage of 60 mg/kg body weight each. Median values are given. Further details are given in Table 13.
The following symbols are used: ▪=saline, ★=gemcitabine (Gemzar®), ∇=CGt10, Δ=CGt9, ⋄═CGt7.
The X-axis shows the time after treatment [d], the Y-axis shows the mean body weight [% of start value.
Each measurement was carried out with a group of 9 mice. Conjugates were administered 3 times, each time at a dosage of 3 mg/kg for CGt10 and CGt7 and 7.5 mg/kg for CGt9. gemcitabine (Gemzar®) was administered 3 times, each time at a dosage of 60 mg/kg body weight each. Median values are given. Further details are given in Table 13.
Centrifugation was performed using a Sorvall Evolution RC centrifuge (Thermo Scientific) equipped with a SLA-3000 rotor (6×400 mL vessels) at 9000 g and 4° C. for 5-10 min.
Ultrafiltration was performed using a Sartoflow Slice 200 Benchtop (Sartorius AG) equipped with two Hydrosart Membrane cassettes (10 kDa Cutoff, Sartorius). Pressure settings: p1=2 bar, p2=0.5 bar.
Filtration: Solutions were filtered prior to size exclusion chromatography and HPLC using syringe filters (0.45 μm, GHP-Acrodisc, 13 mm) or Steriflip (0.45 μm, MilliQ).
Analytical HPLC spectra were measured on a Ultimate 3000 (Dionex) using a LPG-3000 pump, a DAD-3000a diode array detector and a C18 reverse phase column (Dr. Maisch, Reprosil Gold 300A, C18, 5 μm, 150×4.6 mm). Eluents were purified water (Millipore)+0.1% TFA (Uvasol, MERCK) and acetonitrile (HPLC grade, MERCK)+0.1% TFA. Standard gradient was: 2% ACN to 98% ACN in 30 min.
Size exclusion chromatography was performed using an Akta Purifier (GE-Healthcare) system equipped with a P-900 pump, a P-960 sample pump using an UV-900 UV detector and a pH/IC-900 conductivity detector. A HiPrep 26/10 desalting column (53 mL, GE-Healthcare) was used together with a HiTrap desalting column as pre-column (5 mL, GE-Healthcare). Fractions were collected using the Frac-902 fraction collector.
Freeze-drying: Samples were frozen in liquid nitrogen and lyophylized using a Christ alpha 1-2 LD plus (Martin Christ, Germany) at p=0.2 mbar.
UV-vis absorbances were measured at a Cary 100 BIO (Varian) in either plastic cuvettes (PMMA, d=10 mm) or quarz cuvettes (d=10 mm, Hellma, Suprasil, 100-QS) using the Cary Win UV simple reads software.
(a) Synthesis of allyl-HES
Hydroxyethyl starch (Lot. 073121, Fresenius Kabi, Linz) (HES1) was thoughtfully dried prior to use on an infra-red heated balance at 80° C. until the mass remained constant. In a 500 ml round bottom flask equipped with a magnetic stirring bar and a rubber septum, 20 g of hydroxyethyl starch was dissolved in 200 ml of dry DMF under an inert atmosphere. After the HES had dissolved, 0.63 g of sodium hydride (60% w/w in paraffin) were added in one portion and the resulting cloudy solution was allowed to stir for 1 h at room temperature followed by the addition of 0.94 ml allyl bromide. The reaction mixture was allowed to stir over night, resulting in a yellow, clear solution. The solution was then slowly poured into 1400 ml of isopropanol and the precipitate collected by centrifugation. The precipitated polymer was re-dissolved in water and subjected to ultrafiltration (20 volume exchanges with water). Freeze-drying of the retentate yielded 18.9 g (94%) of a colourless solid.
(b) Synthesis of thiol-HES D1
In a glass beaker, 10.0 g of allyl-HES were dissolved in 200 ml of a 4*10−4 M EDTA solution. 35 mg of tetrahydrothiopyran-4-one were added and the solution was allowed to stir on a magnetic stirring plate. 5 g of potassium persulfate (Ozone) and 2.12 g sodium hydrogen carbonate were mixed in dry state and the mixture was added in small portions to the HES-solution resulting in the formation of thick foam. The mixture was stirred at ambient temperature for 2 h. The mixture was directly subjected to ultrafiltration (20 volume exchanges with water). The retentate was split into two aliquots, each of them used for independent preparations.
One aliquot (˜5 g HES) was poured into 180 ml of a 1:1 mixture of isopropanol and MTBE resulting in precipitation of the polymer, which was collected by centrifugation. The precipitate was re-dissolved in 50 ml of DMF, transferred into a 100 ml screw-cap bottle. 23 ml of ethanedithiol were added and the resulting mixture degassed by purging with inert gas for several minutes. 7 ml of a 0.1 M sodium bicarbonate solution were added, the bottle was tightly closed and stirred for 2 days at ambient temperature. The resulting clear solution was poured into 500 ml of isopropanol and the precipitate collected by ultrafiltration. The polymer was re-dissolved in 100 ml of water and subjected to ultrafiltration (20 volume exchanges with water). The resulting retentate (100 ml) was transferred into a 250 ml round bottom flask equipped with a magnetic stirring bar. The solution was degassed by purging with argon for several minutes. 0.5 g of sodium borohydride were added and the resulting mixture was allowed to stir over night at ambient temperature. The reaction was quenched by addition of 1 ml of acetic acid. The solution was subjected to ultrafiltration (15 volume exchanges against 20 mM acetic acid+2 mM EDTA followed by 5 volume exchanges against 20 mM acetic acid). The retentate was freeze dried to give 5.13 g of a colorless solid.
Molecular weight: Mw=88.7 kD; Mn=60.9 kD; PDI=1.46.
Hydroxyethyl starch as used in the preparation was thoughtfully dried prior to use either on an infra-red heated balance at 80° C. until the mass remained constant or by leaving in a drying oven over night at 80° C. In a round bottom flask equipped with a magnetic stirring bar and a rubber septum under inert gas, HES was dissolved in formamide to give a 20% solution. After the addition of collidine, the clear solution was cooled in an ice-water bath. Then, mesyl chloride was added dropwise and the reaction mixture kept in the ice bath for ˜1 h. The cooling bath was removed and the solution allowed to warm up to room temperature. After additional 1 h of stirring, potassium thioacetate was added as a solid and the resulting amber solution was allowed to stir over night at the given temperature. After cooling to room temperature, the reaction mixture was diluted 5:1 with water and subjected to ultrafiltration (concentration to a 10% w/w HES solution followed by 15-20 volume exchanges with water). The retentate was used immediately in the next step. Alternatively, the thioacetyl-HES can be lyophilized and stored without signs of degradation.
A 10% (w/v) solution of thioacetyl-HES derived from GP 1.1 in water was filled in a round bottom flask equipped with a magnetic stirring bar and a rubber septum under an inert gas atmosphere. The solution was degassed by passing a stream of inert gas through the mixture while continuous stirring for ˜10 minutes. A 1 M sodium hydroxide solution was added (20% of total volume), followed by addition of solid sodium borohydride (10% w/w of HES). The resulting solution was allowed to stir under inert gas for 2 h. The reaction was quenched by addition of acetic acid (˜0.5 ml/gram HES, pH=5-7). The product was purified by ultrafiltration (15-20 volume exchanges with a 20 mM solution of acetic acid in water). Freeze-drying of the retentate afforded SH-HES as a colorless solid.
The cytostatic compound gemcitabine was used as compound M. Such cyctostatic compound is commercially available and sold, for example, by company Sigma-Aldrich as Gemcitabine hydrochloride.
In a round bottom flask, 1.0 g of gemcitabine hydrochloride was dissolved in 5 ml of DMF. 0.5 ml of triethylamine were added and the resulting solution was stirred for 5 minutes at room temperature. The solution was cooled to 0-5° C. followed by the dropwise addition of chloroacetyl chloride (0.55 ml) in 5 minutes time, stirred for 2 h at 0-5° C. and allowed to warm up to room temperature. The solvents were removed under reduced pressure and the crude product purified via column chromatography on silica (DCM /methanol 9:1) to give 1.0 g (77.5%) of an off white solid.
IR (KBr; cm−1): 1682.82, 1737.48, 3227.37
1H NMR (400 MHz; DMSO-d6): δ=4.11 (m, 1H), 4.23 (m, 1H), 4.38-4.45 (m, 2H), 4.47 (s, 2H), 6.12 (t, J=7.6 Hz, 1H), 6.20 (d, J=7.6 Hz, 1H), 6.65 (bs, 1H, OH), 7.86 (d, J=7.6 Hz, 1H), 8.80 (s, 1H, NH), 9.89 (s, 1H, NH).
MS (ESI): m/z =340.
A 100 ml 2-neck round bottom flask was charged with gemcitabine hydrochloride (2.0 g; 6.67 mmol), triethylamine (0.9 ml, 6.66 mmol) and DMF (10 ml) under nitrogen atmosphere. The reaction mixture was cooled to 0-5° C. and a solution of 2-bromopropionyl bromide (1.05 ml, 9.99 mmol) in 5 ml of DMF was added dropwise. The reaction mixture was warmed to 20-25° C. and stirred for 2 h. The reaction was quenched by adding water (40 ml) and extracted with DCM (2×40 ml). The combined DCM layer was evaporated at 40° C. under vacuum. The residue was purified by column chromatography on silica using 4% methanol in DCM as eluant to furnish the product as off-white solid (550 mg, 17%; 1.14 mmol).
IR (KBr; cm−1): 1680.48, 1735.64, 3393.97
1H NMR (400 MHz; DMSO-d6): δ=1.61 & 1.74 (2×d, 3H, J=6.4 Hz), 4.15 (m, 1H), 4.26 (t, 1H), 4.47-4.50 (m, 2H), 4.81 (m, 1H), 6.11-6.17 (m, 2H), 6.58 (br s, 1H), 7.86 (d, 1H), 8.43 & 9.43 (br s, 2H)
MS (ESI): m/z=398 (M+H)+ & 400 (M+2+H)+
A 100 ml 2-neck round bottom flask was charged with gemcitabine hydrochloride (3.0 g; 10.0 mmol), triethylamine (1.39 ml, 10.0 mmol) and DMF (20 ml) under nitrogen atmosphere. The mixture thus obtained was cooled to 0-5° C. and a solution of 2-bromo-2-methylpropionyl bromide (1.2 ml, 10.0 mmol) in DMF (15 ml) was added dropwise over 1 h. The reaction mixture was warmed to 20-25° C. and stirred for 1 h followed by evaporation at 50° C. The residue thus obtained was purified by column chromatography on silica using 3% methanol in DCM to 5% methanol in DCM to yield gemcitabine 5′-bromoisobutyryl ester, 420 mg (8.5%; 0.85 mmol).
IR (KBr; cm−1): 1733.98, 3328.87
1H NMR (400 MHz; DMSO-d6): δ=1.98 (s, 6H), 4.14 (m, 1H), 4.27 (br s, 1H), 4.44-4.54 (m, 2H), 5.85 (d, 1H), 6.23 (s, 1H), 6.53 (d, 1H), 7.52 (d, 2H), 7.59 (d, 1H)
MS (ESI): m/z=412 (M+H)+ & 414 (M+2+H)+
A 50 ml Schlenk flask was charged with cytarabine (2.0 g; 8.22 mmol) and 20 ml of dry methanol. The suspension was stirred and hydrochloric acid (7.0 ml, 1.25 M in methanol; 8.75 mmol) was added under nitrogen. The mixture was stirred for 3 h at room temperature followed by evaporation. The residue was treated with dry diethyl ether in an ultrasonic bath. The ether was removed under vacuum to yield cytarabine hydrochloride (2.07 g; 7.39 mmol; 89.9%) as a white powder.
A Schlenk tube was charged with cytarabine hydrochloride (500 mg; 1.79 mmol) and 20 ml of dry DMPU under nitrogen. Chloroacetyl chloride (71 μl; 893 μmol) was added at room temperature. The reaction was monitored by HPLC. Portions of chloroacetyl chloride had to be added to complete the reaction (in this case: 12 portions of totally 140 μl chloroacetyl chloride (2) (1.76 mmol)). The reaction mixture was poured into a mixture of diethyl ether and pentane (2:1, totally 600 ml). The precipitate was dissolved in 5 ml of methanol. This solution was added dropwise into 300 ml of ether. The precipitate was dried under vacuum to yield 770 mg of chloroacetyl cytarabine hydrochloride containing residual DMPU as a pale pink solid, which was used in the conjugation step without further purification.
1H-NMR (DMSO-d6): δ=9.80 (s, 1H), 8.75 (s, 1H), 7.83 (d, J=7.8 Hz, 1H), 6.16 (d, J=7.8 Hz, 1H), 6.05 (d, J=3.9 Hz, 1H), 4.43 (s, 2H), 4.44-4.34 (m, 2H), 4.09 (dd, J=3.9 Hz, J=2.6 Hz, 1H), 4.05 (m, 1H), 3.96 (t, J=2.8 Hz, 1H)
MS (ESI): m/z=396.04 [M+H+, 35Cl]+, 398.03 [M+H+, 37Cl]+
A Schlenk tube was charged with maleimidopropionic acid (2.0 g; 11.82 mmol) and thionyl chloride (4.0 ml; 54.86 mmol). The mixture was heated at reflux for 20 minutes followed by evaporation. The residue was washed three times with each 10 ml of dry pentane. Then it was dried at 10−3 mbar to yield maleimidopropionyl chloride (2.17 g; 11.57 mmol; 98%) as a yellow solid.
A Schlenk tube was charged with cytarabine hydrochloride (prepared as described above, 509.7 mg; 1.82 mmol) and 17.5 ml of dry DMPU. Maleimidopropionyl chloride (288.4 mg; 1.54 mmol) was added under nitrogen followed by 1.5 ml of dry DMPU. The resulting suspension was stirred at room temperature to yield a solution after 10 minutes. The reaction was monitored by HPLC. Portions of a maleimidopropionyl chloride solution (prepared from 600 mg of maleimidopropionyl chloride and 600 μl of DMPU) were added until the HPLC indicated full conversion (625 μl added). The solution was poured into diethyl ether/pentane (2:1; 600 ml) followed by centrifugation. The residue was dissolved in 10 ml of methanol. This solution was dropped into 300 ml of diethyl ether followed by centrifugation. The residue was dried under vacuum to yield 900 mg of maleimidopropionyl cytarabine hydrochloride containing residual DMPU. The material was used in the conjugation experiments without further purification.
1H-NMR (DMSO-d6): δ=9.84 (s, 1H), 8.75 (s, 1H), 7.81, (d, J=7.8 Hz, 1H), 7.07 (s, 2H), 6.15 (d, J=7.9 Hz, 1H), 6.02 (d, J=3.6 Hz, 1H), 4.30 (dd, J=11.6 Hz, J=8.3 Hz, 1H), 4.18 (dd, J=11.7 Hz, J=4.0 Hz, 1H), 4.05-3.97 (m, 2H), 3.92 (m, 1H), 3.66 (t, J=6.9 Hz, 2H), 2.63 (t, J=7.0 Hz, 2H)
MS (ESI): m/z=395.12 [M+H+]+
A 100 ml round bottom flask was charged with temsirolimus (2.0 g; 1.94 mmol) and 15 ml of DCM. The clear solution was cooled to −15° C. to −10° C. and 4-pyrrolidino pyridine (0.32 g, 2.1 mmol) was added under nitrogen. A solution of bromoacetyl bromide (0.39 g, 1.9 mmol) in 2 ml of DCM was added dropwise (20 minutes) into the reaction. The mixture was stirred further for 40 minutes when TLC analysis indicated formation of three non-polar products. The reaction mixture was diluted with 10 ml of DCM followed by water (5 ml). The DCM layer was separated, dried over MgSO4 and evaporated under vacuum to give white foam. The crude product was subjected to column chromatography on silica using a gradient of 10% acetone in hexane to 20% acetone in hexane to furnish temsirolimus bromoacetyl monoester (682 mg, 30%; 0.59 mmol) as white foam.
IR (KBr; cm−1): 1643.7, 1731.0, 3456.7
MS (ESI): m/z=1172 (M+Na)+ & 1174 (M+2+Na)+
A 100 ml round bottom flask was charged with temsirolimus (3.0 g; 2.90 mmol) and 15 ml of DCM. The clear solution was cooled to −20° C. to −15° C. and 4-pyrrolidino pyridine (0.43 g, 2.90 mmol) was added under nitrogen. A solution of 2-bromopropionyl bromide (0.63 g, 2.90 mmol) in 2 ml of DCM was added dropwise (20 minutes) into the reaction. The mixture was stirred further for 40 minutes when TLC analysis indicated formation of three non-polar products. The reaction mixture was diluted with 10 ml of DCM followed by water (5 ml). The DCM layer was separated, dried over MgSO4 and evaporated under vacuum to give white foam. The crude product was subjected to column chromatography on silica using a gradient of 10% acetone in hexane to 20% acetone in hexane to furnish temsirolimus (2-bromopropionyl) monoester (850 mg, 25%, 0.72 mmol) as white foam.
IR (KBr; cm−1): 1640.56, 1731.4, 3438.7
MS (ESI): m/z=1181 (M+NH4)+ & 1183 (M+2+NH4)+
A 100 ml round bottom flask was charged with temsirolimus (2.0 g; 1.90 mmol) and 10 ml of DCM. The clear solution was cooled to −20° C. to −15° C. and 4-pyrrolidino pyridine (0.37 g, 2.40 mmol) was added under nitrogen. The solution of 2-bromo-2-methylpropionyl bromide (0.26 ml, 2.00 mmol) in 2 ml of DCM was added dropwise over a period of 20 minutes. The mixture was stirred further for 30 minutes when TLC analysis indicated formation of three non-polar products. The reaction mixture was diluted with 10 ml of DCM followed by water (5 ml). The DCM layer was separated, dried over MgSO4 and evaporated under vacuum to give white foam. The crude product was subjected to column chromatography on silica using a gradient of 5% acetone in hexane to 20% acetone in hexane to furnish temsirolimus (2-bromoisobutyryl) monoester (1.4 g, 61%, 1.19 mmol) as white foam.
IR (KBr; cm−1): 1640.7, 1732.7, 3444.0
MS (ESI): =1195 (M+NH4)+ & 1197 (M+2+NH4)+
A 100 ml round bottom flask was charged with temsirolimus (3.0 g; 2.9 mmol) and 15 ml of DCM. The clear solution was cooled to −20° C. to −15° C. and 4-pyrrolidino pyridine (0.6 g, 4.0 mmol) was added under nitrogen. The solution of methacryloyl chloride (0.32 g, 3.1 mmol) in 2 ml of DCM was added dropwise into the reaction. The mixture was stirred further for 2 h when TLC analysis indicated formation of two non-polar products. The reaction mixture was diluted with 10 ml of DCM followed by water (5 ml). The DCM layer was separated, dried over MgSO4 and evaporated under vacuum to give white foam. The crude product was subjected to column chromatography on silica using a gradient of 2% acetone in DCM to 15% acetone in DCM to furnish temsirolimus 42-methacryloyl monoester (900 mg, 28%; 0.82 mmol) as white foam.
IR (103r; cm−1): 1642.1, 1722.9, 3443.9
MS (ESI): m/z=1115.6 (M+NH4)
A 100 ml 2-neck round bottom flask was charged with temsirolimus (538 mg; 0.52 mmol) and 5 ml of DCM under nitrogen atmosphere. The solution was cooled to −15 to −10° C. and a solution of maleimidopropionyl chloride (98 mg, 0.53 mmol) in DCM (5 ml) was added dropwise. The reaction mixture was stirred for 30 minutes and directly subjected to column chromatography on silica using 50% ethyl acetate in hexane to obtain temsirolimus maleimidopropionyl ester (59 mg, 9%, 0.04 mmol).
IR (KBr; cm−1): 1641.2, 1715.3, 3448.0
MS (ESI): m/z=1198.7 (M+NH4)+
In a 100 ml 3-neck flask equipped with a magnetic stirring bar, a dropping funnel, and a thermometer, 500 mg of everolimus, 94 mg of bromoacetic acid and 32 mg of DMAP were dissolved in 20 ml of dichloroethane. The mixture was cooled to 0° C. 132 mg of diisopropylcarbodiimide (DIC) were dissolved separately in 5 ml of dichloroethane and then added to the reaction mixture under control of the temperature (0° C. to 2° C.). The reaction was kept at 0° C. and monitored by HPLC. After 45 minutes, the reaction mixture was diluted with 100 ml of DCM and quenched with 100 ml of a NaHCO3 solution (0.5%). After the phases were separated, the organic phase was washed with 100 ml of 0.1N HCl solution and 50 ml of brine. The organic phase was dried with sodium sulfate. Afterwards the solvent was evaporated under reduced pressure. The crude product purified by column chromatography on silica (dichloromethane:methanol 60:1) to give 310 mg (0.287 mmol, 55%) of the title compound as off-white solid.
TLC (DCM:MeOH//10:1): Rf=0.55
MS (ESI; MeOH): m/z=1102.48 [M(81Br)+Na+]; 1100.95 [M (79Br)+Na+]
A 100 ml 3-neck flask was equipped with a magnetic stirring bar, a dropping funnel and an inside thermometer. The flask was loaded with 500 mg of everolimus, 115 mg of 3-maleimido-propionic acid and 32 mg of DMAP. The mixture was dissolved in 20 ml of dichloroethane and cooled to 0° C. 0.162 ml of diisopropylcarbodiimide was diluted with 20 ml of DCE and then added to the reaction mixture at 0-2° C. After 2 h at 0° C., the reaction was diluted with 100 ml of DCM and quenched with 100 ml of a 0.5% NaHCO3 solution. After the phases were separated the organic phase was washed with 100 ml of 0.1 N HCl solution and 50 ml of brine. The organic phase was dried with sodium sulfate and evaporated under reduced pressure. The crude product was purified by column chromatography on silica (DCM:methanol//60:1) to give the title compound (240 mg, 0.216 mmol, 43%) as colorless solid.
TLC (DCM:MeOH//10:1): Rf=0.6
MS (ESI): m/z=1131.60 [M+Na]+
In a 100 ml round bottom flask equipped with a magnetic stirring bar, 2.5 g of thiol HES (2) were dissolved in 71 ml DMF. 284 mg of chloroacetyl-gemcitabine (3) was added and the resulting solution degassed by purging with inert gas for several minutes. 477 μL of diisopropyl ethylamine (DTEA) were added and the reaction mixture was stirred over night at ambient temperature. The reaction was quenched by addition of 1.24 g of iodoacetic acid, stirred for additional 30 minutes and finally poured into 500 ml of cooled isopropanol. The precipitate was collected by centrifugation. The crude conjugate was dissolved in 100 ml water, filtered (0.45 μm bottle top filter) and purified via size exclusion chromatography. The fractions, containing polymer, were pooled and freeze-dried to yield 2.43 g (97%) of a colorless solid.
Molecular weight: Mw=104.6 kD; Mn=60.9 kD; PDI=1.72.
In a round bottom flask equipped with a magnetic stirring bar, septum and inert gas inlet, the appropriate thiol-HES derivative was dissolved in DMF under an argon atmosphere. After addition of the drug derivative, argon was bubbled through the solution for several minutes under constant stirring. DIPEA was added and the resulting reaction mixture stirred at room temperature over night. Ethyl bromoacetate was added, stirring was continued for 30 minutes and the reaction mixture poured into isopropanol (˜7 times the volume of the solution). The precipitated polymer was collected by centrifugation, dissolved in water, filtered and purified by size exclusion chromatography.
In a round bottom flask equipped with a magnetic stirring bar, septum and inert gas inlet, the appropriate thiol-HES derivative was dissolved in DMF under an argon atmosphere. After addition of the drug derivative, argon was bubbled through the solution for several minutes under constant stirring. DBU was added and the resulting reaction mixture stirred for 2 h at room temperature. Ethyl bromoacetate was added, stirring was continued for 30 minutes and the reaction mixture poured into isopropanol (−7 times the volume of the solution). The precipitated polymer was collected by centrifugation, dissolved in water, filtered and purified by size exclusion chromatography.
In a round bottom flask equipped with a magnetic stirring bar, septum and inert gas inlet, the appropriate thiol-HES derivative was dissolved in a mixture of DMF and either 0.1 M phosphate buffer pH 7 or 0.04 M citrate buffer pH 6.4 (as indicated in table 5) under an argon atmosphere. Argon was bubbled through the solution for several minutes under constant stirring. The drug derivative was added and the resulting reaction mixture stirred for 2 h at room temperature. Ethyl bromoacetate or iodoacetic acid (as indicated in table 5) was added, stirring was continued for 30 minutes and the reaction mixture poured into isopropanol (˜7 times the volume of the solution). The precipitated polymer was collected by centrifugation, dissolved in water, filtered and purified by size exclusion chromatography.
A stock solution of 4 mg/ml of 5,5′-dithio-bis(2-nitrobenzoic acid), Eliman's reagent, in 0.1 M sodium phosphate buffer+1 mM EDTA (pH 8) buffer was freshly prepared.
A 0.2 mg/ml solution of sample in buffer was prepared and 1 ml of this solution filled into a 2 ml vial. An additional vial containing 1 ml of plain buffer was used as blank. The samples were treated with 100 μL of the reagent stock solution, placed into a mixer and mixed at 750 rpm, 21° C. for 15 minutes. The sample solutions were transferred into plastic cuvettes (d=10 mm) and measured for absorbance at 412 nm. The amount of thiols present in the vial was calculated according to the following formula (A=absorbance of sample, A0=absorbance of blank):
considering the concentration of 0.2 mg/ml and 1 cm3=1 ml:
The final value was calculated as the average loading from the three samples.
The thiol content of the product of the thio-HES (2) was determined to be 223 nmol/mg.
1 ml of a 0.5 mg/ml solution of a HES-drug conjugate in the appropriate solvent was measured at the absorbance maximum (see table 4a) (gemcitabine at 270 nm) in a plastic cuvette (d=1 cm) using pure water as blank. The absorption of the blank was subtracted from the conjugate and the drug content calculated as follows:
The molar extinction coefficients were obtained from a calibration curve of the drugs in the specific solvents at the appropriate wavelength.
The loading is calculated as
with cconjugate being the concentration of the sample solution, e.g. 0.5 mg/ml.
With a known molecular weight for the drug (e.g. 263.2 g/mol for gemcitabine), the drug loading can also be expressed in mg drug/gram conjugate:
Loading[mg/g]=Loading[μmol/g]*Mw[g/mol]/1000
The gemcitabine content of CGt1 was, e.g., determined to be 163 μmol/g or 42.9 mg/g.
The “mean molecular weight” as used in the context of the present invention relates to the weight as determined according to MALLS-GPC (Multiple Angle Laser Light Scattering).
For the determination, 2 Tosoh BioSep GMPWXL columns connected in line (13 tun particle size, diameter 7.8 mm, length 30 cm, Art. no. 08025) were used as stationary phase. The mobile phase was prepared as follows: In a volumetric flask 3.74 g Na-Acetate*3H2O, 0.344 g NaN3 are dissolved in 800 ml Milli-Q water and 6.9 ml acetic acid anhydride are added and the flask filled up to 11.
Approximately 10 mg of the hydroxyalkyl starch derivative were dissolved in 1 ml of the mobile phase and particle filtrated with a syringe filter (0.22 mm, mStarII, CoStar Cambridge, Mass.)
The measurement was carried out at a flow rate of 0.5 ml/min.
As detectors a multiple-angle laser light scattering detector and a refractometer maintained at a constant temperature, connected in series, were used.
Astra software (Vers. 5.3.4.14, Wyatt Technology Cooperation) was used to determine the mean Mw and the mean Mn of the sample using a dn/dc of 0.147. The value was determined at λ=690 nm (solvent NaOAc/H2O/0.02% NaN3, T=20° C.) in accordance to literature (W. M. Kulicke, U. Kaiser, D. Schwengers, R. Lemmes, Starch, Vol. 43, Issue 10 (1991), 392-396).
aphosphate buffer pH 7 used;
bcitrate buffer pH 6.4 used.
Table 8: Overview of synthesized Hydroxyethyl starch drug conjugates
Adult female NMRI:nu/nu mice (TACONIC Europe, Lille Skensved, Denmark) bred in the own (EPO) colony were used throughout the study. At the start of experiment they were 6-8 weeks of age and had a median body weight of 19.0 to 32.6 g.
All mice were maintained under strictly controlled and standardized barrier conditions. They were housed—maximum five mice/cage—in individually ventilated cages (Macrolon Typ-II, system Techniplast, Italy). The mice were held under standardized environmental conditions: 22±1° C. room temperature, 50±10% relative humidity, 12 hour-light-dark-rhythm. They received autoclaved food and bedding (Ssniff, Soest, Germany) and acidified (pH 4.0) drinking water ad libitum.
Animals were randomly assigned to 12 experimental groups with 8 mice each. At treatment initiation the ears of the animals were marked and each cage was labeled with the cage number, study number and animal number per cage.
Table 9 provides an overview of the animal conditions.
The human pancreas carcinoma ASPC-1 was used as s.c. xenotransplantation model in immunodeficient female NMRI:nu/nu mice.
The cells were obtained from ATCC and are cryo-preserved within the EPO tumor bank. They were thawed, expanded in vitro and transplanted as cell suspension subcutaneously (s.c.) in female NMRI:nu/nu mice. The tumor line ASPC-1 is used for testing new anticancer drugs or novel therapeutic strategies. It was therefore selected for this study. ASPC-1 xenografts are growing relatively fast and uniform.
For experimental use 107 tumor cells/mouse from the in vitro passage were transplanted s.c. into the flank of each of 10 mice/group at day 0.
At palpable tumor size (30-100 mm3) treatment started. The application volume was 0.2 ml/20 g mouse body weight. The test compounds, the vehicle controls and the reference compounds were all given intravenously (i.v.).
Tumor growth inhibition was used as therapeutic parameter. Additionally, body weight change was determined as signs for toxicity (particularly, potential hematological or gastrointestinal side effects).
Tumor diameters were measured twice weekly with a caliper. Tumor volumes were calculated according to V=(length x (width)2)/2. For calculation of the relative tumor volume (RTV) the tumor volumes at each measurement day were related to the day of first treatment. At each measurement day the median and mean tumor volumes per group and also the treated to control (T/C) values in percent were calculated (Tables 11-13).
Individual body weights of mice were determined twice weekly and mean body weight per group was related to the initial value in percent (body weight change, BWC).
On the day of necropsy mice were sacrificed by cervical dislocation and inspected for gross organ changes.
Descriptive statistics were performed on the data of body weight and tumor volume. These data are reported in tables as median values, means and standard derivations, see Tables 11-13. Statistical evaluation was performed with the U-test of Mann and Whitney with a significance level of p≦0.05, using the Windows program STATISTICA 6.
All Gemcitabine-conjugates were stored in a freeze-dried form at −20° C. until use. Solutions were prepared immediately before injection by solving the conjugates in saline solution by vortexing in combination with centrifugation until a clear solution of the necessary concentration of the drug was obtained.
All solutions were prepared and injected under sterile conditions.
Gemcitabine (Gemzar®, charge A4781790 200 mg) was obtained from Lilly Deutschland GmbH and was stored in the dark at −20° C. until use. The final solution of Gemzar® was prepared immediately before injection by mixing the appropriate volume of the original stock solution (200 mg) with saline (0.9%, infusion solution, Ch.-Nr 0205A231, B. Braun Melsungen AG, Germany).
As a further control, saline solution was intravenously administered.
The results summarized in tables 11-13 (
The athymic nude mouse is immunodeficient, thus enabling the xenotransplantation and growth of human tumors. Subcutaneous tumor implantation is a well-described methodology allowing visualization and quantification of tumor growth.
Mouse strain: NMRI nu/nu, female
Animals supplied by: Charles River, Germany
Age of mice at implantation: 5-7 weeks
All experiments were conducted according to the guidelines of the German Animal Welfare Act (Tierschutzgesetz). Animal health was examined prior to tumor implantation and randomization to ensure that only animals without any symptoms of disease were selected to enter testing procedures. During the experiments, animals were monitored daily regarding tumor burden, general condition, feed and water supply.
Animals were arbitrarily numbered during tumor implantation using ear clips. At the beginning of the experiments, each cage was labelled with a record card indicating the experiment number, date of tumor implantation, date of randomization, tumor type, tumor number and passage, mouse strain, gender, and individual mouse numbers. After randomization, the group identity, test compound, dosage, schedule, and route of administration were added.
The animals were housed in autoclaved individually ventilated cages (TECNIPLAST Sealsafe™-IVC, TECNIPLAST, Hohenpeissenberg, Germany). Depending on group size, they were housed in either type III cages or type II long cages. Dust-free bedding Lignocel® PS 14 was used (ssniff Spezialdiaten GmbH, Soest, Germany). The cages including the bedding were changed weekly. The temperature inside the cages was maintained at 25±1° C. with a relative humidity at 60±10%. The animals were kept under a natural daylight cycle.
The animals were fed autoclaved ssniff NM complete feed for nude mice (ssniff Spezialdiäten GmbH, Soest, Germany) and had access to sterile filtrated and acidified (pH 2.5) tap water. Bottles were autoclaved prior to use; they were changed twice a week. Food and water were provided ad libitum.
The tumor xenografts LXFL-529 (Fiebig H H, Berger D P, Dengler W A, Wallbrecher E, Winterhalter B R: Combined In Vitro/In Vivo Test Procedure with Human Tumor Xenografts for New Drug Development. Contrib. Oncol., Basel, Karger, 1992, Vol. 42, pp 321-351) used in this study were derived from surgical specimen from patients treated at the University Hospital in Freiburg, Germany, and directly implanted into nude mice. Prior to surgery, most of the patients had not received any chemotherapy.
Following their primary implantation into nude mice (passage 1), the tumor xenografts were passaged until establishment of stable growth patterns. Master stocks of early passage xenografts were then frozen in liquid nitrogen. Usually, a particular master stock batch itself is only used for maximally 30 passages. Therefore, the xenografts closely reflect the initial primary histology.
Tumor fragments were obtained from xenografts in serial passage in nude mice. After removal from donor mice, tumors were cut into fragments (4-5 mm diameter) and placed in PBS until subcutaneous implantation. Recipient mice were anaesthetized by inhalation of isoflurane. A small incision was made in the back and one tumor fragment per animal was transplanted with tweezers. The mice were monitored daily.
At randomization, tumor-bearing animals were stratified according to tumor volume into treatment and vehicle (control) groups. Only animals carrying one tumor of appropriate size (approximately 50-250 mm3) were considered for randomization. Mice were randomized when the required number of mice qualified for randomization. The day of randomization was designated as day 0, which was also the first day of dosing.
All test items were formulated in 0.9% NaCl solution and given as i.v. bolus injection despite everolimus, which was given per oral.
Everolimus (Lot. 1101012750e was purchased from Sequoia Research Products. Individual treatment schedules and results can be extracted from table 14.
Measurement of tumor volume and body weight as well as calculations of relative tumor volumes were carries out analogue to the procedure described in 1.3.
The results compiled in table 14 reveal that both HES-everolimus conjugates perform comparably to the native drug without any signs of toxicity. In the first 7 days of the experiments, both conjugates result in a higher tumor growth inhibition than the native drug. As for temsirolimus, all conjugates show a distinct advantage in tumor growth inhibition without any observable toxicity. Compared to the faster releasing conjugate CTm1, both slower releasing conjugates CTm2 and CTm3 show a slight additional advantage.
| Number | Date | Country | Kind |
|---|---|---|---|
| 1616/DEL/2010 | Jul 2010 | IN | national |
| 10008727.9 | Aug 2010 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2011/003462 | 7/11/2011 | WO | 00 | 4/18/2013 |
| Number | Date | Country | |
|---|---|---|---|
| 61375330 | Aug 2010 | US |
